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Traditional  anticancer  agents  are  mainly  targetted  on  the  DNA 
replication  process  in  the  nucleus.  However,  with  the  advancements  in 
modern  biology,  a  new  class  of  anticancer  drugs  has  emerged.  These 
compounds  target  on  enzymes  involved  in  the  earlier  part  of  the  cancer 
cell  cycle.  Protein  kinase  C  (PKC)  is  one  such  enzyme  which  has  been 
under  intensive  investigation  because  of  its  ability  to  cause  tumour 
promotion.  It  belongs  to  a  family  of  enzymes  which  catalyse  the 
phosphorylation  of  serine  and  threonine  residues  using  ATP.  As  well  as 
being  a  natural  direct  PKC  inhibitor,  sphingosine  (A)  can  also  inhibit  PKC 
indirectly  by  inhibiting  phosphatidic  acid  phosphohydrolase  (PAP). 
PAP  catalyses  the  hydrolysis  of  diacylglycerol,  the  main  PKC  activator. 
Since  N-methylsphingosine  and  N,  N-dimethylsphingosine  are  better  PKC 
inhibitors  than  sphingosine,  it  appears  that  the  bulkiness  around  the 
amino  group  is  important  for  inhibition. 
The  first  stage  of  the  project  was  to  establish  reaction  conditions 
for  carrying  out  methylation,  dimethylation  and  trimethylation  of  a 
primary  amino  group  in  compounds  which  are  analogues  of 
sphingosine.  A  selection  of  N-methylated,  N,  N-dimethylated  and  N,  N,  N- 
trimethylated  analogues  of  sphingosine  was  synthesised  from  (R)-,  and 
(S)-phenylalaninol  and  (1S,  2S)-2-amino-l-phenylpropane-1,3-diol. 
They  were  tested  on  two  PAP  enzymes  under  the  supervision  of  Dr 
Pamela  Scott  at  the  Department  of  Medical  Oncology,  University  of 
Glasgow.  The  results  suggest  that  there  is  no  clear  correlation  between 
the  amount  of  inhibition  and  the  bulkiness  around  the  amino  group. 
However  increasing  the  bulkiness  around  the  amino  group  in  some 
cases  did  lead  to  an  improvement  in  the  inhibition. 
The  tested  compounds  differ  from  sphingosine  in  the  hydrophobic 
moiety.  Since  they  had  shown  much  less  inhibitory  effect  on  PAP  than 
sphingosine,  the  length  of  the  hydrophobic  alkyl  chain  is  likely  to  be  a 
key  structural  feature  for  inhibition.  A  range  of  sphingosine  analogues 
each  containing  a  triple  bond  was  synthesised  diastereoselectively. 
Sphingosine  was  synthesised  using  the  same  route.  However,  only  a 
small  amount  was  synthesised,  which  was  too  small  to  be  used  for 
further  reactions. A  novel  enantioselective  synthesis  ý  of  sphingosine  analogues  was 
proposed  and  its  effectiveness  was  tested  by  applying  it  to  the 
synthesis  of  (1R,  2S)-2-ethylamino-l-phenylpropane-1,3-diol  and  N- 
ethylsphingosine. 
A  selection  of  sphingosine  analogues  was  tested  on  a  range  of 
cancer  cell  lines  under  the  supervision  of  Dr  A.  T.  McGown  at  the 
Paterson  Institute,  Manchester.  The  sphingosine  analogues  containing  a 
triple  bond  had  IC50  values  in  the  region  of  1gM  against  these  cell 
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Cancer  -  An  Overview 
1.1  History  of  Cancer 
Cancer  is  the  second  highest  killing  disease  of  our  time,  after 
heart  disease.  In  the  USA  it  is  estimated  that  one  in  three  people  will 
develop  cancer  at  some  point  in  their  life.  1  Even  with  the  advanced 
technology  in  cancer  therapy,  cancer  still  has  a  profound  effect  on  the 
population.  Its  statistics  cast  fear  over  people.  The  disease  is  not  a  new 
health  problem  because  it  has  been  present  throughout  the  history  of 
mankind.  It  started  with  the  discovery  of  some  Egyptian  mummies 
diagnosed  with  bone  cancers.  During  that  period,  the  disease  was 
believed  to  be  a  curse  from  God  to  punish  sinners.  Such  misconception 
was  held  until  the  Middle  Ages  when  questioning  began.  One  of  the 
first  investigations  into  the  cause  of  cancer  was  investigated  by  Sir 
Percival  Pott  around  1775.  He  discovered  that  young  boys  working  as 
chimney  sweeps  had  a  high  mortality  rate  due  to  scrotal  cancer.  The 
chimney  soot  was  to  blame  but  the  development  of  cancer  was  found 
only  to  occur  on  chronic  exposure.  Such  observation  was  important  but 
the  biological  aspects  of  tumours  were  to  remain  a  mystery  until  the 
discovery  of  the  microscope  in  the  19th  century.  With  this  equipment, 
cancer  was  established  as  a  cellular  disease  and  most  of  the  research 
was  then  focused  into  three  areas:  the  cause,  biological  properties  and 
treatment  of  cancer. 
1.2  Causes  of  Cancer 
Cancer  is  a  disease  at  the  cellular  level  as  it  causes  abnormal  cell 
proliferation.  This  is  due  to  genetic  alteration  which  results  in  a  change 
in  gene  expression.  But  there  is  the  question  of  what  causes  the  genetic 
information  to  be  altered.  Epidemiological  studies  have  shown  that 
exposure  to  a  variety  of  different  external  factors  is  responsible.  These 
factors  include  viruses,  a  wide  variety  of  chemicals,  X-rays  and  ultra- 
violet  radiation.  Fuller  knowledge  of  these  factors  coupled  with  their 
avoidance  could  prevent  90%  of  cancers.  2 
1 1.2.1  Radiation 
The  majority  of  skin  cancers  is  caused  by  solar  radiation.  It  is  the 
ultra-violet  light  that  damages  cells  at  their  genetic  level,  causing  a  high 
frequency  of  mutations,  DNA  damage  and  chromosome  abnormalities. 
Chronic  exposure  may  result  in  melanoma,  a  form  of  skin  cancer  which 
is  considered  to  be  the  most  lethal  due  to  its  behaviour.  This  form  of 
tumour  metastasises,  that  is,  it  invades  neighbouring  tissues  and 
organs,  and  therefore  cannot  be  easily  removed  through  surgical  means. 
It  is  this  form  of  skin  cancer  that  mainly  accounts  for  cancer  mortality. 
However,  prolonged  exposure  to  sunlight  does  not  always  lead  to  death. 
Non-melanoma  is  the  less  harmful  form  of  melanoma  and  can  be 
treated  effectively  by  surgery. 
1.2.2  Medical  X-Rays 
X-rays  were,  discovered  by  Roentgen  in  1895.  Initially,  they  were 
used  to  treat  cancer.  But  after  an  X-ray  technician,  who  was  testing 
manufactured  X-ray  tubes,  died  from  metastatic  cancer,  the  use  of  X- 
rays  was  questioned.  By  1908,  animal  experiments  had  showed  that  X- 
rays  were  carcinogenic.  The  risk  was  proportional  to  the  degree  of 
exposure.  3  Despite  this  discovery,  X-rays  are  still  used  to  treat  non- 
malignant  diseases.  In  Israel,  X-rays  are  administrated  to  the  head  and 
upper  body  to  treat  ringworm  of  the  scalp.  Israel  now  has  the  third 
highest  incidence  of  thyroid  cancer  in  the  world.  4  In  contrast, 
Denmark,  where  X-rays  have  never  been  used  to  treat  non-malignant 
diseases,  has  one  of  the  lowest  rates  of  thyroid  cancer  in  the  world.  5 
Nowadays,  X-rays  are  used  for  the  detection  of  skeletal  deformities  and 
for  treatment  of  certain  types  of  solid  tumours.  Since  they  are 
carcinogenic,  they  have  to  be  used  carefully  and  in  small  controlled 
doses. 
1.2.3  Chemicals 
In  some  work  areas  the  handling  of  chemicals  cannot  be  avoided. 
Employees  in  science  and  industry  have  new  legislation  (Control  of 
Substances  Hazardous  to  Health  act)  to  help  minimise  the  risk  of 
working  with  chemicals.  Even  if  we  are  not  handling  them  we  are  still 
2 at  risk  in  society,  mainly  from  the  effects  of  tobacco.  Cigarette  smoke 
could  be  lethal  because  it  contains  50  known  carcinogens  including 
arsenic,  benzene,  '  nitrosoamines  and  naphthylamine.  This  mixture  is 
the  main  cause  of  lung  cancer  which  accounts  for  one  third  of  cancer 
mortality.  There  is  a  connection  between  the  intake  of  smoke  and  life 
expectancy.  A  30  year-old  man  smoking  40  cigarettes  a  day  can  expect 
to  lose,  on  average,  eight  years  from  his  life-span,  as  well  as  increasing 
his  risk  of  cardiovascular  and  respiratory-  disease.  6  Other  cancers 
which  have  been  linked  to  cigarette  smoke  are  cancers  of  the  oral 
cavity,  pharynx,  oesophagus,  bladder,  kidney  and  pancreas.  The 
incidence  of  lung  cancer  is  increasing  as  a  result  of  changing  lifestyles. 
This  is  due  to  the  trend  of  more  women  smoking  as  well  as  more 
adolescents. 
1.2.4  Medicines  that  Cause  Cancer 
Like  medical  X-rays,  some  medications  have  the  ability  to  induce 
a  second  cancer  as  a  result  of  their  actions  on  normal  cells.  This  is  a 
side  effect  that  a  patient  may  have  to  face  after  treatment.  These 
cancer-causing  drugs  have  been  removed  from  current  practice  but 
other  potential  carcinogens  still  remain  in  use.  The  benefits  that  these 
drugs  bring  generally  outweigh  the  side  effects. 
1.2.4a  Anticancer  Drugs 
Despite  their  ability  to  cause  cancer,  anticancer  drugs  are  still 
used  in  chemotherapy.  This  will  be  discussed  later  in  this  chapter. 
Anticancer  drugs  are  used  to  target  all  rapidly  proliferating  cells,  that 
is,  cancer  cells,  and  any  normal  rapidly  dividing  cells.  One  example  of  a 
normal  cell  that  is  most  affected  by  such  drugs  is  the  bone  marrow 
forming  cells.  The  effect  of  these  drugs  on  normal  cells  might  induce  the 
development  of  a  second  cancer.  Nevertheless,  the  benefits  of  these 
drugs  outweigh  the  possibility  that  they  will  induce  the  development  of 
a  second  cancer. 
3 1.2.4b  Hormones 
In  the  early  1970s,  incidences  of  vaginal  and  cervical  cancer 
among  young  women  were  becoming  noticeable.  The  mothers  of  these 
women  had  been  treated  with  the  synthetic  oestrogen, 
diethylstilbestrol  (DES),  during  their  pregnancy  back  in  the  1940s  and 
1950s.  This  practice  no  longer  exists.  However,  oestrogen  itself  is  used 
to  treat  menopause  symptoms  and  osteoporosis  (bone  thinning). 
Postmenopausal  hormone  replacement  therapy  involves  the  use  of  high 
doses  of  oestrogen.  Unfortunately  this  is  a  long-term  treatment,  and 
therefore  carries  the  risk  of  developing  endometrial  cancer.  This  type 
of  hormone  replacement  therapy  is  still  practised  because  the  risks  can 
be  reduced  by  the  administration  of  another  hormone,  progesterone,  as 
a  co-drug. 
1.2.5  Oncogenic  Viruses 
The  common  cold,  herpes,  polio,  influenza  and  measles  are  all  due 
to  viral  infections.  Viruses  invade  cells  to  use  the  cells'  biological 
machinery  to  reproduce.  These  oncogenic  viruses  incorporate  their 
RNA  into  the  DNA  of  a  normal  cell.  This  allows  the  virus  to  place  its 
genetic  make-up  into  the  cells  reproduction  system  to  produce  more 
RNA  tumour  viruses.  The  invaded  cell  then  ruptures  releasing  virus 
progeny  to  infect 
.  neighbouring  normal  cells.  An  example  of  this 
oncogenic  virus  is  Hepatitis  B. 
1.3  Cell  Cycle  and  Growth 
The  range  of  causes  of  cancer  increases  the  difficulty  of  finding 
the  appropriate  treatment.  In  order  to  do  this,  understanding  of  how  a 
cell  survives  and  reproduces  is  needed.  Cellular  processes  are 
presented  as  a  cell  cycle  in  which  there  are  four  kinds  of  cellular 
events.  Overall,  a  parental  cell  duplicates  its  genetic  material  and 
passes  one  copy  of  each  to  its  two  newly  formed  daughter  cells. 
When  the  parental  cell  is  in  the  G1  phase,  its  metabolites  become 
active  and  it  is  ready  for  DNA  replication  which  happens  in  the  S  phase 
of  the  cycle  (Diagram  1).  By  this  time,  the  cell  has  two  copies  of  its 
4 genetic  complement,  and  it  is  at  its  premitotic  stage  (G2  phase).  In  the 
remaining  phase  of  the  cycle  (M  phase),  cell  division  occurs  to  form  two 
daughter  cells.  Each  cell  contains  one  copy  of  the  parental  genetic 
material. 
The  lengths  of  the  M,  S  and  G2  phases  do  not  vary  considerably 
from  one  cell  type  to  another.  The  length  of  of  GI  phase  varies 
depending  on  how  soon  newly  formed  cells  are  needed.  Liver  cells 
have  a  G1  phase  of  a  few  weeks  since  there  is  no  urgent  need  for  them 
to  reproduce.  In  contrast,  bone  marrow  cells  have  a  Gi  phase  of  a  few 
hours  in  order  to  replace  themselves  efficiently.  There  are  cells 
however  which  are  permanently  fixed  at  the  GI  phase.  These  include 
nerve  cells  and  adult  brain  cells.  Therefore  the  rate  of  proliferation  of  a 
cell  depends  on  how  long  it  spends  in  the  Gi  phase.  There  are  some 
cells  that  stay  in  the  Gi  phase  and  have  entered  a  phase  outside  the  cell 
cycle  (GO  phase).  They  can  leave  the  GO  phase  and  return  to  G1,  thus 
entering  the  cell  cycle,  if  the  cell  is  induced  by  an  external  signal.  A 
wound  on  a  piece  of  connective  tissue  would  induce  the  synthesis  of 
skin  fibroblasts. 
After  the  M  phase,  normal  daughter  cells  differentiate  to  undergo 
a  programmed  cell  death  since  they  are  constantly  being  replaced  by 
new  cells.  This  keeps  the  cell  population  constant.  With  cancer  cells, 
5 they  fail  to  die  since  they  do  not  differentiate.  Instead  they  go  on  to 
the  S  phase  of  the  cell  cycle  having  lost  the  ability  to  remain  in  the  G1 
phase.  They  go  on  to  reproduce  further  daughter  cells  which  also  fail  to 
differentiate.  Thus,  cancer  cells  are  continuously  proliferating. 
1.4  Current  Cancer  Therapies 
There  are  three  treatments  used  in  practice  today:  surgery, 
radiotherapy  and  chemotherapy.  The  choice  of  treatment  depends  on 
the  nature  of  the  cancer. 
Surgery  is  effective  against  most  localised  tumours  except  brain 
tumours.  It  is  useful  in  treatment  of  malignant  melanoma  which 
appears  as  lesions  on  the  skin.  Therefore,  it  can  be  easily  seen  and 
detected  early.  The  success  of  surgery  depends  on  the  removal  of  all 
cancerous  cells  leaving  none  behind  to  continue  the  life  cycle.  This  type 
of  treatment  is  promising  since  there  are  no  chemicals  involved  which 
may  affect  the  body  elsewhere.  However  it  has  its  limitations.  . 
Once 
cancer  cells  have  metastasised,  it  is  difficult  to  ensure  that  all  of  them 
have  been  removed.  Also,  most  cancers  are  undetected  until  they  have 
metastasised.  Therefore,  it  is  often  too  late  for  surgical  treatment.  At 
this  stage  radiotherapy  or  chemotherapy  is  required. 
Radiotherapy  is  sometimes  used  instead  of  surgery  on  localised 
tumours-  because  it  can  kill  the  cancer  cells  as  well  as  the  invaded 
adjacent  cells.  However,  some  cancer  cells  can  only  be  removed  by  a 
combination  of  radiotherapy  and  surgery.  The  role  of  radiotherapy  is 
to  induce  mutations  by  damaging  DNA.  DNA  damage  can  be  lethal  to 
any  cell  especially  to  those  that  are  rapidly  proliferating  since  they  use 
DNA  much  quicker.  Thus  radiation  targets  selectively  on  cells  with  a 
short  cell  cycle.  However  this  provides  a  limitation  to  its  use.  Not  only 
are  the  cancer  cells  destroyed  but  also  normal  rapidly  proliferating 
cells.  It  is  the  S  phase  of  the  cell  cycle  that  is  most  likely  to  be  affected. 
In  practice,  radiotherapy  is  spread  over  a  month  to  allow  any  resting 
cancer  cells  left  to  move  into  the  S  phase,  as  well  as  giving  the  patient  a 
chance  to  recover  from  the  side  effects  of  the  treatment.  A  number  of 
side  effects  are  due  to  the  killing  of  normal  proliferating  cells  such  as 
cells  of  the  bone  marrow,  skin  cells  and  the  cells  that  form  hair. 
6 Sometimes,  tumours  have  already  metastasised  by  the  time  of 
diagnosis.  Surgery  and  radiotherapy  are  no  longer  effective  towards 
these  tumours.  At  this  stage,  chemotherapy  will  be  required.  The  basis 
of  chemotherapy  is  to  administer  a  combination  of  drugs  to  interfere 
with  the  process  of  cell  division.  The  main  drawback  of  this  treatment 
is  that  the  drugs  are  largely  non-selective  and  can  induce  a  second 
cancer.  It  is  common  to  administer  a  combination  of  drugs  during 
chemotherapy  in  case  cancer  cells  develop  resistance  to  any  one  of  the 
drugs.  Chemotherapy  may  be  used  in  combination  with  surgery  and 
radiotherapy  and  is  the  only  real  hope  for  patients  with  metastatic 
cancer. 
1.5  Anticancer  Drugs 
It  is  of  paramount  importance  to  organic  chemists  to  understand 
the  mode  of  action  of  anticancer  drugs  to  provide  them  with  a 
foundation  for  the  design  of  better  ones.  The  three  main  groups  of 
anticancer  drugs  are  alkylating  agents,  antimetabolites  and  natural 
products. 
1.5.1  Alkylating  Agents 
The  largest  group  of  DNA  damaging  drugs  are  the  alkylating 
agents  which  originate  from  the  use  of  mustard  war  gases.  The  parent 
compound,  nitrogen  mustard,  forms  covalent  bonds  with  nucleophilic 
centres  in  DNA  and  other  biological  molecules.  These  centres  include 
amine,  phosphate  and  hydroxy  groups  on  nucleic  acids,  nucleotides  and 
enzymes.  A  modified  nucleic  acid  is  formed  when  alkylation  occurs 
once.  However,  -there-  are  some  drugs-  that  have  two  alkylating  sites. 
These  agents  crosslink  two  adjacent  strands  of  DNA  in  its  helical  form, 
making  it  impossible  for  the  double  helix  to  unwind  and  replicate.  The 
lone  pair  of  nitrogen  of  the  drug  intramolecularly  displaces  the  chloride 
to  form  an  aziridinium  ion  (1)  which  reacts  readily  with  an  electron  rich 
site  to  generate  a  modified  nucleic  acid  (Scheme  1). 
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Nitrogen  mustard  is  too  reactive  to  be  of  much  clinical  use. 
Instead  a  derivative,  cyclophosphamide  (2),  is  widely  used  for  the 
treatment  of  carcinoma  of  the  breast  and  of  the  bronchus.  In  contrast 
to  its  parent  compound,  it  can  be  administered  orally  since  it  remains 
inactive  until  its  target  site  has  been  reached.  Its  stability  is  aided  by 
the  delocalisation  of  the  nitrogen  lone  pair  with  the  P=O  bond. 
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After  a  combination  of  enzymatic  and  chemical  activation,  the 
drug  is  transformed  into  active  phosphoramide  mustard  alkylating 
agent  (Scheme  2).  If  a  single  alkylation  step  only  occurs  then  it  could 
lead  to  mispairing  of  bases  or  strand  breakage.  However,  the  remaining 
chloroethyl  group  could  react  with  another  molecule  of  guanine  in  the 
opposite  strand  of  DNA  to  form  a  crosslink.  Ifosfamide,  melphalan  and 
chlorambucil  are  other  drugs  developed  as  a  result  of  the  success  of 
cyclosphosphamide. 
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Nitrosoureas  are  another  group  of  alkylating  agents.  The  most 
frequently  one  used  in  cancer  therapy  is  bischloroethylnitrosourea 
(BCNU,  3). 
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Nirosoureas  are  lipid  soluble  and  therefore  are  able  to  cross  the 
blood-brain  barrier  and  so  are  frequently  used  to  treat  brain  tumours. 
BCNU,  like  cyclophosphamide,  is  inactive  until  it  undergoes  metabolism 
to  release  a  number  of  cytotoxic  compounds.  An  isocyanate  is  one  of 
these  metabolites,  which  can  react  to  form  covalent  bonds  with 
proteins,  causing  some  cytotoxicity.  But  it  is  the  alkylation  step  that  is 
ultimately  responsible  for  most  of  the  cytotoxicity. 
1.5.2  Antimetabolites 
Generally,  anticancer  agents  act  in  several  different  ways  to 
inhibit  cell  division.  Antimetabolites  often  act  by  interfering  with  DNA 
synthesis.  When  a  cell  has  entered  the  S  phase  of  its  cycle,  it  has  a 
reserve  of  metabolites  from  the  G1  phase.  The  bindings  of  natural 
metabolites  onto  enzymes  are  essential  for  the  synthesis  of  DNA.  If 
analogues  of  these  metabolites  are  present,  they  too  will  bind  onto  the 
enzymes  making  the  enzyme  inactive.  Antimetabolites  are 
administered  to  mimic  the  natural  metabolites  present  in  the  S  phase 
and  thus  compete  for  enzymes.  Therefore,  cells  that  are  rapidly 
dividing  will  have  a  higher  mortality  rate.  These  cells  are  producing 
their  metabolites  quicker,  which  in  turn  means  their  enzymes  are 
inactivated  sooner. 
Antimetabolites  inhibit  cellular  enzymes  involved  in  the  synthesis 
of  one  or  more  of  the  nucleotides,  the  precursors  of  DNA.  They  also 
inhibit  the  synthesis  of  DNA  itself.  Methotrexate,  5-fluorouracil, 
cytosine  arabinose,  mercaptopurine  and  6-thioguanine  are  all 
antimetabolites  which  inhibit  DNA  synthesis  and  are  clinically  used. 
10 5-Fluorouracil  (5-FU,  4)  mimics  the  pyrimidine  bases  uracil  (5) 
and  thymine  (6)  of  DNA.  5-FU  is  converted  into  its  corresponding  5-FU 
nucleotide  which  inhibits  thymidylate  synthetase  irreversibly  once  it 
has  incorporated  into  the  cell  cycle  (Diagram  2).  This  antimetabolite  is 
used  for  the  treatment  of  solid  tumours  and  cancers  of  the  breast  and 
gastrointestinal  tract.  Bone  marrow  suppression  and  sickness  are  the 
side  effects  which  may  be  severe  in  cases  of  high  doses. 
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Tetrahydrofolic  acid  (THA)  is  a  co-factor  for  thymidylate 
synthetase  (Diagram  2).  Removal  of  THA  will  indirectly  block  the 
synthesis  of  DNA.  Methotrexate  (7),  an  analogue  of  folic  acid  (8),  is 
11 used  for  reducing  the  production  of  THA  by  competing  for 
dihydrofolate  reductase,  an  ý  enzyme  that  catalyses  the  reduction  of 
dihydrofolate  to  tetrahydrofolate.  Methotrexate  is  used  to  treat  acute 
leukaemia  and  choriocarcinoma. 
Other  useful  antimetabolites  include  cytosine  arabinose,  a 
nucleoside  mimic  used  to  treat  myeloid  leukaemia  in  adults;  6- 
mercaptopurine,  a  purine  antagonist;  and  6-thioguanine,  which  also 
inhibits  purine  synthesis. 
1.5.3  Natural  Products 
Vincristine  (9)  and  vinblastine  (10)  are  two  common  alkaloids 
used  in  cancer  therapy. 
, 
These  compounds  inhibit  the  process  of  mitosis 
by  binding  to  the  microtubules  protein  tubulin.  Before  mitosis  can  take 
place,  chromosomes  are  held  in  a  certain  orientation  by  these 
microtubules,  also  known  as  spindles.  By  binding  to  tubulin,  these 
alkaloids  disrupt  the  mitotic  spindles  and  block  the  cell  division  at  the 
12 M  phase  of  the  cell  cycle.  Vincristine  is  used  to-  treat  leukäeinias  and 
lymphomas,  and  vinblastine  is  used  for  Hodgkin's  disease. 
Taxol  (11),  a  taxane,  is  isolated  from  the  bark  of  Taxus  brevifolia. 
It  is  a  potent  anticancer  drug  and  is  mainly  used  for  treating  breast  and 
ovarian  cancers.  Like  vincristine  and  vinblastine,  it  affects  the  mitotic 
spindles.  Taxol  has  been  shown  to  stimulate  the  formation  of 
microtubules  and  also  to  prevent  their  breakdown.  10  Any  interference 
in  the  spindle  formation  will  lead  to  an  inbalance  of  microtubules.  Such 
inbalance  prevents  normal  cell  division  from  taking  place.  Cancer  cells 
are  most  affected  because  they  are  rapidly  proliferating.  Although 
taxol  is  an  effective  anticancer  drug,  its  use  is  limited  because  of  its 
poor  water  solubility  and  the  difficulty  in  transporting  the  drug  to  the 
site  of  action.  Instead,  a  phosphate  derivative  (12)  is  used  because  it  is 
more  stable  and  is  water  soluble.  Unfortunately,  only:  small  amounts  of 
taxol  can  be  isolated.  Therefore  taxol  has  to  be  synthesised.  Due  to  its 
complexity,  the  total  synthesis  of  taxol  was  not  achieved  until  1994  by 
the  groups  of  Nicolaou  l,  l  and  Holton.  12  Analogues  of  taxol  such  as 
taxotere  are  proving  to  be  very  effective  in  treating  cancers. 
13 1.5.4  Miscellaneous  Anticancer  Agents 
Some  chemotherapeutic  drugs  cannot  be  categorised  under  the 
three  previous  headings.  The  enzyme  asparaginase  is  used  to  treat 
acute  leukaemias.  It  breaks  down  the  amino  acid  asparagine  which  is 
important  for  both  protein  and  DNA  syntheses.  Asparagine  is 
generated  in  normal  cells  whereas  leukaemic  cells  rely  on  the  blood 
supply  for  asparagine  for  growth.  Therefore  treatment  with 
asparaginase  reduces  the  supply  of  asparagine  to  leukaemic  cells  and  so 
controls  their  growth. 
Cisplatin  (13)  is  one  of  the  few  inorganic  anticancer  drugs.  It  is  a 
square  planar  complex  of  platinium  with  two  chlorides  cis  to  one 
another.  Its  mode  of  action  is  very  similar  to  that  of  alkylating  agents. 
The  chlorides  can  be  replaced  by  nucleophilic  sites  on  proteins  or 
nucleic  acids.  Dialkylation  can  occur  to  produce  DNA  cross-linkage  or 
monoalkylation  can  produce  a  modified  protein  or  DNA  molecule. 
14 Although  the  mechanism-  is  '  not  '  fully  known,  N-7  of  guanine'-is  'probably 
the  base  that  undergoes  the  SN2  displacement.  Interestingly,  the  trans- 
isomer  appears  to  be  completely  unable  to  induce  DNA  cross-linkages  of 
the  double  helix. 
, 
Cisplatin  is  used  for  treatment  of  testicular  cancer  as 
well  as  being  used  in  combination  with  other  drugs  in  treating  a  variety 
of  solid  tumours. 
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Unlike  alkylating  agents  which  directly  react  with  DNA  molecules, 
there  are  some  chemotherapeutic  drugs  which  can  cause  DNA  damage 
indirectly  by  interacting  with  the  enzyme,  topoisomerase  II  (Diagram 
3).  Topoisomerase  II,  acts  to  break  and  rejoin  DNA  strands  within  the 
cell,  and  is  required  for  a  number  of  cell  processes  including  DNA 
replication.  -  Etoposide  and  teniposide  are  chemotherapeutic  drugs  that 
are  used  to  inhibit  the  rejoining  process  by  forming  a  covalent  complex 
with  topoisomerase  II  and  DNA.  Thus  any  DNA  already  broken  cannot 
be  rejoined  causing  the  DNA  molecule  to  cleave  permanently,  leading 
eventually  to  cell  death.  Inhibition  of  topoisomerase  II  also  occurs  with 
the  natural  products  daunomycin  and  doxorubicin. 
15 1.6  Further  Drug  Development 
Patients  are  sometimes  misled  to  believe  that  cancer  therapy  will 
cure  them  from  the  disease.  The  truth  is  that  over  the  past  fifty  years 
of  intense  research,  there  has  been  no  single  drug  found  which  will 
banish  cancer  cells  completely. 
Whilst  patients  are  undergoing  therapy,  they  may  also  suffer  the 
side  effects  of  anticancer  drugs.  This  is  the  price  paid  to  extend  the 
patient's  life.  Since  the  discovery  of  DNA,  anticancer  drugs  have  been 
designed  to  target  on  it.  The  nucleus  of  a  cell  was  the  main  point  of 
focus,  that  is,  until  more  was  known  about  how  signals  travel  within  the 
cell.  Signal  transduction  pathways  leading  to  cell  division  and 
sometimes  tumour  promotion  were  identified  and  so  provided  a  fuller 
picture  of  the  cell's  behaviour.  This  expanded  the  range  of  drug  design. 
If  a  certain  biochemical  pathway  was  found  to  lead  to  a  faster  rate  of 
cell  proliferation,  a  synthetic  drug  could  be  introduced  to  try  to  block 
this  pathway.  Thus  a  new  field  of  targets  was  identified.  The  area  of 
16 focus  shifted  from  the  nucleus  to  other  parts  of  the  cell,  in  particular, 
the  cytoplasmic  enzymes  involved  in  signal  transduction  pathways. 
Future  drugs  will  be  developed  to  target  tumour  promoting 
enzymes,  instead  of  DNA.  DNA  is  at  the  heart  of  the  cell  and  damaging 
or  modifying  it  will  ultimately  cause  side  effects.  Thus  new  drugs  will 
be  developed  to  reduce  these  side  effects. 
17 CHAPTER  TWO 
Cell  Signalling  and  Cancer 
Cell  growth  and  differentiation  of'  normal  cells  are  carefully 
regulated  by  external  signals.  These  external  signal  molecules  are 
growth  factors,  neurotransmitters  and  hormones.  Binding  of'  these 
signals  onto  specific  cell  surface  receptors  triggers  a  series  of'  reactions 
inside  the  cell  (Diagram  4).  This  cascade  of  reactions  serves  to  transmit 
a  signal  from  the  exterior  surface  of  a  cell  to  its  nucleus.  't'his  will  alter 
the  gene  expression  in  the  nucleus  which  in  turn  will  alter  the  cell 
hchaviour. 
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Growth  factors  are  a  group  of'  small  secreted  proteins,  typically 
IO  amino  residues  long.  They  hind  onto  cell  surface  receptors  (growth 
factor  receptors)  which  serve  as  external  sensors.  Info-Illation  in  the 
form  of  a  signal  is  transmitted  Iron  the  extracelluIll-  matrix  to  the 
18 interior  of  the  cell.  Overall,  information  on  the  cell  environment  is  sent 
to  its  nucleus  resulting  in  a  change  in  gene  expression.  This  in  turn 
produces  cell  growth  and  division.  Many  growth  factor  receptors  are 
members  of  a  family  of  proteins  that  function  as  protein  tyrosine 
kinases  (PTKs). 
Although  the  functions  of  many  growth  factors  and  their 
receptors  have"'  been  established14,  the  exact  sequence  of  '  events  in 
signal  transduction  is  still  not  fully  understood.  This  area  of  research  is 
still  active.  Nevertheless,  some  of  the  cellular  reactions  involved  in  PTK 
mediated  growth  have  been  identified.  The  understanding  of  these 
pathways  opens  up  a  new  area  for  chemotherapeutic  drug 
development.  A  synthetic  drug  can  be  used  to  target  a  known  receptor 
in  the  signal  transduction  pathways  so  that  it  can  intercept  the  signal 
from  reaching  the  nucleus.  This  will  arrest  the  growth  of  transformed 
cells  which  is  the  ultimate  aim  of  cancer  therapy. 
2.2  Role  of  Protein  Kinase  C  in  Cell  Growth 
The  PTK  receptor  consists  of  two  domains:  intracellular  and 
extracellular  because  it  is  partially  embedded  in  the  cell  membrane 
(Diagram  5).  Binding  of  a  growth  factor  onto  the  receptor  activates  four 
distinct  target  molecules  in  the  cytoplasm.  Phospholipase  C  is  the  most 
important  target  molecule  activated.  It  catalyses  the  hydrolysis  of 
phosphatidylinositol  4,5-bisphosphate,  generating  diacylglycerol  (DAG) 
and  inositol  triphosphate.  These  two  compounds  appear  to  play  an 
important  role  in  regulating  cell  division.  Inositol  triphosphate  opens 
up  the  calcium  channel  allowing  the  calcium  concentration  to  increase 
in  the  cytoplasm.  An  increase  of  calcium  will  lead  to  the  activation  of 
several  other  calcium-stimulated  protein-serine/threonine  kinases. 
DAG  activates  the  enzyme  protein  kinase  C  (PKC),  a  protein- 
serine/threonine  kinase. 
PKC  can  stimulate  cells  to  divide;  thus  it  must  be  carefully 
regulated  by  the  cell  to  prevent  it  from  being  overexpressed.  Therefore 
the  amounts  of  diacylglycerol  present  in  the  cell  are  crucial  for  cell 
division.  The  triol  is  only  produced  in  small  quantities  by  the 
hydrolysis  of  phosphatidyl  4,5-bisphosphate  but  most  of  it  is  derived 
19 from  the  breakdown  of  phosphatidylcholine  by  the  sequential  action  of 
phospholipase  D  and  phosphatidic  acid  phosphohydrolyase.  In 
conclusion,  unregulated  activity  of  PKC  and  the  disruption  of  DAG 
production  can  contribute  to  tumour  formation.  Over  the  last  few  years 
some  metabolites  of  sphingolipids  have  found  to  be  regulators  of  both 
PKC  and  DAG. 
Cytoplasm 
PIP2 
domain  "' 
Extracellular 
I  p3  +  DAG 
1 
activate  calciu 
ions  influx 
Nucleus 
Serine  /  threonine 
phosphorylation 
Diagram  515 
Tyrosine 
phosphorylation 
Outside  the  cell 
PLC  =  Phospholipase  C 
PIP2  =  Phosphatidylinositol 
4,5-bisphosphate 
DAG  =  Diacylglycerol 
IP3  =  Inositol 
1,4,5-triphosphate 
HH 
OH  RCOOCýH2 
OH  OP 
OP  H  RCOOCH 
PO  H 
,I  ...  --..  H  OH 
1i"2Vr 
Ip3  DAG 
P=  phosphate 
R=  hydrocarbon  chains 
20 2.3  Natural  Inhibitors  of  Protein  Kinase  C 
Sphingolipids  are  located  in  the  cell  membrane  and,  like  many 
other  lipids,  were  thought  only  to  have  a  structural  function,  that  is, 
they  allowed  desired  nutrients  to  travel  across  the  membrane.  Over 
the  last  decade,  metabolites  of  membrane  lipids  have  been  shown  to 
play  an  important  role  in  cell  functions  and  to  act  as  mediators  to  the 
cells'  environment.  In  particular  sphingosine  and  related  compounds 
which  are  metabolites  of  sphingolipids,  have  attracted  a  lot  of  attention 
as  a  result  of  their  ability  to  inhibit  PKC.  In  the  past  few  years 
sphingoid  bases  have  emerged  as  a  new  of  class  of  bioregulatory 
substances.  Current  evidence  suggests  exogenous  sphingosine  is 
involved  in  the  signal  transduction  pathways,  and  at  present  there  is 
little  evidence  for  effects  of  endogenous  sphingosine.  The  mode  of 
action  of  exogenous  sphingosine  on  protein  kinases  and  the  possible 
role  of  endogenous  sphingosine  in  modulating  signal  transduction 
pathways  will  be  discussed  later  in  this  chapter.  Understanding  of  the 
biosynthesis  of  sphingolipids  has  provided  a  better  insight  into  how 
endogenous  sphingosine  could  be  generated  and  how  it  could  then  be 
used  to  inhibit  PKC  indirectly. 
2.4  Biochemistry  of  Sphingolipids  and  Sphingosine 
The  backbone  of  all  sphingolipids  is  sphingosine,  a  long 
unsaturated  hydrocarbon  chain  containing  an  aminodiol.  The  structure 
of  sphingosine  and  its  reported  syntheses  are  discussed  in  chapter  3. 
The  amino  group  of  each  sphingolipid  is  linked  to  a  fatty  acid  by  an 
amide  bond.  The  difference  between  each  lipid  is  the  head  group 
attached  to  the  primary  hydroxyl  group.  In  sphingomyelin  the  primary 
hydroxyl  group  is  substituted  by  a  phosphorylcholine  unit  whereas  in 
glycosphingolipids,  a  sugar  molecule  is  linked  to  the  hydroxyl  group  by 
a  glycoside  bond.  Sphingolipids  and  their  metabolites  are  found  not 
only  in  mammalian  tissues  but  also  in  plants.  Phytosphingosine  is  one 
example  that  is  present  in  both  mammalian  tissues  (such  as  kidneyl6 
and  liver  17)  and  plants.  18 
The  biosynthesis  of  sphingolipids  and  sphingosine  has  been 
established  and  is  well  documented.  19  Palmitoyl  CoA  and  serine 
21 condense  to  form  3-ketosphinganine  ý  which  is  then  reduced  to 
dihydrosphingosine  (Scheme  3).  Dihydrosphingosine  can  either  be  used 
directly  in  the  biosynthesis  of  sphingolipids  or  after,  its  conversion  into 
sphingosine.  The  amino  group  of  sphingosine  is  acylated  with  a  long- 
chain  acyl  CoA  to  form  ceramide  (N-acylsphingosine).  This  is  the  key 
intermediate  from  which  all  sphingolipids  are  synthesised  by  coupling 
with  various  head  groups  to  the  primary  hydroxyl  group. 
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Scheme  3:  The  biosynthesis  of  sphingosine  and  sphingolipids 
22 Sphingomyelinases  catalyse  the  hydrolysis  of  sphingolipids  to 
their  corresponding  ceramides  and  polar  head  groups  or,  to  their 
lysosphingolipids  and  fatty  acids.  These  enzymes  are  found  in 
lysosomes  and  in  plasma  membranes.  The  latter  require  magnesium 
ions  for  activation.  The  action  of  a  plasma  membrane  ceramidase  on 
ceramide  produces  sphingosine.  The  excess  of  sphingosine  can  be 
reacylated  and  then  is  fed  back  into  sphingolipid  biosynthesis.  On  the 
other  hand,  sphingosine  can  be  removed  by  undergoing 
phosphorylation  and  by  subsequent  degradation  into 
phosphorylethanolamine  and  palmitaldehyde.  20 
2.5  Role  of  Exogenous  Sphingosine 
The  inhibitory  effect  of  exogenous  sphingosine  and  other 
naturally  occurring  sphingoid  bases  on  PKC  was  discovered  by  Hannun 
and  co-workers.  21,22  Further  studies  show  that  lysosphingolipids  are 
also  potential  inhibitors  of'  PKC.  With  these  discoveries,  sphingoid  bases 
provided  a  better  insight  into  signal  transduction  pathways.  With  the 
knowledge  that  sphingosine  inhibits  PKC  and  the  fact  that  it  is  used  in 
more  and  more  studies,  its  role  in  cell  growth  begins  to  become 
apparent.  Interestingly,  sphingosine  was  found  to  stimulate  other 
protein  kinases,  in  particular,  the  epidermal  growth  factor  receptor 
tyrosine  kinase  and  human  epidermoid  carcinoma  cells.  23-26  An 
important  discovery  into  the  effects  of  some  sphingosine  analogues  on 
protein  kinases  was  noted  by  Igarashi  et  al.  26  '  They  reported  that  N,  N- 
dimethyl-L-erythro-sphingosine  is  a  specific  stimulator  of  epidermal 
growth  factor  receptor  tyrosine  kinase  but  N,  N-dimethyl-D-erythro- 
sphingosine,  D-erythro-sphingosine,  and  several  lyso-sphingolipids  are 
all  inactive.  In  addition,  they  also  reported  that  N,  N-dimethyl-D  - 
erythro-sphingosine  is  a  better  inhibitor  than  the  pure  synthetic  D- 
erythro-sphingosine.  27  However,  N,  N-dimethyl-D-erythro-sphingosine 
stimulated  another  protein  tyrosine  kinase,  src  kinase  while  D-erythro- 
sphingosine  inhibited  its  activity.  In  short,  exogenous  sphingosine  has 
multiple  effects  on  several  protein  kinases. 
23 2.6  Endogenous  Sphingosine 
2.6.1  Production  of  Endogenous  Sphingosine 
A  model  of  the  sphingolipid  cycle  has  been  postulated21  to 
illustrate  how  sphingosine  may  be  generated  inside  the  cell  (Diagram 
6).  Endogenous  sphingosine  may  be  obtained  by  hydrolysis  of 
sphingolipids  followed  by  deacylation  of  ceramide.  The  free 
sphingosine  could  then  be  used  as  a  modulator  of  cell  function.  The 
action  of  sphingosine  could  be  then  terminated  by  either  reacylation  so 
that  it  could  be  reused  ý  in  sphingolipid  biosynthesise-  or  by 
phosphorylation  followed  by  degradation. 
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Diagram  6:  The  sphingolipid cycle 
The  main  drawback  in  earlier  studies  of  endogenous  sphingoid 
bases  as  cell  regulators  was  that  there  was  no  way  of  knowing  whether 
or  not  endogenous  free  sphingoids  existed  inside  the  cell.  Recently, 
Kobayashi  et  al.  28  developed  a  sensitive  HPLC  method  for  quantitation 
of  endogenous  sphingoid  bases.  This  technique,  along  with  the  use  of  a 
radioenzymatic  method,  developed  by  Van  Veldhoven  et  al.,  2  9 
confirmed  that  endogenous  sphingoid  bases  are  present  in  different 
24 amounts  depending  on  the  cell  type.  Both  methods  also  confirmed  the 
biosynthetic  pathways  operating  in  the  sphingolipid  cycle.  More 
studies  were  carried  out  on  endogenous  sphingoid  base  activation 
inside  the  cell.  Of  particular  interest  were  the  findings  by  Kolesnick  et 
al.  30,31  They  were  the  first  group  to  demonstrate  that  DAG,  and  not 
phorbol  ester,  stimulated  the  activity  of  an  endogenous 
sphingomyelinase,  causing  an  increase  in  ceramide  and  sphingosine 
levels.  The  activation  of  PKC  by  DAG  seems  to  stimulate  the  breakdown 
of  sphingolipid  yielding  the  PKC  inhibitor  sphingosine. 
2.6.2  Indirect  Inhibition  of  Protein  Kinase  C  by  Endogenous 
hingosine 
Sphingosine  can  modulate  the  level  of  DAG  by  inhibiting  its 
production  and  activating  its  breakdown.  It  is  a  potent  inhibitor  of 
phosphatidic  acid  phosphohydrolase  (PAP),  the  enzyme  which 
hydrolyses  phosphatidic  acid  to  form  DAG.  Brindley  et  al.  32  have 
shown  that  there  are  two  distinct  types  of  PAP  activities  in  rat  liver. 
Phosphatidic  acid  phosphohydrolase  .1  (PAPI)  is  dependent  on 
magnesium  ions  for  its  activity  and  is  involved  in  the  synthesis  of 
triacylglycerols,  phosphatidylcholine  and  phosphatidylethanolamine. 
PAPI  is  believed  to  be  inactive  in  the  cytosol  and  only  becomes  active 
when  it  is  translocated  to  the  endoplasmic  reticulum.  The  other  type  of 
phosphatidic  acid  phosphohydrolase,  PAP2,  does  not  require 
magnesium  ions  for  its  activty  and  is  located  in  the  plasma  membrane. 
It  is  believed  that  PAP2  is  involved  in  signal  'transduction. 
The  other  enzyme  which  is  affected  by  sphingosine,  as  recently 
shown  by  Sakane  et  al.,  33  is  diacylglycerol  kinase  isozyme.  This 
isozyme  converts  DAG  into  phosphatidic  acid  and  can  be  activated  by 
sphingosine.  Sphingosine  may  reduce  most  of  the  DAG  levels  by 
inhibiting  PAP2  enzyme  and  by  activating  the  DAG  removal  isozyme. 
Therefore  it  can  inhibit  PKC  indirectly  by  decreasing  the  amount  of  DAG 
available  for  its  activation.  Kolesnick  has  proposed  a  model  (Diagram  7) 
to  help  to  explain  how  endogenous  sphingosine  terminates  PKC 
activation.  31  According  to  this  model,  the  levels  of  DAG  and 
sphingosine  are  mutually  dependent  and  are  well  balanced.  For 
instance,  the  action  of  DAG  may  be  terminated  by  activating  a 
25 membrane  .  sphingomyelinase  to  generate  free  sphingosine,  thus 
completing  a  complementary  cycle. 
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Diagram  731:  Dual  action  of  sphingosine  on  diacylglycerol  signal  termination 
The  various  routes  which  have  been  used  to  synthesise 
sphingosine  and  related  compounds  are  discussed  in  the  next  Chapter. 
26 CHAPTER  THREE 
Review  of  Sphingosine 
3.1  The  Structure  of  Sphingosine 
Sphingosine  (14)  is  termed  as  a  regulatory  compound2l,  22  and  is 
the  backbone  of  all  sphingolipids.  Such  lipids  are  important  in  cell 
growth,  cell  adhesion  and  cell  recognition.  Since  they  constitute  most  of 
the  cell  membrane,  they  are  compounds  of  increasing  interest  as  they 
should  provide  a  better  insight  into  the  role  and  function  of  cell 
surfaces.  As  discussed  in  Chapter  2,  sphingosine  is  also  important  in 
the  inhibition  of  Protein  Kinase  C.  Unfortunately  only  small  amounts  of 
partially  pure  sphingosine  and  its  derivatives  can  be  extracted  from 
plants  and  mammals.  This  fact  is  the  driving  force  for  organic  chemists 
to  set  up  some  novel  syntheses  in  which  large  amounts  of  sphingosine 
could  be  prepared  in  the  laboratory,  so  that  a  variety  of  sphingolipids 
could  be  synthesised. 
Sphingosine  is  a  2-amino-1,3-diol  with  an  E-double  bond  between 
C-4  and  C-5,  two  chiral  centres  and  a  long  alkyl  chain.  Its  structure  is 
basically  made  up  of  two  parts:  hydrophobic  and  hydrophilic  moieties. 
Since  there  are  two  chiral  centres  present,  there  are  four  possible 
stereoisomers.  Naturally  occurring  sphingosine  has  the  (2S,  3R)-[D- 
erythro]  -configuration. 
27 The  three  approaches  that  have  been  largely,.  used,  for  the 
synthesis  of  sphingosine  involve:  1)  the  use  of  achiral  materials  to 
achieve  synthesis  of  racemic  material;  2)  diastereoselective  synthesis 
from  simple  chiral  starting  materials  such  as  (S)-serine  and  sugar 
compounds;  and  3)  the  use  of  versatile  reactions  such  as  Sharpless 
asymmetric  epoxidation  to  achieve  enantioselective  synthesis.  The 
most  common  disconnection  (Scheme  4)  is  the  breakage  of  the  bond  (b) 
as  the  aminodiol  synthon  is  readily  available  from  (S)-serine  and  many 
natural  sugar  compounds.  Disconnection  (a)  remains  most  attractive 
and  requires  the  synthesis  of  two  new  chiral  centres  in  one  or  two 
steps.  Asymmetric  aldol  reaction  using  a  chiral  auxiliary  is  frequently 
used  to  achieve  the  stereoselectivity.  Racemic,  diastereoselective,  and 
enantioselective  syntheses  of  sphingosine,  in  that  order,  are  covered  in 
the  following  review.  The  literature  survey  presented  here  covers  the 
year  1952  onwards. 
28 Scheme  4:  Retrosynthesis  of  sphingosine 
3.2  Synthesis  of  Racemic  Sphingosine 
This  section  reviews  various  ways  in  which  the  synthesis  of 
racemic  erythro-sphingosine  and  its  derivatives  were  achieved.  Most 
workers  used  an  asymmetric  synthesis  to  prepare  racemic  erythro- 
sphingosine  except  for  the  very  early  literature  where  the  primary  aim 
was  probably  to  synthesise  sphingosine,  irrespective  of  its 
configuration. 
Grob  and  Gadient34  were  the  first  group  to  synthesise  racemic 
sphingosine  and  a  derivative  in  1952.  Their  synthesis  is  one  of  the 
shortest  in  the  literature  but  they  made  no  attempt  to  tackle  the 
stereochemical  problem  and  thus  all  four  stereoisomers  were  formed. 
29 Condensation  of  2-pentadecynal  (15)  with.  2-nitroethanol  gave  all,  four 
stereoisomers  of  2-nitro-4-octadecyn-1,3-diol  (16)  (Scheme  5).  The 
th  re  o  -racemate  .  was  separated  from  the  erythro  -racemate  by 
chromatography.  The  nitro  group  was  then  reduced  with  zinc,  and 
hydrochloric  acid  to  the  amino  group.  Partial  reduction  of  the  triple 
bond  in  the  erythro-racemate  with  lithium  aluminium  hydride  gave 
racemic  erythro-sphingosine  (17)  whereas  on  prolonged  exposure 
under  hydrogen  atmosphere,  the  triple  bond  was  completely  reduced  to 
afford  racemic  erythro-dihydrosphingosine  (18). 
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Scheme  5:  Synthesis  of  (±)-Z-  and  E-erythro-sphingosine  and 
(L)-erythro-dihydrosphingosine  by  Grob  and  Gadient.  34 
An  improved  synthesis  of  racemic  sphingosine  was  developed  by 
Schmidt  and  co-workers  starting  with  a  C16  aß-unsaturated  aldehyde 
(Scheme  6).  35,36  They  had  already  established  the  reaction  conditions, 
in  which  high  diastereoselectivity  would  be  obtained  when  the  a- 
carbanion  of  the  protected  glycine  was  treated  with  a  simple 
C  13H27 
NO2  _C13H27 
(16) 
anti  :  syn  =1.1 
OH 
30 aldehyde.  37  These  conditions  were  then  applied  to  the  condensation  of 
aC  16  aß  -unsaturated  aldehyde  with  the  same  anion  which  afforded 
exclusively  the  erythro-product  (19).  The  stereospecificity  may  be  due 
to  the  size  of  the  disilylated  amino  group  which  disfavours  the 
formation  of  the  Z-enolate.  The  course  of  the  reaction  probably  goes 
through  a  chair-like  transition  state  which  is  held  by  the  lithium  ion. 
Reduction  of  the  amino  acid  with  lithium  aluminium  hydride  followed 
by  triacetylation  gave  racemic  N,  0,0-triacetylsphingosine.  It  was 
important  to  carry  out  the  acetylation  step  as  this  protected  the  amino 
group  from  being  oxidised  in  air. 
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Scheme  6:  Synthesis  of  (±)-erythro-sphingosine  by  Schmidt  et  a1.35,36 
0  1sH27 
In  contrast  to  the  previous  synthesis,  Garigipati  and  Weinreb3  8 
developed  a  more  efficient  route  which  employed  an  intramolecular 
Diels-Alder  reaction  to  construct  the  relative  configuration  on  the  cyclic 
system.  Myristic  aldehyde  was  converted  in  three  steps  into  (Z,  E)  - 
carbamate  (20),  which  upon  treatment  with  thionyl  chloride  and 
pyridine  afforded  sulfinylcarbamate  (21)  (Scheme  7).  Cycloaddition  of 
the  compound  occurred  at  room  temperature  to  give  the  Diels-Alder 
adduct  (22).  The  bicyclic,  product,  upon  treatment  with 
phenylmagnesium  bromide,  underwent  a  2,3-sigmatropic 
rearrangement  via  a  five-membered  ring  transition  state  to  give  the 
desired  product  with  a  E-double  bond.  Basic  hydrolysis  provided  the 
racemic  erythro-sphingosine. 
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Scheme  7:  Synthesis  of  (t)-erythro-sphingosine  by  Garigipati  and  Weinreb.  38 
In  1985  Cardillo  et  al.  39-41  managed  to  achieve  another 
diastereoselective  synthesis  of  racemic  sphingosine,  using  the  same 
starting  material  as  Weinreb's  group.  The  dienol  was  tranformed  into 
its  trischloroacetimidate  (23).  Regioselectivity  of  the  cyclisation  was 
uncertain,  because  compound  (23)  can  either  undergo  a  5-exo  or  6- 
endo  closure  in  the  presence  of  N-iodosuccinimide  (Scheme  8).  Since 
only  the  6-membered  oxazine  ring  was  formed,  the  reaction  must  have 
been  governed  by  an  electronic  factor.  Cleavage  of  the  oxazine  followed 
by  treatment  with  amberlyst  A  26  in  the  carbonate  form  gave  the 
corresponding  unsaturated  aziridine  (24).  Racemic  erythro-N- 
acetylsphingosine  was  produced  in  two  steps:  protonation  of  the 
aziridine  and  regioselective  opening  of  the  ring  with  amberlyst  A  26  in 
uO 
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11 
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32 the  acetate  form.  Basic  hydrolysis  of  racemic  erythro-N- 
acetylsphingosine  afforded  racemic  erythro-sphingosine. 
Scheme  8:  Synthesis  of  (±  )-eiythro-sphingosine  by  Cardillo  et  al.  39  41 
3  .3  Diastereoselective  Synthesis  of  D-ervthro-  phinl;  osine 
This  section  reviews  the  various  diastereoselective  approaches 
that  have  been  used  to  prepare  D-erythro-sphingosine  and  its 
derivatives.  The  idea  was  to  start  the  synthesis  with  homochiral 
starting  material  so  that  it  could  be  used  to  control  the  stereochemical 
outcome  of  the  formation  of  the  new  chiral  centre. 
3.3.1  Diastereoselective  Synthesis  of  D-erythro-Sphingosine 
using  Carbohydrates 
Many  carbohydrates  are  ideal  homochiral  starting  materials  in 
sphingosine  syntheses.  They  are  commercially  available,  inexpensive 
and  their  absolute  configurations  are  known.  In  addition,  their 
functional  groups  are  useful  for  manipulation. 
The  diastereoselective  synthesis  of  D-erythro-sphingosine  and  its 
derivatives  (Scheme  9)  by  Reist  and  Christie,  42,43  commences  from 
33 readily  available  3-amino-3-deoxy-1,2:  5,6-di-O-isopropylidene-a-D- 
allofuranose  (25)  which  was  transformed  in  three  steps  into  its  di- 
protected  aldehyde  (26).  Wittig  condensation  of  the  aldehyde  with 
tetradecyltriphenylphosphonium  bromide  afforded  Z-  and  E-isomers 
(27)  as  a  mixture.  Acid  hydrolysis  of  the  acetal  followed  by  standard 
sodium  periodate  oxidation  and  reduction  reactions  gave  the 
unsaturated  diol  (28).  Hydrogenation  of  the  diol  using  10%  palladium 
on  charcoal  reduced  the  the  double  bond  completely  as  well  as 
removing  the  benzyl  group  to  afford  D-erythro-dihydrosphingosine 
(29).  Interestingly,  when  the  ethyl  carbamate  (30)  was  used  instead  of 
benzyl  carbamate,  Wittig  coupling  in  the  presence  of  lithium  salt  gave 
only  the  E-isomer.  Using  standard  deprotection  steps  as  before,  the 
corresponding  diol  (31)  was  formed.  Basic  hydrolysis  of  the  crude 
product  with  barium  hydroxide  afforded  D-erythro-sphingosine  (14). 
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Scheme  9:  Synthesis  of  D-erythro-sphingosine  and  D-erythro-dihydrosphingosine  by 
Reist  and  Christie.  42,43 
A  similar  approach  was  adopted  by  Ogawa  et  al.  using  1,2:  5,6-di- 
O-isopropylidene-a-D-glucofuranose  as  starting  material  (Scheme 
10).  44,45  Wittig  coupling  was  applied  to  introduce  the  double  bond. 
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35 The  ratio  of  E-alkene  to'  its  Z-isomer  was  43:  57.  The  crucial  difference 
between  this  approach  and  that  of  Reist  and  Christie,  ý  is  that  the  former 
used  irradiation  in  order  to  improve  the  E-  and  Z-ratio  to  94:  6.  The  free 
secondary  alcohol  was  converted  into  its  mesylate  before  carrying  out 
the  three  steps  required  for  transforming  the  acetal  into  the  diol.  The 
diol  was  then  protected  as  a  macrocyclic  structure  (32).  In  order  to 
establish  the  erythro-configuration,  SN  2  displacement  had  to  be 
performed  on  the  mesylate  group  using  sodium  azide.  Reduction  of  the 
azide,  acylation  and  deprotection  gave  D-erythro-ceramide  (33). 
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Scheme  10:  Synthesis  of  D-  erythro-ceramide  by  Ogawa  et  al.  44,45 
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36 Gigg  and  co=workers  "made  full  use  of  oxazoline  chemistry  to 
prepare  intermediates  for  the  synthesis  of  sphingoglycolipids.  The 
strategy  of  this  approach  (Scheme  11)46,47  involves  cleaving  a 
phenyloxazoline  (34)  to  give  a  benzamide  (35),,  which  cyclises  with  the 
mesylate  to  generate  a  new  oxazoline  (36).  Through  the  course  of 
cyclisation  the  erythro-configuration  was  established.  The  epoxide  was 
made  in.  4  steps.  . 
Hydrolysis  of  the  acetal  followed  by  dimesylation  and 
selective  displacement  of  the  primary  mesylate  by  sodium  benzoate 
gave  the  benzoate  (37).  The  benzoate  was  readily  converted  into  the 
oxirane  (38)  with  sodium  methoxide  in  chloroform-methanol. 
Alkylation  with  a  Grignard  reagent,  followed  by  deprotection  of  the 
acetal  gave  the  triol  (39).  This  triol  was  then  converted  into  the  D- 
erythro-sphingosine  phenyloxazoline  derivative  (40). 
Despite  its  length,  the  synthesis  of  (2S,  3R  )-  and  (2S,  3S)- 
sphingosine  developed  by  Obayashi  and  Schlosser48  is  well  designed. 
This  is  because  the  whole  synthesis  can  be  performed  on  a  large  scale 
without  affecting  the  yields.  D-(+)-Mannose  was  transformed  into  the 
bromodihydrofuran  (41)  (Scheme  12).  This  was  the  key  intermediate 
which  underwent  dehalogenation  in  the  presence  of  n-butyllithium  and 
caused  the  5-membered  ring  to  collapse  to  generate  the  carbinol  (42). 
Alkylation  by  the  acetylide  and  SN2  displacement  of  the  mesylate  by 
lithium  azide  gave  the  azide  with  the  desired  stereochemistry.  The  last 
step  involved  reduction  of  the  triple  bond  and  the  azide  as  well  as 
deprotection.  The  success  of  this  synthesis  was  heightened  by  the  fact 
that  threo-sphingosine  was  obtained  via  this  route  by  using  D-(+)- 
ribono-1,4-lactone  as  starting  material. 
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Scheme  11:  Synthesis  of  D-  erythro-sphingosine  by  Gigg  and  co-workers.  46,47 
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Scheme  12:  Synthesis  of  erythro-  and  threo-sphingosine  by  Obayashi  and 
Schlosser.  48 
In  addition  to  the  contribution  made  in  the  synthesis  of  racemic 
sphingosine,  Schmidt  and  Zimmermann49,50  developed  a  route  to  D- 
erythro-sphingosine  starting  from  D-galactose  (Scheme  13).  This  sugar 
was  converted  into  its  4,6-0  -benzylidene-D-galactose  which  upon 
treatment  with  sodium  metaperiodate  provided  the  desired  2,4-0- 
39 benzylidene-D-threose  (43).  However,  in  the  same  year,  Kiso  et  al.  5  1 
showed  that  2,4-O-benzylidene-D-threose  could  be  obtained  from  two 
different  sugars.,  Wittig  coupling  of  the  2,4-O-benzylidene-D-threose 
with  hexadecanylidene  triphenylphosphorane  in  the  presence  of 
lithium  bromide  gave  exclusively  the  E-eiscosentriol  (44).  The 
mesylate  of  the  alcohol  was  converted  into  the  azide  as  before. 
Deprotection  followed  by  reduction  of  the  azide  yielded  D-erythro- 
sphingosine. 
In  contrast  to  the  above  syntheses,  Kamikawa  et  al.  used  'a  six- 
membered  ring  sugar,  as  opposed  to  five,  as  starting  material  and 
achieved  diastereoselective  synthesis  of  D-erythro-sphingosine  (Scheme 
14).  52  Mercuric  ý  ion-assisted  acid  hydrolysis  of  3,4,6-tribenzyloxy-D- 
galactal  yielded  hydroxy-E-enal  (45).  Reduction  of  the  aldehyde  gave 
the  diol  which  was  then  protected  as  the  diacetate  (46).  Coupling  of 
dodecylmagnesium  bromide  cuprate  with  the  allyl  acetate  gave  the 
desired  a  -substitution  product.  Displacement  of  the  acetate  group  to 
obtain  the  azide  with  complete  inversion  of  the  stereochemistry  was 
carried  out  via  three  steps:  methanolysis,  mesylation  and  formation  of 
the  azide.  Reduction  of  the  azide  followed  by  deprotection  gave  D- 
erythro-sphingosine. 
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Scheme  13:  Synthesis  of  D-erythro-sphingosine  by  Schmidt  and 
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Scheme  14:  Synthesis  of  D-  erythro-sphingosine  by  Kamikawa  et  a1.52 
Adopting  a  new  approach,  Inazu  et  al.  carried  out  the  synthesis  of 
D-erythro-sphingosine  by  starting  from  2,3-O-isopropylidene-D- 
glyceric  acid  methyl  ester  (47),  which  when  coupled  with  dimethyl 
methylphosphonate,  generated  the  phosphonate  (48)  (Scheme  15).  5  3 
Wittig  condensation  with  myristic  aldehyde  in  the  presence  of  caesium 
carbonate  gave  exclusively  the  E  -product  (49).  High 
diastereoselectivity  in  the  reduction  of  the  unsaturated  ketone  was 
achieved  with  L-Selectride.  Hydrolysis  of  the  acetal  followed  by 
treatment  of  the  triol  with  benzaldehyde  afforded  the  six-membered 
ring  acetal.  Displacement  of  the  free  hydroxyl  group  by  sodium  azide 
with  inversion  of  stereochemistry  was  achieved  in  the  usual  manner 
(mesylation  and  formation  of  the  azide).  Reduction  of  the  azide 
followed  by  deprotection  gave  D-erythro-sphingosine. 
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Scheme  15:  Synthesis  of  D-erythro-sphingosine  by  Inazu  et  al.  53 
3.3.2  Diastereoselective  Synthesis  of  D-e  ry  th  ro  -Sphingosinc 
using  Serine 
Another  homochiral  building  block  which  has  made  an  important 
impact  in  the  diastereo  selective  synthesis  of  D-erythro-sphingosine  is 
(S)-serine.  Use  of  serine  as  a  'starting  material  has  an  advantage  over 
most  sugars.  There  is  no  need  to  carry  out  the  typical  three  steps 
which  convert  the  threo-triol  into  its  erythro-aminodiol  as  the  amino 
group  is  already  present  in  serine. 
Newman54  reported  a  short  and  highly  stereoselective  synthesis 
of  D-erythro-sphingosine  in  1973.  (S)-Serine  was  converted  into  the 
aldehyde  (50)  by  N-phthaloylation,  O-acetylation,  acid  chloride 
formation  and  catalytic  hydrogenation  (Scheme  16).  Addition  of  trans- 
pentadecenyldiisobutylalane  to  the  aldehyde  gave  a  4:  1  mixture  of 
erythro-  and  threo-isomers.  The  diastereoisomers  were  separated  by 
chromatography.  The  conformation  of  the  aldehyde  controlled  the 
43 outcome  of  the  diastereomeric  mixture.  Fortunately  the  preferred 
conformation,  according  to  the  proton  NMR  spectrum,  was  the  one  that 
gave  predominantly  the  a  ry  th  ro-isomer,  when  attacked  by  the 
organometallic  reagent. 
Scheme  16:  Synthesis  of  D-erythro-sphingosine  by  Newman.  54 
The  approach  adopted  by  Tkaczuk  and  Thornton55  was  based  on 
the  sphingosine  synthesis  of  Newman.  (S)-Serine  methyl  ester56  was 
protected  as  an  oxazoline  which  was  then  reduced  to  the  aldehyde  with 
diisobutylaluminium  hydride  (Scheme  17).  Treatment  of  this  aldehyde 
with  E-pentadecenyldiisobutylalane  gave  the  sphingosine  oxazoline  and 
its  epimer  as  a  1:  1  mixture.  These  isomers  could  be  separated 
chromatographically.  Acid  hydrolysis  of  the  erythro-isomer  followed 
by  N-acylation  with  p-nitrophenyl  oleate  afforded  the  corresponding  D- 
erythro-N-oleoyl-  l  -O-benzoylsphingosine.  Base  hydrolysis  provided  D- 
erythro-ceramide  (33). 
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Scheme  17:  Synthesis  of  erythro-  and  threo-  sphingosine  derivatives  by  Tkaczuk  and 
Thornton.  55 
Kozikowski  and  Wa57  were  the  first  group  to  incorporate  fluorine 
into  sphingosine.  Fluorine  is  a  good  replacement  for  an  hydroxyl  group 
because  they  are  similar  in  size  and  fluorine  can  also  act  as  a  hydrogen 
bond  acceptor.  D-erythro-Sphingosine  oxazoline  was  prepared  using 
the  procedure  of  Tkaczuk  and  Thornton.  55  Reaction  of  sphingosine 
oxazoline  with  2-chloro-1,1,2-trifluorotriethylamine  afforded  the 
corresponding  fluoro  derivative  (51)  as  well  as  the  allylic 
CsFi5/ 
45 rearrangement  product  (52)  (Scheme  18).  Since  the  fluoro  derivative 
(51)  was  isolated  as  a  single  stereoisomer,  the  reaction  must  have 
occurred  via  an  SN2  mechanism.  Hydrolysis  of  the  oxazoline  gave  E- 
threo-2-amino-3-fluoro-octadec-4-en-l-ol  (53). 
Scheme  18:  Synthesis  of  a  fluorine-containing  isostere  of  sphingosine  by 
Kozikowski  and  Wa.  57 
A  new  improved  procedure  had  been  developed  by  Garner  et  al. 
for  the  synthesis  of  D-erythro-sphingosine  from  another  stable 
protected  serine  aldehyde  (Scheme  19).  58  The  efficacy  of  this 
aldehyde  as  a  chiral  building  block  was  also  demonstrated  by  Herold,  5  9 
Liotta  et  al.  60  and  Radunz  et  al.  61  N-BOC-(S)-Serine  methyl  ester  was 
transformed  into  the  aldehyde  (54)  by  acetalisation  and  reduction  with 
diisobutylaluminium  hydride.  Treatment  with  1-pentadecynyllithium 
gave  the  corresponding  erythro-sphingosine  2,2-dimethyloxazolidine 
and  its  epimer  as  a  9:  1  mixture.  These  diastereoisomers  were  readily 
separated  chromatographically.  Birch  reduction  followed  by  acid 
hydrolysis  afforded  D-erythro-sphingosine.  However,  on  exposure  to 
Lindlar  hydrogenation  cis-erythro-sphingosine  was  obtained. 
Interestingly,  high  threo-selectivity  was  observed  on  addition  of  1- 
pentadecynyllithium  to  the  aldehyde  in  the  presence  of  anhydrous  zinc 
bromide  with  dry  ether  as  a  solvent.  It  is  noteworthy  that  the  2,2- 
46 dimethyloxazolidine  (55)  and  its  epimer  can  be  interchanged  via  a 
Mitsunobu  inversion  at  the  C-3  centre. 
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Scheme  19:  Synthesis  of  D-erythro-sphingosine  by  Garner  et  a1.,  58  Herold,  59  Liotta 
et  a1.60  and  'Radunz  et  a1.61 
In  contrast  to  the  synthesis  of  Garner  et  al.,  Rapoport  and 
Boutin62  took  two  steps  to  synthesise  the  ynol  (56)  instead  of  one.  a'- 
Amino-ap  -ynone  was  synthesised  initially  and  then  treated  with 
sodium  borohydride  to  achieve  the  diastereoselectivity  (Scheme  20). 
N-Z-(S)-Serine  was  reacted  with  isobutylchloroform  ate  to  generate  a 
mixed  anhydride  which  was  then  quenched  with  isoxazolidinc.  N-Z-(S)- 
Serine  isoxazolidide  (57),  being  analogous  to  Weinreb's  amide  deserves 
to  be  mentioned.  This  amide  can  only  react  with  one  mole  of  the 
nucleophile,  due  to  the  lithium  ion  complexing  to  both  oxygens,  giving 
rise  to  a  stable  intermediate  which  cannot  undergo  further  alkylation. 
Alkylation  of  the  amide  (57)  with  an  excess  of  1-pentadecynyllithium 
afforded  the  corresponding  ap-ynone.  Diastereoselective  reduction  of 
the  ketone  with  sodium  borohydride  gave  anti-  and  syn-isomers  as  a 
H 
(54) 
OH 
0 
HN 
ýL 
O- 
47 4:  1  mixture.  Chromatography  followed  by  Birch  reduction  afforded  D- 
erythro-sphingosine  and  its  epimer. 
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Scheme  20:  Synthesis  of  D-erythro-sphingosine  by  Rapoport  and  Boutin.  62 
3.4  Enantioselective  Synthesis  of  Sphingosine 
Enzymic  reaction,  Sharpless  asymmetric  epoxidation  and 
asymmetric  aldol  reaction  are  the  three  approaches  that  have  been 
frequently  employed  to  introduce  the  stereochemical  centres  in  one 
step.  Only  a  few  groups  have  employed  enzymes  to  achieve 
enantioselective  synthesis.  In  most  cases,  epoxidation  and  the  aldol 
reaction  are  more  favoured. 
Earlier  work  of  enantioselective  synthesis  of  D-erythro- 
sphingosine  via  Sharpless  asymmetric  epoxidation  was  carried  out  by 
V  as  el  la  et  al.  6  3,64  The  enynol  (58)  was  synthesised  from 
epichlorohydrin  as  shown  in  Scheme  21.  Sharpless  asymmetric 
epoxidation  of  the  enynol  gave  the  desired  epoxide  and  the  free  alcohol 
was  then  converted  into  a  carbamate.  This  carbamate  was  then 
subjected  to  sodium  hydride  to  generate  the  nitrogen  anion.  The  key 
ýr 
N  H2 
48 step  in  this  synthesis  was  the  regioselective  intramolecular  opening  of 
the  oxirane  by  the  nitrogen  anion  of  the  carbamate  to  afford  the 
erythro-carbamate  (59).  Treatment  with  lithium  and  ethylamine 
afforded  selective  reduction  of  the  triple  bond  and  debenzylation.  Basic 
hydrolysis  of  the  oxazolidinone  gave  D-erythro-sphingosine. 
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Scheme  21:  Synthesis  of  D-  erythro-sphingosine  by  Vasella  et  a/.  63,64 
In  an  approach  to  (+)-aplidiasphingosine,  Mori  and  Umemura 
prepared  the  key  intermediate  triene  (60),  from  optically  pure  (R)- 
methyl  citronellate  in  16  steps  (Scheme  22).  65  The  triene  (60)  was 
epoxidised  with  tert-butylhydroperoxide  in  the  presence  of  titanium 
(IV)  isopropoxide  and  (+)-diethyl  tartrate  to  give  the  epoxy  alcohol 
(61).  Cleavage  of  the  oxirane  with  ammonia  gave  a  (3:  1)  mixture  of 
diastereoisomers.  Both  isomers  were  purified  by  column 
chromatography.  The  absolute  stereochemistry  of  the  threo- 
aplidiasphingosine  was  confirmed  by  direct  comparison  with  the 
natural  product. 
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49 Scheme  22:  Synthesis  of  (+)-aplidiasphingosine  by  Mori  and  Umemura.  65 
A  new  route  was  established  by  Katagawa  et  al.  in  which  all 
sphingosine  stereoisomers  were  synthesised  from  Z-  and  E-1,4- 
butenediol  (Scheme  23).  66  Z-1,4-Butenediol,  used  to  prepare  D-threo- 
sphingosine,  was  converted  into  its  (2R,  3  S)-epoxide  in  4  steps: 
monoacylation  of  the  diol,  protection  of  the  free  alcohol,  alkaline 
hydrolysis  of  the  acetate  to  generate  the  allyl  alcohol  system  and 
Sharpless  epoxidation.  Upon  treatment  with  Ti(OiPr)2(N3)2,  the 
epoxide  was  opened  regioselectively  to  give  the  1,3-diol  (62).  It  was 
converted  into  the  aldehyde  (63)  through  successive  reactions: 
diprotection  of  the  diol,  reduction  of  the  azide,  N-acetylation,  selective 
deprotection  and  Swern  oxidation.  Wittig  condensation  of  the  aldehdye 
(63)  with  tetradecyltriphenylphosphonium  bromide  gave  a  mixture  of 
Z-  and  E-isomers.  The  ratio  of  this  mixture  was  improved  in  favour  of 
the  E-isomer  by  irradiation  of  the  crude  product  in  the  presence  of 
diphenyldisulfide.  Removal  of  the  protecting  groups  afforded  D-threo- 
50 sphingosine.  Interestingly  opening  of  the  (2R,  3R)-epoxide  with  azide 
led  to  a  mixture  of  1,2-diol  (64)  and  1,3-diol  (65)  in  the  ratio  of  1:  14. 
Using  the  same  conditions  as  before,  the  1,3-diol  was  then  transformed 
into  D-erythro-sphingosine. 
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Scheme  23:  Synthesis  of  erythro-  and  threo-sphingosine  by  Katagawa  et  al.  ss 
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51 Nicolaou  et  al.  reported  enantioselective  synthesis  of  sphingosine 
using  an  asymmetric  aldol  reaction  with  an  aß-unsaturated  aldehyde 
(Scheme  24).  67  The  strategy  was  based  on  the  work  of  Evans  and  co- 
workers.  68  The  oxazolidinone  derivative  (66)  was  transformed  into  its 
boron  enolate  and  condensed  with  C16  aß-unsaturated  aldehyde  to 
afford  a  mixture  of  syn-adducts.  The  diastereoisomers  were  separated 
by  column  chromatography.  SN2  displacement  of  the  bromide  with 
sodium  azide  gave  the  corresponding  azide.  Silylation  of  the  secondary 
alcohol  followed  by  reductive  cleavage  of  the  chiral  auxiliary  provided 
the  monoprotected  alcohol  (67).  Finally,  D-erythro-sphingosine  was 
obtained  by  desilylation  and  reduction  of  the  azide. 
1)  Bu2BOTf,  NEt3 
)W- 
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3)  H202 
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C  13H27 
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Scheme  24:  Synthesis  of  D-erythro-sphingosine  by  Nicolaou  et  al.  67 
C 
13H27 
The  key  step  of  the  synthesis  of  Ito  et  al.  69  was  to  employ  the 
chiral  (aminoalkyl)ferrocenylphosphine-gold  (I)  complex  to  catalyse  the 
asymmetric  aldol  reaction  (Scheme  25).  Reaction  of  C16  aß-unsaturated 
syn  :  anti  =  95:  5 
52 aldehyde  with  methyl  isocyanoacetate  (68)  in  the  presence  of  this 
complex  gave  a  quantitative  yield  of  methyl  5-[(E)-l-pentadecenyl]-2- 
oxazoline-4-carboxylate  consisting  of  anti-  and  syn-isomers  in  a  ratio  of 
89:  11.  A  chiral  shift  reagent,  Eu(dcm)3,  was  used  to  calculate  the 
enantiomeric  excess.  Hydrolysis  and,  reduction,  followed  by  acetylation 
provided  the  D-threo-N-  acetylsphingosine.  Synthesis  of  D-erythro- 
sphingosine  was  readily  achieved  from  the  threo-isomer  by  carrying 
out  a  Mitsunobu  inversion  at  C-3. 
CN 
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Scheme  25:  Synthesis  of  erythro-  and  threo-  sphingosine  by  Ito  et  a!.  69 
Schollkopf  et  al.  developed  a  new  enantioselective  synthesis  of  D- 
erythro-sphingosine  via  an  asymmetric  aldol  reaction  from  the 
bislactim.  ether  of  cyclo-(L-Val-Gly)  (69)  (Scheme  26).  70  Aldol  addition 
of  the  lithiated  derivative  of  the  bislactim  ether  to  an  aß-unsaturated 
aldehyde  normally  gave  exclusively  the  syn-adduct  with  high 
diastereoselectivity.  However,  when  the  C16  aß-unsaturated  aldehyde 
53 was  used,  a  1:  1  mixture'  of  syn-and  anti-adducts  was  observed.  The 
yield  of  the  hydrolysis  step  was  improved  when  the  hydroxyl  group 
was  protected.  Reduction  of  the  ester  followed  by  debenzylation  with 
lithium  and  ethylamine  afforded  D-erythro-sphingosine. 
Scheme  26:  Synthesis  of  D-erythro-sphingosine  by  Schollkopf  et  a1.70 
A  ..  _  lengthy  enantioselective  sphingosin-  synthesis  via  enzymic 
reaction  was  reported  by  Findeis  and  Whitesides  (Scheme  27).  71 
Fumarase  (E.  C.  4.2.1.2)  was  used  to  transform  achiral  chlorofumaric  acid 
into  L-threo-chloromalic  acid  by  stereospecific  hydration  of  the  carbon- 
carbon  double  bond.  Reduction  of  the  diacid  followed  by  acetalisation 
gave  the  corresponding  hydroxy  acetonide  which,  upon  treatment  with 
benzyl  isocyanate  gave  the  carbamate  (70). 
, 
Deprotonation  of  the  Nil 
resulted  in  a  direct  SN2  displcement  of  the  chloride.  The  acetal  was 
converted  into  its  aldehyde  (71)  in  5  steps.  Reaction  of  the  aldehyde 
with  lithiated  phenyl  n-tetradecanyl  sulfone  followed  by  acetylation 
yielded  the  acetoxy  sulfone  as  a  mixture  of  diastereoisomers,  which  on 
Na-Hg  reduction  produced  predominantly  the  E-alkene.  Debenzylation 
followed  by  basic  hydrolysis  gave  D-erythro-sphingosine. 
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Scheme  27:  Synthesis  of  D-erythro-sphingosine  by  Findeis  and  Whitesides.  71 
3.5  Conclusion 
The  importance  of  sphingosine  is  emphasised  by  the  high  number 
of  papers  published  over  the  last  40  years.  Since  the  work  has  been 
carried  out  worldwide,  its 
-importance  must  be  fundamental. 
.  Although 
there  are  many  different  and  reliable  sphingosine  syntheses,  this  area 
of  research  will  remain  active  until  the  role  of  sphingosine  derivatives 
becomes  clear.  Therefore  organic  chemists  will  continue  to  try  to 
develop  novel  and  more  efficient  syntheses,  thus  making  sphingosine 
derivatives  more  readily  available  for  biological  evaluation. 
55 CHAPTER  FOUR 
Synthesis  and  Biological  Evaluation  of  Phenylalaninol  and 
(1S,  2S)-2-Amino-l-phenylpropane-1,3-diol  Derivatives 
4.1  Introducton 
The  initial  aim  of  this  project  was  to  establish  simple  and  reliable 
methods  for  carrying  out  acylation,  methylation  and  dimethylation  of  a 
primary  amino  group  in  compounds  which  arc  analogues  of 
sphingosine.  Various  groups  attached  to  the  amino  group  of 
sphingosine  have  been  shown  to  play  an  important  role  in  the 
inhibition  of  both  PKC  and  PAP  enzymes.  2  6  N,  N-  Dimethy  1- 
sphingosine27  for  instance  was  found  to  be  a  better  inhibitor  of  PKC 
and  PAP  enzymes  than  sphingosine  itself.  Sphingosine  was  not 
employed  as  the  starting  material  in  our,  work  because  of  its  cost. 
Cheaper  alternatives  were  used  instead.  (R)-Phenylalaninol  (72),  (S)- 
phenylalaninol  (73)  -  and  (lS,  2S)-2-amino-l-phenylpropane-l,  3-diol 
(74)  were  used  to  establish  the  key  reactions.  They  arc  commercially 
available  and  were  chosen  because  they  have  features  in  common  with 
sphingosine  such  as  functional  groups  in  similar  positions  and  a 
hydrophobic  region. 
OH 
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4.2  Synthesis  of  Phenylalaninol  Analogues 
N-Acetylation 
The  synthesis  of  these  known  compounds  proved  to  be 
straightforward  under  standard  conditions.?  2  (R  )-N,  0- 
56 Diacetylphenylalaninol  (75)  and  its  enantiomer  (76)  were  prepared 
using  acetic  anhydride  and  pyridine  in  THE  These  compounds  were 
isolated  in  greater  than  80%  yield.  Being  enantiomers,  both  have  the 
same  spectroscopic  properties  but  different  signs  for  the  optical 
rotation.  Their  IR  spectra  showed  strong  absorptions  at  1684  and  1772 
cm-1  due  to  the  amide  carbonyl  and  the  ester  carbonyl  respectively. 
Their  1H  NMR  spectra  showed  two  singlets  at  1.96  and  2.10 
corresponding  to  the  methyl  groups. 
N-Methylation 
N-Methylation  of  the  primary  amine  in  compounds  (72),  (73)  and 
(74)  cannot  be  achieved  selectively  using  methyl  iodide  and  a  base. 
The  problem  lies  in  the  fact  that  the  monomethylated  products  are 
likely  to  be  more  reactive  than  the  starting  material.  The  inductive 
effect  of  the  methyl  group  makes  the  product  able  to  react  further  to 
generate  N,  N-dimethylated  and  N,  N,  N-timethylated  products.  Even 
with  the  use  of  one  equivalent  of  methyl  iodide,  the  problem  is  still  not 
resolved  because  as  soon  as  the  product  is  formed,  it  will  compete  with 
the  starting  material  for  methyl  iodide. 
In  order  for  mono-methylation  to  take  place,  the  nitrogen  of  (S)- 
phenylalaninol  (73)  had  to  be  protected  as  its  butyloxycarbonyl 
derivative  (Scheme  28).  This  protection  was  carried  out  as  described?  3 
with  di-tert-dibutyldicarbonate  in  dioxane  and  water.  The  product  (77) 
was  isolated  in  96%  yield  after  chromatography.  The  IR  spectrum  of 
the  compound  showed  absorptions  at  1686  and  3418  cm-  1 
corresponding  to  the  carbamate  carbonyl  and  the  hydroxyl  groups 
respectively.  The  BOC  group  gave  a  characteristic  resonance  in  the  111 
NMR  spectrum  of  a  singlet  at  8  1.41  due  to  the  tert-butyl  group. 
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Scheme  28:  Synthesis  of  (S)-N,  O-dimethylphenylalaninol 
Coggins  and  Benoiton74  had  prepared  a  variety  of  N-methylated 
derivatives  from  N-BOC  derivatives  using  sodium  hydride  and  methyl 
iodide  in  THE  Methylation  of  (S)-N-BOC-phenylalaninol  using  these 
conditions  gave  the  desired  N-methylated  methyl  ether  (78)  in  5% 
yield.  The  IR  spectrum  of  the  amine  showed  a  strong,  absorption  at 
2850  cm-1  due  to  the  stretching  of  the  CH.  The  1H  NMR  spectrum 
showed  two  methyl  singlets  at  8  2.30  and  3.18  due  to  the  N-methyl  and 
O-methyl  groups  respectively. 
However  this  reaction  also  gave  two  unexpected  products:  the 
cyclic  carbamate  (79)  and  N-BOC-O-methylphenylalaninol  (80).  Since 
three  equivalents  of  sodium  hydride  were  used,  the  dianion  of  N-BOC- 
phenylalaninol  could  have  formed  initially  as  an  intermediate  (81) 
which  can  be  methylated  on  the  nitrogen  and  oxygen  atoms.  O- 
Methylation,  in  theory,  was  more  favoured  because  the  nitrogen  site  is 
sterically  hindered  by  the  tert-butyl  group  as  well  as  being  less 
58 nucleophilic  than  the  alkoxide.  However,  once  the  oxygen  atom  was 
methylated  (82),  the  yield  of  the  product  (78)  suggested  that  the 
nitrogen  was  reluctant  to  carry  out  further  alkylation.  When  N- 
methylation  occurred  first,  the  nucleophilic  oxygen  ,  attacked  either 
another  mole  of  methyl  iodide  to  give  the  product  (78),  or  the 
carbamate  carbon  causing  an  expulsion  of  the  tert-butoxide  to  afford 
the  cyclic  carbamate  (79).  The  proposed  mechanisms  are  shown  in 
Scheme  29.  The  IR  and  1H  NMR  spectra  of  N-  BO  C-  O-  methy  1- 
phenylalaninol  were  similar  to  those  of  (78).  The  IR  spectrum  of  the 
cyclic  carbamate  showed  absorption  at  1750  em-1  corresponding  to  the 
stretching  of  the  carbamate  carbonyl  bond.  The  1H  and  13C  NMR 
spectra  of  the  carbamate  showed  no  resonance  in  the  region  expected 
for  the  methyl  groups  of  the  tert-butyl  group. 
Scheme  29:  Formation  of  N-methylated  product  and  by-products 
59 The  final  step  was  to  deprotect  the  BOC  group  of  (78)  with  1M  HCl 
in  ethyl  acetate  to  give  (S)-N,  O-dimethylphenylalaninol  (83).  The  IR 
spectrum  of  the  poduct  showed  a  broad  absorption  ca.  3431  em-1  for 
the  NH  stretch,  and  the  loss  of  the  absorption  corresponding  to  the 
carbamate  carbonyl  group.  The  IH  and  13C  NMR  spectra  also  showed 
the  disappearance  of  the  BOC  group. 
To  minimise  the  above  side  reactions  it  was  necessary  to  protect 
the  hydroxyl  group  of  N-BOC-phenylalaninol.  It  was  protected  as  the 
tert-butyldimethylsilyl  ether  (84)  (Scheme  30)  which  was  prepared 
using  imidazole  and  tert-butyldimethylsilyl  chloride  (TBDMSCI)  and 
DMF.  The  yield  of  the  reaction  was  89%.  The  IR  spectrum  of  (84) 
showed  absorptions  at  1089  and  840  cm-1  due  to  the  stretching  of  the 
Si-O  bond.  The  1H  NMR  spectrum  showed  a  singlet  at  8  -0.03  due  to  the 
geminal  dimethyl  groups  attached  to  the  silicon,  and  a  singlet  at  8  0.88 
corresponding  to  the  methyl  groups  of  the  tert-butyl  group. 
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Scheme  30:  Attempted  synthesis  of  N-methylphenylalaninol 
Methylation  of  N-BOC-O-TBDMS-phenylalaninol  (84)  using  sodium 
hydride  and  iodomethane  was  unsuccessful  giving  mainly  the  starting 
material.  The  conditions  for  this  reaction  were  varied  as  shown  in 
Table  1.  As  shown  in  Table  1,  no  success  was  achieved  despite  the 
range  of  solvents,  temperature  and  time. 
60 Table  l 
Reagents  Conditions  Product 
MeI  (7  equiv.  ),  room  temperature,  starting  material,  80% 
NaH  (1.5  e  uiv.  ),  THE  24  h 
Mel  (7  equiv.  ),  room  temperature,  starting  material,  50% 
NaH  (3  equiv.  ),  THE  24  h 
Mel  (7  equiv.  ),  reflux  3  h,  starting  material  and 
NaH  (3  equiv.  ),  THE  24  h  product 
MeI  (7  equiv.  ),  room  temperature,  starting  material,  70% 
NaH  (1.5  e  uiv.  ),  DMF  24  h 
Mel  (7  equiv.  ),  reflux  3  h,  starting  material  and 
NaH  (3  equiv.  ),  DMF  24  h  product 
Grieco  and  Bahsas7  5  reported  a  novel  method  for  the  N- 
methylation  of  a  variety  of  amino  acid  derivatives  and  dipeptides  via  a 
retro  aza  Diels-Alder  reaction,  see  Scheme  31.  Two  key  features  in  this 
reaction  make  it  an  attractive  method  of  N-methylation.  Firstly,  it 
proceeds  without  racemisation  and  also,  only  the  amino  group  will  react 
so  protection  of  the  hydroxyl  group  is  not  required.  The  reaction  was 
reported  to  proceed  via  the  acid-catalysed  formation  of  the  iminc 
adduct  of  the  amino  acid  and  formaldehyde,  and  subsequent  trapping 
of  this  adduct  via  an  aza  Diels-Alder  reaction.  The  retro  aza  Diels-Alder 
reaction  then  proceeded  smoothly  in  the  presence  of  trifluoroacetic 
acid.  Triethylsilane  reduced  the  liberated  immonium  ion  to  the  N- 
methyl  compound. 
Scheme  31:  N-Methylation  of  amino  acids  and  dipeptides  via  retro  aza 
75  Diets-Alder  reactions  by  Grieco  and  Bahsas. 
61 Treatment  of  (S)-phenylalaninol  (73)  with  formaldehyde,  acetic 
acid  and  cyclopentadiene  gave  the  corresponding  aza  Diels-Alder 
product  (85)  as  a  mixture  of  diastereoisomers  (Scheme  32).  These 
diastereoisomers  did  not  need  to  be  separated  because  they  would  give 
the  same  N-methylated  product  ,  on  reduction.  The  expected 
absorptions,  due  to  the  stretching  of  O-H  and  C=C  groups,  were  found  at 
3401  and  1680  cm-1  respectively.  The  1H  NMR  spectrum  was  complex 
but  it  was  clear  that  the  resonances  at  S  5.94  and  6.25  must  be  due  to 
the  alkene  hydrogens.  Fortunately,  the  13C  NMR  spectrum  of  (85)  was 
more  informative.  All  the  signals  were  accompanied  by  a  smaller  signal 
indicating  that  it  was  a  diastereomeric  mixture.  The  reduction  step 
failed  to  generate  the  N-methylated  compound.  A  variety  of  reducing 
agents  was  employed  but  none  of  them  proved  to  be  successful.  This 
reaction  was  abandoned. 
Scheme  32:  Attempted  synthesis  of  N-methylphenylalaninol  via  a 
retro  aza  Diels-Alder  reaction 
The  last  method  employed  to  form  the  N-methylated  product  was 
reductive  formylation  of  the  amine.  Meier  and  Ruechardt76  reported  a 
general  procedure  for  making  N-acylated  derivatives  using  carboxylic 
acids.  In  their  procedures,  salts  were  obtained  when  carboxylic  acids 
were  treated  with  ammonia  or  amines.  The  salts  could  be  pyrolysed  to 
62 give  amides.  Treatment  of  (S)-phenylalaninol  with  excess  formic  acid 
and  toluene  under  reflux  gave  the  diformylated  product  (86)76  in  83% 
yield  after  purification  by  column  chromatography  (Scheme  33).  The 
IR  spectrum  of  (86)  showed  absorptions  at  1668,1718  and  3400  em-1 
corresponding  to  the  stretching  of  amide  carbonyl,  ester  carbonyl  and 
N-H  respectively.  The  IH  NMR  spectrum  showed  a  broad  singlet  at  8 
8.07  with  a  relative  intensity  of  2  due  to  the  two  hydrogens  adjacent  to 
the  carbonyls. 
Scheme  33:  Synthesis  of  N-methylphenylalaninol 
Reduction  of  the  diformylated  product  (86)  was  carried  out  using 
lithium  aluminium  hydride  in  THE  and  gave  the  N-methylated  product 
(87)  in  74%  yield  after  purification  by  column  chromatography.  The 
compound  seemed  to  be  pure  by  TLC  but  both  its  1H  and  13C  NMR 
spectra  showed  that  it  was  only  partially  pure.  Further  purification  on 
silica  column,  chromatography  was  attempted  but  without  any  success. 
The  impurity  was  not  the  starting  material  since  the  1H  NMR  spectrum 
proved  the  reduction  had  gone  to  completion  as  the  resonance  at  6  8.07 
had  disappeared.  Also  present  in  the  lH  NMR  spectrum  was  a  sharp 
singlet  at  8  2.33  corresponding  to  the  N-methyl  group.  This  resonance 
was  accompanied  by  a  small  sharp  singlet  at  8  2.28  probably  due  to  the 
impurity. 
63 N,  N,  -Dimethvlation 
Feldkamp  et  al.  77  reported  a  simple  one-pot  method  for  N,  N- 
dimethylation  via  reductive  amination.  The  reaction  was  reported  to 
proceed  via  the  acid-catalysed  formation  of  the  imine  adduct  of  the 
primary  amine  and  formaldehyde,  which  was  subsequently  reduced 
with  hydrogen  gas  over  a  palladium  and  charcoal  catalyst.  Due  to  the 
fact  that  the  N-methylated  product  still  contained  an  N-H  group,  the 
reductive  amination  could  be  repeated  a  second  time  to  yield  a  N,  N- 
dimethylated  derivative.  Treatment  of  (S)-phenylalaninol  with  acetic 
acid,  formaldehyde,  hydrogen,  palladium  and  charcoal  afforded  the 
known  N,  N-dimethylated  product  (88)78  (Scheme  34).  The  product 
was  isolated  in  54%  yield  after  column  chromatography.  The  IR 
spectrum  showed  an  absorption  at  3390  cm-1  corresponding  to  the 
hydroxyl  group.  The  1H  NMR  spectrum  showed  a  sharp  singlet  at  8 
2.56  due  to  the  methyl  groups  attached  to  the  nitrogen. 
Scheme  34:  Synthesis  of  N,  N-dimethylphenylalaninol 
An  unexpected  product,  (S)-3-methyl-4-benzyloxazolidine  (89), 
was  also  isolated  in  this  reaction.  One  possible  way  this  by-product  was 
generated  is  shown  in  Scheme  35.  Since  4-benzyloxazolidine  (90)  did 
not  form  as  a_  by-product-  in  this  reaction,  this  may  suggest  that  the 
reduction  of  the  immonium  ion  was  faster  than  the  cyclisation  of  the 
alcohol  to  the  imine.  However,  when  the  secondary  immonium  ion  was 
64 formed,  the  reduction  was  slower,  and  some  of  the  secondary  imine  had 
cyclised  to  form  (S)-3-methyl-4-benzyloxazolidine  (89).  The  IR 
spectrum  of  this  "  compound  only  showed  absorptions  of  C-H  stretches. 
The  1H  NMR  spectrum  showed  a  methyl  singlet  at  S  2.47  due  to  the  N- 
methyl  group.  Also  an  AB  pattern  was  observed  at  8  4.01  and  4.39 
with  a  geminal  coupling  constant  of  4.4  Hz.  These  signals  were  slightly 
more  deshielded  than  a  typical  0-methyl  group,  suggesting  that  the  CH2 
group  must  be  sandwiched  between  an  oxygen  atom  and  an  electron 
withdrawing  group.  Similar  results  were  obtained  when  the  other 
enantiomer  (72)  was  subjected  to  the  reaction  conditions  of  Feldkamp 
et  al.  77 
Scheme  35:  Formation  of  N,  N-dimethylphenylalaninol  and  by-product 
65 N  N,  N-Trimethylation 
(S)-N,  N,  N-Trimethylphenylalaninol  iodide  (91)79  was  prepared  in 
61%  yield  by  treatment  of  (88)  with  methyl  iodide  in  diethyl  ether 
(Scheme  36).  The  expected  absorption  due  to  the  OH  '  was  found  at  3200 
cm-1.  The  IH  NMR  spectrum  showed  a  singlet  at  S  3.21  for  the  methyl 
groups  attached  to  the  nitrogen.  Although  small  traces  of  impurities 
were  present  according  to  the  1H  spectrum,  compound  (91)  was 
sufficiently  pure  for  biological  testing. 
Scheme  36:  Synthesis  of  N,  N,  N-trimethylphenylalaninol  iodide 
4.3  Synthesis  of  (1S,  2S)-2-Amino-l-pl  en  o  pane-1,3- 
diol  Derivatives 
With  the  reaction  conditions  established  for  N-acetylation,  N- 
methylation,  N,  N-dimethylation  and  N,  N,  N-trimethylation  of  an  aminol, 
it  was  of  great  interest  to  see  whether  these  conditions  could  be  applied 
to  (1S,  2S)-2-amino-l-phenylpropane-1,3-diol,  an  aminodiol.  The  extra 
hydroxyl  group  proved  to  be  more  problematic  than  anticipated.  More 
side  products  were  observed.  N-Methylation  using  sodium  hydride  and 
methyl  iodide  proved  to  be  unsuccessful  as  expected.  In  the  case  of 
reductive  formylation,  triformylation  of  the  aminodiol  occurred. 
Although  apparently  pure  by  TLC,  both  lH  NMR  and  13C  NMR  spectra 
showed  that  there  were  extra  signals  present.  This  mixture  could  not 
be  purified  further  by  column  chromatography.  It  was  decided  to  carry 
out  the  reduction  with  this  partially  purified  product.  The  reduction 
step  yielded  a  complex  mixture  from  which  the  desired  product  could 
not  be  isolated.  Although  N-methylation  of  2-amino-l-plhenylpropane- 
1,3-diol  did  not  occur  with  the  established  reaction  conditions,  a  new 
synthesis  was  devised  to  carry  out  N-methylation  specifically  on  an 
aminodiol.  It  was  the  success  of  this  synthesis  that  opened  up  a  new 
66 route  by  which  N-methylsphingosine  could  be  synthesised.  Details  of 
this  method  are  discussed  in  Chapter  6. 
Out  of  the  three  established  reaction  conditions,  N,  N- 
dimethylation  proved  to  be  the  most  reliable.  Treatment  of  (1S,  2S)-2- 
amino-  1-phenylpropane-l,  3-diol  with  acetic  acid,  formaldehyde, 
hydrogen  gas,  and  a  palladium  and  carbon  catalyst  afforded  a  complex 
mixture  (Scheme  37).  Fortunately,  the  known  product  (92)80  was 
purified  by  careful  column  chromatography.  The  O-H  stretch  was  found 
at  3400  cm-1.  The  1H  NMR  spectrum  showed  a  sharp  singlet  at  S  2.34 
with  a  relative  intensity  of  6  due  to  the  methyl  groups  attached  to  the 
nitrogen. 
Scheme  37:  Synthesis  of  (1  S,  2S)-2-dimethylamino-1-phenylpropane-1,3-diol 
4.4  Biological  Testing  of  (R)  and  (S)-Phenylalaninol  and 
(1S.  2S)-2-Amino-l-nhenylpropanc-l,  3-diol  Analogy  'S  I  I 
The  biological  testing  of  some  of  these  compounds'  was  carried  out 
by  Dr.  Pamela  Scott81  at  the  Department  of  Medical  Oncology  at  the  CRC 
Beatson  Laboratories  in  Glasgow.  Our  initial  aim  was  to  study  and 
compare  the  inhibitory  effect  of  these  derivatives  with  sphingosine  on 
PAP  enzymes. 
67 4.5  Biological  Assays 
Determination  of  N-ethylmaleimide  (NEM)-sensitive  PAP  (PAPI) 
activity 
Each  assay  contained  in  a  final  volume  of  0.1  ml:  PAPI  Cocktail 
(see  below)  (20  ml),  H2O  (45  ml),  rat  liver  cytosol  plasma  membrane 
(PAPI)  (10ml),  3H-phosphatidate  /phosphatidyl-choline  (3:  2)  (20  ml), 
and  drug  (5m1).  The  assays  were  started  by  addition  of  the  test 
compound.  The  incubation  was  carried  out  for  60  minutes  at  37  oC 
after  which  time  the  reactions  were  stopped  by  addition  of 
chloroform/methanol  (19:  1)  (2.2  ml)  containing  0.08%  olive  oil  and 
aluminium  oxide  (1  g).  After  centrifuging  each  test  tube  for  10  minutes 
to  remove  unreacted  3H-phosphatidate  which  precipitated  with 
aluminium  oxide,  1  ml  of  the  top  phase  from  each  test  tube  was 
transferred  to  a  scintillation  vial  which  was  then  placed  in  a  water  bath 
at  90  OC  so  that  the  solvents  would  evaporate  off.  These  vials  now 
contained  only  the  3H-diacylglycerol  and  the  radioactivity  of  each  vial 
was  measured  in  a  Scintillation  Counter  (model  1600  TR;  Canberra 
Packard).  -  The  above  experiment  was  carried  out  with  three-  different 
concentrations  of  each  drug  (0.2,0.6,1.2  mM),  including  propranolol  as 
a  reference  and  with  3  control  assays  that  contained  no  enzyme. 
Determination  of  (NEM)-insensitive  PAP  (PAP2)  activity 
Each  assay  consisted  of  PAP2  cocktail  (see  below)  (20  ml),  rat 
liver  cytosol  plasma  membrane  (45  ml),  H2O  (45  ml),  311-phosphatidate 
(20  ml)  and  drug  (5  ml).  The  reactions  were  started  by  addition  of  the 
test  compound  and  the  incubations  were  terminated  after  60  minutes 
at  37  oC  by  addition  of  chloroform/methanol  (19:  1)  (2.2  ml)  containing 
0.08%  olive  oil.  The  unreacted  3H-phosphatidate  was  removed  by 
adding  aluminium  oxide  (1  g).  The  radioactivity  of  the  3H- 
diacylglycerol  was  measured.  The  above  experiment  was  carried  out 
with  three  different  concentrations  of  each  drug  (0.2,0.6,1.2mM), 
including  propranolol  as  a  reference  and  with  3  control  assays  that 
contained  no  enzyme. 
68 PAPI  and  PAP2  cocktails 
PAPI  PAP2 
Dithiothreitol  (DTT)  80  ml  ------ 
Magnesium  30  ml  ------- 
Tris/maleate  buffer 
(pH  6.5) 
500  ml  500  nil 
N-ethylmaleimide 
(NEM) 
--------  6.8  mg 
Triton  X-100  -------  500  ml 
Water  1390  ml  990  ml 
4.5.1  Results  of  Biological  Assays 
The  following  Table  2  records  the  percentage  of  PAP  inhibition  for 
some  of  the  compounds  in  the  assays  previously  described. 
Table  2 
PAPI  PAP2 
Compounds  %  inhibition  %  inhibition 
(mmol)  (mmol) 
0.2  0.6  1.2  0.2  0.6  1.2 
OH  0  0  0  0  6  6 
/  H2 
(72) 
a  off  0  5  3  6  3  5 
/  H2  N 
(73) 
HO  HO  62  86  89  8  29  41 
C13H27 
(74)  NH2 
HO  HO  91  100  4  50 
C13H27 
NMe31 
69 Table  2 
(cont.  ) 
IiIIIJi 
OAc 
/  AcHN 
8  14  33  1  5  10 
(75) 
Cf  OAc 
AcHN 
9  38  2  12  3 
(76) 
45  60  56  0  0  2 
(89) 
5  20  58  13  10  10  r  ý  Ni 
/ 
(159) 
_ 
OH 
/  Me2N 
7  16  42  9  10  37 
(158) 
oH 
Me2N 
21  29  25  4  29  27 
(88) 
OH  23  42  38  0  0  0 
/  Me3N+  I' 
(91) 
OH  34  43  46  15  0  0 
OH 
(92) 
26  26  29  0  0 
(79)  0 
ro  anolol  0  31  58  I l_  0  0  3 
From  the  Table,  it  is  clear  that  most  of  the  analogues  show  little 
inhibition  of  PAP2  activity  compared  to  N,  N,  N-  trimethylatcd 
sphingosine  but  have  some  significant  inhibitory  effects  on  PAPI 
activity.  Unfortunately,  PAP2  is  the  enzyme  that  is  involved  in  tumour 
promotion  via  signalling  processes.  The  most  promising  inhibitors  of 
70 the  PAPI  enzyme  were  (R)-  and  (S)-4-benzyl-3-methyloxazolidine. 
(S)-4-Benzyl-3-methyloxazolidine  (89)  inhibited  45%  of  PAPI  activity 
at  0.2  mmol.  This  compound  was  a  better  inhibitor  than  propanolol,  a 
classical  drug  for  the  inhibition  of  PAP  activities.  (R)  -4  -Benzyl-3- 
methyloxazolidine  displayed  similar  inhibitory  effects  to  propanolol  on 
both  PAP  enzymes.  Evidently  (R)-  and  (S)-phenylalaninols  showed 
little  inhibitory  effect  on  both  PAP  enzymes.  Converting  the  primary 
amine  into  either  its  secondary  amine  or  amide  increased  the  inhibitory 
effects  on  both  enzymes.  By  analogy  with  the  corresponding 
quaternised  sphingosine,  N,  N,  N-trimethylphenylalaninol  iodide  was 
expected  to  be  the  most  potent  inhibitor  of  the  compounds  prepared. 
However,  it  did  not  inhibit  PAP2  activity  at  all.  Consequently,  we  could 
not  conclude  that  increasing  the  bulkiness  around  the  amine  group 
would  increase  the  inhibitory  effect  on  both  PAP  enzymes. 
Also,  it  is  difficult  to  relate  these  results  from  the  cell-free  PAP 
assays  to  what  could  happen  in  whole  cells.  Concentrations  of  the  drug, 
substrate,  enzyme  and  diacylglycerol  in  cells  are  much  lower  than  the 
corresponding  test  tube  assay.  There  are  other  factors  that  have  to  be 
taken  into  consideration.  For  instance  the  uptake  of  the  drug  by  the 
cells  and  the  purity  of  the  enzymes.  Unfortunately  the  enzymes  used 
in  the  experiments  are  only  partially  pure  which  means  that  there  are 
other  enzymes  present  in  the  reaction  that  could  interfere.  Since  the 
concentrations  of  phosphatidate  and  diacylglycerol  are  very  low  in  the 
cells,  it  is  better  to  examine  the  test  compounds  in  a  test  tube  assay 
initially  to  give  some  indication  as  to  whether  they  have  any  affect  on 
the  PAP  activitites.  If  a  test  compound  from  the  selection  shows 
promising  inhibitory  effects  on  the  PAP  enzymes,  then  a  further  assay 
could  be  used. 
In  conclusion,  a  wide  range  of  inhibition  values  was  obtained 
from  the  above  assays.  There  was  no  clear  correlation  between  the 
inhibition  and  the  bulkiness  around  the  amino  group.  Nevertheless,  in 
most  cases  increasing  the  bulkiness  around  the  amino  group  did  show 
an  improvement  in  the  inhibition.  The  results  probably  imply  that  the 
size  around  the  amino  group  is  not  the  only  feature  for  the  inhibition  of 
PAP  enzymes.  A  key  feature  which  plays  an  important  role  in  the 
inhibition  of  PAP  and  PKC  enzymes  may  be  the  length  of  the 
71 hydrophobic  alkyl  chain.  We  now  directed  our  attention  to  the  total 
synthesis  of  sphingosine.  Once  a  reliable  route  had  been  established,  it 
would  be  used  to  synthesise  -a  variety  of  sphingosine  analogues.  The 
detail  of  this  work  is  discussed  in  Chapter  5. 
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Diastereoselective  Synthesis  of  Sphingosine  Analogues 
5.1  Introduction 
In  the  work  described  in  Chapter  4,  the  main  aim  was  to  find  the 
reaction  conditions  from  which  the  amino  group  of  sphingosine  could  be 
selectively  methylated.  Our  next  aim  was  to  establish  the  methodology 
to  synthesise  sphingosine  analogues  with  alkynyl  chains  of  varying 
lengths.  It  was  also  of  great  interest  to  synthesise  analogues  of 
deoxysphingosine  to  check  how  such  modifications  would  affect  the 
inhibition  of  PKC.  As  previously  mentioned  in  Chapter  3, 
diastereoselective  and  enantioselective  approaches  must  be  employed 
to  synthesise  optically  active  sphingosine.  Most  of  our  work  was  based 
on  a  diastereoselective'  strategy.  However,  an  attempt  was  also  made  to 
synthesis  sphingosine  via  an  enantioselective  approach.  The  details  of 
the  enantioselective  approach  will  be  discussed  in  the  next  Chapter. 
(S)-Serine  is  the  most  frequently  used  starting  material  for  the 
diastereoselective  synthesis  of  sphingosine  and  is  also  the  biological 
starting  material  for  formation  of  sphingosine.  As  well  as  being  cheap, 
it  is  also  readily  available  in  both  enantiomeric  forms.  It  had  been 
reported41,42,54,58,59  that  use  of  serinc  provided  a  shorter  synthetic 
route  to  sphingosine  than  use  of  sugars.  For  these  reasons,  serinc  was 
chosen  as  the  starting  material  for  the  following  syntheses. 
5.2  Preparation  of  Acyclic  Diprotected  Scrinal 
Serine,  like  many  amino  acids,  is  highly  insoluble  in  organic 
solvents.  To  improve  its  solubility  and  carry  out  selective  reactions  it 
has  to  be  protected.  All  the  reported  sphingosine  syntheses  using 
serine  as  the  starting  material  involve  transforming  it  into  its  acctonidc 
serinal.  Surprisingly,  there  is  no  evidence  from  the  literature  where 
acyclic  diprotected  serinal  has  been  used  for  the  synthesis  of 
sphingosine. 
73 Our  aim  was  to  establish  reliable  reaction  conditions  from  which  a 
substantial  amount  of  acyclic  diprotected  serinal  (93)  could  be 
prepared.  This  aldehyde  would  then  be  coupled  with  a  selection  of 
alkyne  chains  to  give  a  range  of  sphingosine  analogues.  The  rationale 
behind  using  acyclic  diprotected  serinal  was  to  test  whether  or  not  it 
would  improve  the  diastereoselective  outcome. 
The  preparation  of  the  acyclic  diprotected  serinal  (93)  is  outlined 
in  Scheme  38.  (S)-Serine  was  first  protected  as  its  methyl  ester  using 
methanol  and  hydrochloride  gas.  The  known  ester  (94)82  was  isolated 
as  a  white  solid  in  94%  yield.  The  IR  spectrum  showed  the  ester 
carbonyl  absorption  at  1747  cm-1.  The  1H  and  13C  NMR  spectra  were 
both  in  accord  with  literature  spectra  of  serine  methyl  ester.  60  When 
serine  methyl  ester  (94)  was  treated  with  triethylamine  and  di-tert- 
butyldicarbonate  in  dichloromethane,  it  gave  the  known  carbamate 
(95)60  in  64%  yield  after  column  chromatography.  The  tent-butyl 
protons  of  (95)  were  present  as  a  large  singlet  at  S  1.42  in  the  1H  NMR 
spectrum.  The  carbamate  carbonyl  carbon  showed  clearly  in  the  13C 
NMR  spectrum  (S  260)  and  the  C=O  stretching  mode  was  present  at 
1712  cm-1  in  the  IR  spectrum. 
Chromatography  also  afforded  an  unexpected  product:  the  di-BOC 
protected  serine  methyl  ester  (96).  This  compound  was  isolated  as  a 
white  solid  in  10%  yield,  and  its  melting  point  confirmed  the  identity  of 
the  compound,  with  mp  94  oC  (lit.  83  94.5  °C). 
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Scheme  38:  Preparation  of  acyclic  diprotected  serinal 
Treatment  of  the  monoprotected  amino  acid  ester  (95)  with  tert- 
butyldimethylsilyl  chloride  and  imidazole  in  dry  DMF  at  room 
temperature  gave  the  diprotected  ester  (97)  in  92%  yield  after 
purification  by  flash  chromatography.  The  IR  spectrum  of  this 
compound  showed  strong  absorptions  at  1752  and  1720  cm-  1 
corresponding  -  to  the  ester  carbonyl  and  the  carbamate  carbonyl 
respectively.  Absorptions  at  1256  and  1088  cm-1  corresponded  to 
stretching  of  the  SiMe2  group  and  Si-O  bond  respectively.  The  1H  NMR 
spectrum  showed  two  singlets  at  S  0.00  and  S  0.01  due  to  germinal 
methyl  groups.  ý  Also  a  singlet  at  8  0.84  due  to  the  methyl  groups  of  the 
tert-butyl  group.  The  signals  of  the  silyl  protecting  group  were 
distinctive  in  the  1H  NMR  spectrum.  The  geminal  methyl  groups  are 
diastereotopic  due  to  the  chiral  centre  and  give  rise  to  two  singlets  at  8 
0.00  and  0.01. 
The  reduction  of  the  ester  into  the  corresponding  aldehyde  (93) 
using  DIBAL-H  in  toluene  proved  to  be  more  difficult  than  first 
Me02C 
0H 
DMF  /  Imidazole 
75 anticipated.  A  variety  of  reaction  conditions  was  used  and  the  results 
are  shown  in  Table  3. 
Table  3 
DIBAL-H  Solvent  Time  Temp  oC  Result 
1.1  equiv.  DCM  0.5  h  -78  mostly 
starting 
material 
2  equiv.  DCM  2h  -78  partial 
reduction 
2  equiv.  DCM  2h  Room  temp  alcohol 
1.1  equiv.  toluene  1h  -78  partial 
reduction 
1.5  equiv.  toluene  2h  -78  mainly 
aldehyde  + 
small  traces 
of  alcohol 
2.5  equiv.  toluene  2h  -78  ca  1:  1 
mixture  of 
alcohol  and 
aldehyde 
It  was  found  that  using  1.5  equivalent  of  DIBAL-H  in  toluene 
produced  the  best  result.  No  attempt  was  made  to  purify  the  aldehyde 
(93)  from  the  alcohol  using  flash  chromatography.  Most  amino 
carboxaldehydes  are  known  to  be  unstable  and  can  racemise  on  silica  or 
if  subjected  to  distillation  conditions.  60  Therefore  the  partially  pure 
aldehyde  was  used  directly  for  the  next  step  to  ensure  the  integrity  of 
the  chiral  centre.  The  yield  of  the  reduction  could  be  estimated  from 
the  lH  NMR  spectrum  of  the  crude  product.  The  aldehyde  proton  was 
distinctive  in  the  1H  NMR  spectrum  showing  a  singlet  at  5  9.59.  The 
aldehyde  carbonyl  carbon  showed  up  clearly  in  the  13C  NMR  spectrum 
(6  199)  and  the  C=O  stretching  mode  was  present  at  1725  cm-1  in  the 
IR  spectrum. 
76 5.3  The  Reaction  of  Acyclic  Diprotected  Scrinal  with  the 
Lithium  Acetylide  of  Alkynes 
Addition  of  an  excess  of  lithium  acetylide  of  hex-1-yne  to  the 
aldehyde  (93)  gave  a  complex  mixture  (Scheme  39).  TLC  showed  five 
spots,  two  of  which  were  the  starting  materials.  Two  of  the  three 
remaining  spots  were  very  close  to  one  another  with  large  Rf  values. 
These  compounds  (99)  were  too  non-polar  to  be  the  desired  carbinol 
(98).  They  were  purified  by  careful  column  chromatography,  and  were 
found  to  have  similar  spectroscopic  data.  The  IR  spectra  of  (100)  and 
(101)  showed  absorptions  at  ca  1248  and  1740  cm-1  corresponding  to 
the  SiMe2  group  and  the  carbamate  carbonyl  respectively.  Also  there 
was  no  O-H  absorption  in  the  IR  spectrum.  While  their  13C  NMR  spectra 
clearly  indicated  the  presence  of  the  carbamate  carbonyl  (S  ca.  158),  the 
O-tert-butyl  group  was  absent  in  both  IH  and  13C  NMR  spectra.  The 
only  difference  between  their  1H  NMR  spectra  was  the  signal  at  S  ca. 
5.0.  This  signal  was  due  to  the  proton  adjacent  to  the  carbamate 
oxygen.  Although  each  signal  was  a  doublet  of  triplets,  the  coupling 
constants  were  different. 
OTBDMS 
L. 
NHBOC 
OýýH 
(93) 
----------------------DO- 
+ 
R  Li 
Scheme  39:  Attempted  synthesis  of  the  carbinol  (98) 
OTBDMS 
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In  addition,  two  NMR  homo-decoupling  experiments  were  carried 
out  to  provide  further  structural  information  about  these  two 
77 compounds  '  (100)  and  (101).  Irradiation  of  the  signal  of  (100)  at  ca.  6 
3.56  caused  the  signals  at  6  3.82  and  4.92  to  collapse  from  a  doublet  of 
triplets  to  a  triplet  and  from  a  triplet  to  a  singlet  respectively.  Also 
homo-decoupling  of  the  signal  at  ca.  S  4.90  caused  each  of  the  signals  at 
6  3.82  and  2.25  to  collapse  to  a  triplet.  The  reaction  must  have  been 
successful  or  else  the  proton  at  6  4.90  would  not  be  coupled  with  the 
methylene  protons  (6  2.25)  nearest  to  the  triplet  bond.  Similar 
experiments  were  carried  out  on  (101)  and  the  same  findings  were 
observed. 
From  the  above  observations,  it  was  concluded  that  (100)  and 
(101)  must  be  the  two  diastereoisomers  (99)  formed  in  approximately 
equal  amounts.  Since  there  were  no  OH  and  O-tert-butyl  groups 
present,  the  OH  therefore  must  have  cyclised  with  the  carbamate.  The 
mechanism  of  this  reaction  is  shown  in  Scheme  40.  The  coupling  of  the 
acetylide  of  hex-1-yne  with  the  aldehyde  (93)  resulted  in  the 
generation  of  an  alkoxide  ion  which  added  to  the  carbamate  carbonyl 
which  then  expelled  the  tert-butoxide  group  to  give  the  cyclic 
carbamate  mixture  (99). 
78 Scheme  40:  Formation  of  the  cyclic  carbamate  ring 
To  differentiate  between  these  two  diastercoisomers,  111  NMR 
spectroscopy  was  employed  as  reported  by  Futagawa  et  al.  84  They 
found  that  the  ring  protons  of  the  erythro-isomer  of  2-oxazolidine 
derivatives  and  2-phenyl-2-oxazoline  derivatives  always  had  a  larger 
coupling  constant  than  those  of  the  threo-isomer.  These  findings  are  in 
agreement  with  use  of  the  Karplus  equation.  The  coupling  constant  for 
the  erythro-isomer  will  have  a  larger  value  because  it  has  a  dihedral 
angle  of  ca.  00.  Thus,  the  configurational  identity  of  the  threo-  and 
erythro-isomers  was  assigned  by  analysis  of  the  1H  NMR  spectra  of 
their  2-oxazolidone  or  2-phenyl-2-oxazoline  derivatives.  The  coupling 
constants  for  the  ring  protons  of  the  diastercoisomers  (99)  were  3.3  and 
5.5  Hz.  We  assigned  the  isomer  with  the  coupling  constant  of  5.5  Hz  to 
be  the  erythro-form  (101)  and  the  isomer  with  the  coupling  constant  of 
3.3  Hz  to  be  the  threo-isomer  (100). 
79 Although  both  diastereoisomers  could  be  separated  by  careful 
column  chromatography,  the  yield  and  the  diastereoselectivity  of  this 
reaction  were  relatively  poor.  Therefore  this  route  cannot  be  used 
generally  to  synthesise  sphingosine  analogues.  In  addition,  when  the 
reaction  was  scaled  up,  the  reduction  step  only  gave  small  traces  of 
aldehyde.  This  problem  coupled  with  the  difficulty  in  purifying  the 
acyclic  diprotected  serinal  forced  us  to  divert  our  attention  to  the 
synthesis  of  aß-ynone  (102)  using  the  diprotected  serine  methyl  ester 
(97),  since  it  is  more  stable  than  its  aldehyde.  The  aß-ynone  (102) 
might  then  be  reduced  diastereoselectively  (Scheme  41). 
5.4  The  Reaction  of  Acyclic  Diprotected  Serine  Methyl  Ester 
with  the  Lithium  Acetylide  of  an  Alkyne 
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Scheme  41:  Attempted  synthesis  of  the  aß-ynone  (102) 
LNHBÖC 
Upon  treatment  of  the  ester  (97)  with  the  lithium  acetylide  of 
hex-1-yne  it  was  expected  that  the  ester  would  undergo  a  nucleophilic 
displacement  to  give  the  corresponding  aß-ynone  (102).  Unfortunately 
this  proved  not  to  be  the  case.  When  the  ester  was  treated  with  the 
lithium  acetylide  of  hex-1-yne  at  -78  0C,  only  the  starting  material  was 
obtained  after  the  work  up.  The  lack  of  success  was  probably  due  to 
the  bulkiness  of  the  protecting  groups  causing  severe  steric  hindrance. 
80 However,  when  the  reaction  was  carried  out  at  0  0C,  a  mixture  of  the 
starting  material  and  a  side  product  were  obtained.  This  side  product 
will  be  discussed  later  in  this  chapter.  In  order  to  overcome  the  steric 
problem,  different  protecting  groups  were  employed. 
The  next  step  was  based  on  a  recent  paper  by  Evans  et  al.  8  5 
detailing  the  transformation  of  N-CBZ-serine  methyl  ester  into  its  cyclic 
diprotected  form.  Treatment  of  (95)  with  2,2-dimethylpropane  and 
PTSA  as  a  catalyst  produced  the  known  acetonide  ester  (103)60  in  70% 
yield.  The  2,2-dimethylpropropane  acts  as  an  acetone  equivalent  when 
treated  under  acidic  conditions,  see  Scheme  42.  These  protecting 
groups  should  reduce  the  steric  hindrance  problem. 
Scheme  42:  Formation  of  the  oxazolidine  ring  system 
The  IR  spectrum  of  the  oxazolidine  (103)  showed  absorptions  at 
1725  and  1702  cm-1  due  to  the  ester  carbonyl  and  carbarnate  carbonyl 
respectively.  No  O-H  absorption  was  observed  in  the  IR  spectrum.  The 
1H  NMR  spectrum  appeared  more  complex  than  the  assigned  structure 
81 would  indicate,  see  Diagram  8.  The  oxazolidine  exists  at  room 
temperature  as  a  mixture  of  rotamers.  86  The  two  ring  methyl  groups 
appeared  as  four  separate  signals  at  6  1.43,1.46,1.57  and  1.60,  two  for 
each  methyl  group.  The  heights  of  these  signals  are  proportional  to  the 
proportional  of  molecules  in  that  particular  rotameric  form.  All  the 
signals,.  appeared  as  pairs  except  for  the  methyl  group  of  the  ester 
which  is  a  singlet. 
Treatment  of  the  oxazolidine  (103)  with  the  lithium  acetylide  of 
hex-1-yne  at  -78  oC  gave  starting  material,  the  desired  aß-ynone  (104) 
and  a  known  by-product  (105).  87  The  aß-ynone  (104)  was  isolated  in 
17%  yield  after  column  chromatography.  The  IR  spectrum  showed 
absorptions  at  1680  and  2225  cm-1  corresponding  to  the  ketone 
carbonyl  and  the  triple  bond,  respectively.  The  ketone  carbonyl  carbon 
showed  up  clearly  in  the  13C  NMR  spectrum  (8  163.4).  This  value  was 
low  compared  to  the  typical  value  for  a  ketone  carbonyl  because  of  the 
conjugation. 
Scheme  43:  Synthesis  of  the  aß-pone  (104) 
The  by-product  isolated  from  the  mixture  was  methyl  2-(tert- 
butyloxycarbonyl)aminoacrylate  (105).  This  product  was  also  found 
previously  in  the  reaction  of  the  acyclic  diprotected  ester  with  the 
lithium  acetylide  of  hex-1-yne.  It  is  UV  active  due  to  a  conjugated 
system.  The  IR  spectrum  showed  absorptions  at  1680  and  1750  cm-1 
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Diagram  8:  1H  NMR  spectrum  of  methyl  (4S)-3-tcrt-butyloxycarhonyl- 
2,2-climcthyloxai.  olicliiic-4-carhoxylatc  (I03) 
83 corresponding  to  the  a  ß-unsaturated  ketone  and  carbamate  carbonyl, 
respectively.  Both  III  and  13C  NMR  spectra  showed  that  only  the  ring 
system  had  been  cleaved  and  the  rest  of  the  functional  groups 
remained  intact.  Only  five  singlets  were  found  in  the  111  NMR 
spectrum.  The  two  new  singlets  at  S  6.08  and  6.10  were  due  to  the 
olefinic  protons.  The  formation  of  this  by-product  is  shown  in  Scheme 
44.  The  acetylide  anion  of  hex-l-yne  could  either  act  as  a  nucleophile 
or  a  base.  When  acting  as  a  base,  it  deprotonated  the  a-hydrogen 
which  subsequently  caused  the  intermediate  (106)  to  eliminate  acetone 
to  generate  a  stable  conjugated  compound  (105). 
Scheme  44:  Formation  of  the  methyl  2-(tert-butyloxycarbonyl)aminoacrylato 
In  order  to  try  to  prevent  this  by-product  from  being  formed,  the 
ester  carbonyl  was  activated  by  a  Lewis  acid  to  enhance  its  reactivity, 
in  the  hope  that  the  yield  of  the  ynone  would  improve.  However, 
addition  of  the  Lewis  acid  to  the  reaction  led  to  a  complex  mixture.  The 
extra  impurities  resulted  probably  from  the  reaction  of  the  nucleophilc 
with  the  carbamate  carbonyl.  The  carbamate  carbonyl  would  have 
been  more  activated  by  the  Lewis  acid  than  the  ester  carbonyl  as  it  has 
a  higher  electron  density. 
84 Since  addition  of  the  Lewis  acid  caused  more  problems  than 
expected,  it  was  decided  to  transesterify  the  methyl  ester  (103)  into  the 
phenyl  ester.  The  phenyl  ester  is  obviously  a  more  reactive  ester  as 
phenoxide  is  a  better  leaving  group.  If  this  did  not  prevent  the 
formation  of  this  by-product  then  the  ester  would  have  to  be  reduced 
to  its  aldehyde,  which  has  been  shown  to  be  stable  to  silica.  86 
The  standard  method  of  transesterification  using  excess  of  phenol 
and  PTSA  with  Dean-Stark  conditions  failed,  to  give  any  product  and 
only  the  starting  material  could  be  isolated.  Another  method  was  tried. 
Upon  treatment  of  the  ester  (103)  with  phenol  and  a  tiny  piece  of 
lithium  metal  in  dry  DMF  at  95  °C,  the  phenoxide  anion  should  displace 
the  methoxy  group  which  would  then  abstract  a  proton  from  the  phenol 
to  give  methanol  and  phenoxide  anion.  Thus  lithium  phenoxide  should 
act  as  a  catalyst  and  the  equilibrium  could  be  displaced  by  distilling  off 
the  methanol.  Unfortunately,  this  proved  not  to  be  case.  Treatment  of 
the  ester  (103)  with  a  catalytic  amount  of  lithium  phenoxide  in  DMF 
and  phenol  at  95  oC  gave  the  methyl  2-(tert- 
butyloxycarbonyl)aminoacrylate  (105).  This  product  was  isolated  in 
95%  yield.  It  came  as  a  surprise  that  the  phenoxide  anion  was  able  to 
deprotonate  the  'cc-hydrogen  as  it  is  a  relatively  weak  base.  In 
conclusion,  the  a-hydrogen  of  the  ester  must  be  relatively  acidic  which 
causes  the  ring  to  collapse.  Therefore  alkynylation  of  the  ester  (103) 
was  abandoned. 
5.5  The  Use  of  the  Acetonide  of  Serinal  with  the  Lithium 
Acetylide  of  an  Alkyne 
Garner  et  al.  86  had  reported  that  the  ester  (103)  could  be 
transformed  into  its  aldehyde  (107)  by  carrying  out  the  reduction  with 
DIBAL  in  toluene  at  -78  °C.  This  aldehyde  was  found  to  be  relatively 
stable  and  could  be  purified  by  column  chromatography  or  distillation. 
The  reduction  of  the  ester  (103)  to  the  acetonide  (107)  ofserinal  was 
achieved  in  62%  yield.  Chromatography  was  carried  out  to  purify  the 
aldehyde.  The  IH  NMR  spectrum  of  (107)  showed  the  aldehyde  proton 
at  6  9.47  and  9.52.  The  13C  NMR  spectrum  showed  the  aldehyde 
85 carbon  at  S  199.1  and  199.3.  Due  to  the  presence  of  rotameric  isomers, 
all  the  signals  were  observed  as  pairs. 
At  this  point,  this  aldehyde  (107)  was  adopted  as  the  starting 
material  for  a  new  approach  to  the  synthesis  of  sphingosine  analogues. 
This  synthesis  is  detailed  in  Scheme  45. 
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Scheme  45:  Attempted  synthesis  of  sphingosine  analogues 
Careful  dropwise  addition  of  vinylmagnesium  bromide  to  a  stirred 
solution  of  (S)-N-(tert-butoxycarbonyl)serinal  acetonide  (107)  was 
successful  in  producing  a  mixture  of  diastereoisomeric  vinyl  alcohols 
(108)  which  was  isolated  in  77%  yield  after  chromatography.  Attempts 
86 to  separate  these  diastereoisomers  by  flash  chromatography  failed.  The 
signals  for  the  alkene  hydrogens  were  found  at  5  5.1  for  the  terminal 
CH2  group  and  5  5.7  for  the  alkene  CH  in  the  III  NMR  spectrum.  The 
13C  NMR  spectrum  was  complex.  The  purity  of  these  diastereoisomers 
was  confirmed  by  microanalysis. 
If  these  diastereoisomers  could  have  been  separated,  the  erythro- 
isomer  would  have  been  subjected  to  ozonolysis  to  give  the  a-hydroxyl 
aldehyde  (109).  The  E-double  bond  would  then  be  introduced  by 
Wittig  reaction.  By  varying  the  Wittig  reagents,  a  selection  of 
sphingosine  analogues  would  have  been  synthesised.  Such  an  aldehyde 
would  be  most  useful  as  an  optically  active  building  block  for  the 
synthesis  of  sphingosine  analogues. 
In  order  to  achieve  the  synthesis  of  sphingosinc  analogues  in  the 
time  constraints,  the  method  of  Garner  et  al.  58  was  employed  (Scheme 
46).  They  reported  that  condensation  of  the  serinal  acetonide  (107) 
with  the  lithium  acetylide  of  pentadec-1-yne  gave  good 
diastereoselectivity  and  both  diastereoisomers  were  separable. 
Treatment  of  the  acetonide  aldehyde  (107)  with  the  lithium  acetylide  of 
pentadec-1-yne  did  indeed  give  the  desired  diastereoisomers  (110) 
which  were  separated  by  careful  column  chromatography.  The  yield  of 
the  major  product  was  68%.  The  optical  rotation  was  identical  to  the 
published  values  8  for  the  erythro-isomer.  The  IR  spectrum  showed 
the  carbamate  carbonyl  and  OH  absorptions  at  1704  and  3277  cm-  1 
respectively.  The  microanalysis  confirmed  the  purity  of  the  compound. 
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Scheme  46:  Attempted  synthesis  of  sphingosine  analogues 
The  use  of  the  methodology  of  Garner  et  al.  was  extended  to 
prepare  the  erythro-isomers  (111)  and  (112).  After  purification  by 
column  chromatography,  erythro-isomer  (111)  was  isolated  in  58% 
yield.  The  IR  spectrum  ,  showed  absorptions  at  1693  and  3308  cm-  1 
due  to  the  carbarmate  carbonyl  and  OH  respectively.  The  1H  NMR 
spectrum  showed  a  broad  doublet  at  5  4.70  for  the  CH  of  the  alcohol 
group,  and  a  broad  singlet  at  8  3.90  for  the  -OH  signal.  The  13C  NMR 
spectrum  showed  signals  at  5  77.8  and  86.1  for  the  triple  bond  carbons. 
The  erythro-isomer  (112)  was  isolated  in  63%  yield  after 
purification  by  column  chromatography.  This  compound  possessed 
spectroscopic  data  similar  to  other  erythro-isomers. 
88 The  diastereoselectivity  could  be  explained  by  assumption  of  a 
transition  state  according  to  the  Felkin-Anh  model.  That  is,  the  a- 
amino  moiety  is  orthogonal  to  the  plane  of  the  carbonyl  group.  The 
nucleophile  then  approaches  the  carbonyl  in  the  direction  which  gives 
the  least  steric  interaction.  Such  an  approach  would  favour  the 
formation  of  the  erythro-isomer,  see  Diagram  9. 
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Diagram  988:  Felkin-Anh  model  (  not  chelation  controlled) 
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The  next  step  was  to  reduce  the  triple  bond  partially  using  Birch 
conditions  as  reported.  5  8  Treatment  of  (110)  with  lithium  and 
ammonia  at  -78  oC  gave  only  small  traces  of  the  trans-product  (113), 
when  compared  to  the  value  of  68%  from  Garner's  procedure.  The 
conditions  for  the  Birch  reduction  were  varied  as  shown  in  Table  4. 
89 Table  4 
Temp  (°C)  Solvent  Time  Result 
2.5  equiv.  of  -78  NH3  2h  traces  of 
sodium  product 
3.0  equiv.  of  -78  NH3  3h  traces  of 
sodium  product 
3.0  equiv.  of  -78  NH3  8h  complex 
sodium  mixture 
4.0  equiv.  of  -78  NH3  4h  traces  of 
sodium  product 
2.5  equiv.  of  Reflux  NH3  and  THE  3h  mainly 
sodium  starting 
material 
2.5  equiv.  of  Reflux  EtNH2  and  3  lh  mainly 
sodium  THE  starting 
material 
2.5  equiv.  of  Reflux  then  EtNH2  and  3h  at  reflux  complex 
sodium  RT  THE  followed  by  mixture 
8hatRT 
Despite  the  variety  of  reaction  conditions  tested,  none  of  them 
succeeded  in  producing  a  better  yield  of  the  trans-product  (113).  The 
lack  of  success  was  probably  due  to  the  lack  of  solubility  of  (110). 
When  (111)  was  subjected  to  Birch  reduction,  the  trans-product 
(114)  was  isolated  in  10%  yield  after  purification  by  column 
chromatography.  The  expected  absorption  due  to  the  stretching  of  the 
C=C  bond  was  found  at  1645  cm-l-  The  1H  NMR  spectrum  showed  a 
doublet  of  doublets  at  6  5.34  for  the  olefinic  proton  nearest  to  the 
alcohol  group  and  a  doublet  of  triplets  at  8  5.66  for  the  other  olefinic 
proton.  The  coupling  constant  between  the  olefinic  protons  was  found 
to  be  15.4  Hz,  suggesting  it  must  be  an  E-double  bond.  Treatment  of 
(114)  with  concentrated  HC1  in  ethyl  acetate  caused  the  compound  to 
polymerise.  Thus  a  milder  deprotection  step  must  be  employed  to 
prevent  the  compound  from  undergoing  polymerisation. 
90 Since  the  partial  reduction  of  the  triple  bond  to  the  E-double  bond 
was  not  as  straightforward  as  anticipated,  it  was  decided  to  keep  the 
triple  bond  in  these  sphingosine  analogues.  This  would  give  us  the 
benefit  of  seeing  whether  or  not  the  E-geometry  of  the  double  bond 
was  an  essential  criterion  for  PKC  inhibition. 
In  the  typical  deprotection  of  the  NBOC-acetonide  ring,  there  are 
two  steps  involved.  Methanol  and  PTSA  were  used  initially  to  open  the 
ring  followed  by  treatment  with  HC1  in  ethyl  acetate  to  cleave  the  BOC 
protecting  group.  The  use  of  HCl  in  ethyl  acetate  was  not  ideal  as 
previously  found.  Such  strong  conditions  might  cause  polymerisation. 
It  was  found  by  accident  that  treatment  of  (110)  with  an  excess  of 
PTSA  in  methanol  at  room  temperature  for  48  h  gave  the  known 
aminodiol  (115)60  which  was  isolated  as  a  yellow  oil  in  87%  yield 
(Scheme  47).  The  IR  spectrum  showed  absorptions  at  2360  cm-1  due 
to  the  carbon  to  carbon  triple  bond.  Another  absorption  at  3356  cm-  I 
(very  broad)  indicating  the  OH  and  NH  stretches  was  also  found  in  the 
IR  spectrum.  Also  no  absorption  was  found  for  the  carbamate  carbonyl 
in  the  IR  spectrum.  Both  IH  NMR  and  13C  NMR  spectra  had  no  signals 
for  the  ring  methyls  and  the  BOC  protecting  group. 
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Scheme  47:  Synthesis  of  sphingosine  analogues  with  a  triple  bond 
91 This  deprotection  procedure  was  used  to  prepare  the  new 
compounds  (2S,  3R)-2-amino-1,3-pentadec-4-ynediol  (116)  and  (2S,  3R)- 
2-amino-1,3-octadec-4-ynediol  (117).  Both  compounds  exhibited 
similar  spectroscopic  data  to  compound  (115).  The  molecular  ions  for 
all  three  aminodiols  could  not  be  detected  because  they  lost  water 
instantaneously  when  injected  into  the  mass  spectrometer. 
Aminodiols  in  general  are  relatively  unstable  and  have  a 
tendency  to  decompose  when  exposed  to  air.  In  order  to  prevent  this 
from  taking  place,  these  compounds  are  normally  protected  as  the 
corresponding  triacetates.  Treatment  of  (111)  with  triethylamine  and 
acetic  anhydride  afforded  the  corresponding  triacetate  (118).  The 
triacetate  was  isolated  as  a  yellow  oil  in  21%  yield.  The  IR  spectrum 
showed  absorptions  at  1547,1659  and  1749  cm-  I  correlating  to  the 
amide  carbonyl  and  ester  carbonyls  respectively.  The  IH  NMR 
spectrum  showed  three  singlets  at  8  1.97,2.00  and  2.01  due  to  the  a- 
methyl  groups.  The  high  resolution  mass  spectrum  gave  a  value  for  the 
molecular  ion  of  339.2065  compared  to  the  calculated  value  of 
339.2046. 
When  (112)  was  exposed  to  triethylamine  and  acetic  anhydride, 
the  triacetate  (119)  was  isolated  as  a  white  solid  in  94%  yield.  The  1H 
NMR  spectrum  showed  three  singlets  at  8  1.97,2.00  and  2.02  for  the  cc- 
methyl  groups.  The  high  resoluton  mass  spectrum  gave  a  value  for  the 
molecular  ion  of  381.2532  in  accordance  with  the  theoretical  value  of 
381.2515. 
Liotta  et  al.  6  0  reported  the  synthesis  of  sphingosine  from 
unprotected  aminodiol  (117)  using  either  Birch  reduction  or  lithium 
aluminium  hydride  reduction.  Birch  reduction  of  (117)  proved  to  be 
unsuccessful.  However,  when  (117)  was  treated  with  lithium 
aluminium  hydride  in  dimethoxyethane  at  reflux,  partially  pure 
sphingosine  (14)  was  isolated  as  an  oil  in  20%  yield.  Attempts  to 
remove  the  impurity  by  column  chromatography  failed.  The  IR 
spectrum  showed  the  C=C  absorption  at  1680  cm'  1.  The  IH  and  13C 
NMR  spectra  were  both  in  accord  with  the  literature  spectra  of 
sphingosine.  60 
92 In  order  to  facilitate  purification,  it  was  decided  to  transform 
sphingosine  into  its  known  triacetate58  which  should  result  in  an  easily 
purified  crystalline  derivative.  The  triacetylation  of  (14)  using  acetic 
anhydride  and  triethylamine  proceeded  in  70%  crude  yield  to  give  an 
oil,  which  was  partially  purifed  by  flash  chromatography.  A  further 
attempt  to  purify  the  triacetate  by  silica  column  chromatography 
caused  it  to  decompose.  Time  constraints  prevented  further 
development  of  this  route. 
5.6  Attempted  nthesis  of  (R2-2-Amino-octadec-4E-en-l-ol 
A  recent  paper  by  Sibi  et  al.  89  detailed  a  general  synthesis  of  4- 
substituted  oxazolidinones.  Cleavage  of  the  oxazolidinone  ring  would 
generate  the  corresponding  aminol.  Such  a  method  was  adopted  for  the 
synthesis  of  (R)-2-amino-octadec-4E-en-l-ol  (120)  as  shown  in  Scheme 
48.  The  starting  material  for  the  synthesis  was  (S)-serine  methyl  ester. 
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Scheme  48:  Attempted  synthesis  of  (R)-2-amino-octadec-4E-en-1-ol  (120) 
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93 (S)-Serine  methyl  ester  was  first  protected  as  its  oxazolidin-2-one 
(121)89  using  phosgene  under  basic  conditions.  The  oxazolidin-2-one 
was  isolated  as  an  oil  in  80%  yield.  The  IR  spectrum  of  (121)  showed 
the  presence  of  the  ester  carbonyl  (1767  cm-1)  and  carbamate  carbonyl 
(1740  cm-1)  absorptions.  The  carbamate  carbonyl  carbon  was  evident 
in  the  13C  NMR  spectrum  and  the  correct  molecular  ion  (in/z  =  145) 
was  present  in  the  mass  spectrum. 
The  reduction  of  (121)  to  the  known  alcohol  (122)89  was 
achieved  in  63%  yield  using  sodium  borohydride  in  ethanol. 
Chromatography  was  required  to  purify  the  alcohol.  The  1H  NMR 
spectrum  showed  two  sets  of  doublets  of  doublets  at  6  3.60  for  the 
methylene  protons  of  the  alcohol  group. 
In  order  to  transform  the  alcohol  (122)  into  a  better  leaving 
group  it  was  converted  into  the  tosylate  (123)89  by  treatment  with 
tosyl  chloride  in  triethylamine.  The  product  was  isolated  by  flash 
chromatography  in  64%  yield.  The  IH  NMR  spectrum  showed  a  singlet 
at  8  2.33  and  an  AA'BB'  system  at  6  7.73  due  to  the  methyl  group  and 
the  p-substituted  benzene  ring  respectively. 
Chromatography  -also  gave  the  ditosylated  product  (124),  not 
reported  previously.  89  The  product  showed  two  methyl  signals  (at  8 
2.35,2.37)  and  two  sets  of  AA'BB'  systems  (at  8  7.26-7.88)  in  the  lH 
NMR  spectrum.  Microanalysis  confirmed  the  purity  of  the  compound. 
Akynylation  of  (123)  with  the  lithium  acetylide  of  pentadec-  l- 
yne  only  led  to  the  recovery  of  both  starting  materials.  No 
improvement  was  achieved  with  the  use  of  an  extra  equivalent  of 
lithium  acetylide.  It  appeared  that  once  deprotonation  had  occurred, 
the  salt  precipitated  and  failed  to  react  further.  It  was  thought  that  the 
problem  might  be  overcome  by  using  a  different  organometallic 
reagent.  However,  the  reaction  was  still  not  successful  even  with  the 
use  of  an  organocuprate.  Several  attempts  were  made  but  none  proved 
to  be  successful.  The  lack  of  success  was  probably  due  to  the  fact  the 
cuprate  did  not  form  in  the  reaction  mixture.  Transmetallation  of  the 
lithium  acetylide  of  an  alkyne  into  its  cuprate  is  known  to  be  a  difficult 
process.  90 However,  addition  of  the  lithium  acetylide  of  pentadec-1-yne  to  a 
stirred,  solution  of  the  ditosylated  product  (124)  was  successful  in 
producing  compound  (125)  in  a  yield  of  23%  (Scheme  49).  The  IR 
spectrum  of  (125)  showed  an  absorption  at  2236  cm-1  corresponding  to 
the  carbon  to  carbon  triple  bond  stretch.  The  13C  NMR  spectrum 
clearly  showed  the  triple  bond  carbons  at  S  72.3  and  90.9.  High 
resolution  mass  spectrometry  gave  a  molecular  ion  of  461.2575  in 
accordance  with  the  theoretical  value  of  461.2599.  There  was  not 
enough  compound  (125)  made  to  continue  the  synthesis  and  time 
constraints  prevented  this  reaction  from  being  repeated  on  a  larger 
scale. 
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Scheme  49:  Towards  (R)-2-amino-octadec-4  E-en-1-ol  (120) 
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To  synthesise  optically  active  sphingosine,  a  diastereoselective  or 
enantioselective  approach  must  be  employed.  In  this  chapter,  we  have 
tried  to  devise  a  novel  synthesis  of  sphingosine  via  a  diastereoselective 
route.  Unfortunately  there  were  several  drawbacks,  such  as  the 
difficulty  in  'separating'  the  diastereoisomers  of  (108)  and  the  Birch 
reduction  of  the  triple  bond  in  (117),  which  could  not  be  overcome. 
Instead  of  continuing  to  try  to  find  better  conditions  for  the  Birch 
reduction,  an  alternative  approach  to  synthesis  of  sphingosine 
analogues  was  attempted  and  is discussed  in  the  next  Chapter. 
95 CHAPTER  SIX 
Enantioselective  Synthesis  of  Sphingosine  Analogues 
6.1  Introduction 
Our  next  aim  was  to  devise  enantioselective  routes  by  which 
optically  active  aminodiol  compounds  with  one  or  more  alkyl  groups 
attached  to  the  amino  group  could  be  synthesised.  (1  R,  2S)-2-N- 
Alkylamino-1-phenylpropane-1,3-diol  (126)  and  N,  N-dialkylamino-l- 
phenylpropane-1,3-diol  (127)  were  the  chosen  targets.  These 
compounds  have  features  in  common  with  sphingosine,  such  as 
functional  groups  in  similar  positions  and  a  hydrophobic  region.  Once 
the  preparations  of  these  aminodiols  were  established,  their  routes 
would  then  be  applied  to  the  total  synthesis  of  monomethylatcd  (128) 
and  dimethylated  sphingosine  (129).  As  discussed  in  Chapter  4, 
monoalkylation  of  (1S,  2S)-2-amino-l-phenylpropane-1,3-diol  could  not 
be  carried  out  using  standard  methods  and  as  for  the  dialkylation  it 
occurred  only  in  poor  yield.  Therefore  to  synthesise  (1R,  2S)-2-N- 
alkylamino-1-phenylpropane-1,3-diol  and  N,  N-dialkylamino-l- 
phenylpropane-1,3-diol  enantiselectively  would  be  a  bonus. 
OH 
OH 
R2  ý  R1 
(126);  R1  =  alkyl  group;  R2  =H 
(127);  R1  =  R2  =  alkyl  group 
C 
13H27  OH 
R3  R4 
(128);  R3  =  alkyl  group;  R4  =H 
(129);  R3  =  R4  =  alkyl  group 
6.2  Attempted  Enantioselective  Synthesis  of  (1  R,  2S)-2- 
Diethylamino-l-phenylpropane-1,3-diol 
Rayner  and  his  co-workers  reported91  a  novel  method  for 
preparing  2,3-diaminoalcohols  via  Lewis  acid  induced  rearrangement  of 
2,3-epoxyamines  (Scheme  50).  The  procedure  deserves  a  mention 
OH 
96 because  the  stereochemical  outcome  was  controlled.  The  initial  step 
utilised  Sharpless  asymmetric  epoxidation  to  prepare  optically  active 
2,3-epoxyalcohol  (130)  which  was  then  transformed  into  its  tosylate 
(131)  by  treatment  with  triethylamine  and  tosyl  chloride.  The  tosylate 
was  then  displaced  by  diethylamine  to  afford  the  corresponding  2,3- 
epoxyamine  (132).  Treatment  of  (132)  with  trimethylsilyl 
trifluoromethanesulfonate  caused  the  nitrogen  lone  pair  to  attack  the 
epoxide  ring  regioselectively  to  give  the  aziridinium 
trifluoromethanesulfonate  (133).  The  less  hindered  position  (C-1)  of 
(133)  was  regiospecifically  attacked  by  a  nucleophile  which  is  normally 
an  amine,  to  give  a  protected  diaminol  (134).  If  the  nucleophile  was 
water  then  the  final  product  would  be  an  aminodiol  instead  of  a 
diaminol.  This  was  basis  for  the  attempted  enantioselective  synthesis 
of  the  dialkylated  aminodiol  (127). 
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Scheme  50:  General  synthesis  of  diaminol  by  Rayner  et  a!.  91 
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97 To  synthesise  the  N,  N-dialkylamino-  l-phenylpropane-l,  3-diol 
(127),  (E)-3-phenylpropen-2-ol  was  chosen  as  the  starting  point  for  the 
synthesis,  as  outlined  in  Scheme  51.  Sharpless  asymmetric  epoxidation 
of  (E)-3-phenylpropen-2-ol  by  the  published  procedure92  gave  the 
desired  epoxide  (135)  which  was  isolated  in  64%  yield  after  purification 
by  column  chromatography.  The  IR  spectrum  of  the  epoxide  showed 
absorptions  at  3342  and  1256  cm-1  due  to  the  OH  and  C-O  respectively. 
Its  1H  NMR  spectrum  showed  a  doublet  at  S  3.90  for  the  CH  nearer  to 
the  phenyl  ring  and  a  multiplet  at  S  3.23  for  the  other  epoxide  CH.  The 
13C  NMR  spectrum  also  showed  the  presence  of  the  two  CH  groups  at  6 
55.6  and  62.6  and  high  resolution  mass  spectrometry  gave  a  molecular 
ion  of  150.0680  in  accordance  with  a  theoretical  value  of  150.0683.  An 
experiment  was  not  carried  out  to  confirm  the  optical  purity  of  the  2,3- 
epoxy  alcohol  (135)  using  the  Mosher  method.  It  was  assumed,  at  this 
stage,  that  the  enantiomeric  excess  for  the  Sharpless  asymmetric 
epoxidation  was  the  same  as  the  value  quoted  in  the  literature  for  the 
same  compound.  92 
Ph 
` 
OH 
Sharpless 
epoxidation  ph'  ý  'OH 
TsCI  (135) 
NEt3 
O 
Ph 
(137) 
NEt2 
:  1)  TMSOTf, 
-78  °C,  CH2CI2 
2)  H20 
OH 
...  i  ýi  ýfLI 
NHEt2 
Dh  r1T.. 
KI,  DMF 
Ph 
(136) 
OH 
rn  un  1 
=  nu  ý 
_N,  ý  ....  ý  ,  %,  \/  \/  (1391 
(138)  11 
Scheme  51:  Attempted  synthesis  (1  R,  2S)-2-diethylamino-1-phenyl- 
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98 The,  2,3-epoxyalcohol  (135)  was  then  transformed  into  its  known 
tosylate.  (136)92  by  treatment  with  tosyl  chloride  and  triethylamine. 
The  tosylate  was  isolated  as  white  crystals  in  80%  yield.  The  IH  NMR 
spectrum  of  (136)  showed  a  singlet  at  8  2.44  for  the  methyl  group  and 
an  AA'BB'  system  at  5  7.28-7.80,  for  -the.  p-substituted  benzene  ring. 
The  high  resolution  mass  spectrum  of  (136)  gave  a  molecular  ion  of 
304.0769  in  accordance  with  a  theoretical  value  of  304.0782. 
Treatment  of.  the  tosylate  (136),  with  diethylamine  and  potassium 
iodide  in  dry  DMF  afforded  a  complex  mixture.  This  mixture  was 
purified  by  flash  chromatography  to  give  the  new  2,3-epoxyaniine 
(137)  in  22%  yield.  The  IR  spectrum  of  the  compund  still  showed  the 
presence  of  the  epoxide  ring.  Its  1H  NMR  spectrum  showed  a  triplet  at 
8  0.97  for  the  .  methyl  groups  and  a  multiplet  at  8  2,51  for  the 
methylene  protons.  The  epoxide  CH  groups  were  also  found  in  the 
expected  region  of  the  1H  NMR  spectrum  and  high  resolution  mass 
spectrometry  gave  a  value  for  the  molecular  ion  of  205.1500  compared 
with  a  theoretical  value  of  205.1517. 
The  key  step  was  the  Lewis  acid  induced  rearrangement  of  the 
2,3-epoxyamine  (137)  to  give  the  corresponding  2- 
trimethylsiloxymethylaziridinium  ion  which  would  then  be  opened 
regioselectively  by  water  to  form  the  aminodiol  (138).  The 
rearrangement  followed  by  the  opening  of  the  ring  should  provide  the 
erythro-configuration.  However,  when  the  epoxyamine  (137)  was 
treated  with  trimethylsilyl  trifluoromethanesulfonate  for  30  minutes 
before  water  was  introduced,  work  up  gave  a  complex  mixture. 
Although  it  could  not  be  purified  by  column  chromatography,  the  III 
NMR  spectrum  of  the  mixture  suggested  that  the  epoxide  ring  had  been 
opened.  The  epoxide  cleavage  was,  also  evident  in  the  13C  NMR 
spectrum.  Chemical  shifts  of  the  CH  groups  suggested  that  the  epoxide 
ring  was  opened  not  by  the  nitrogen  lone  pair  but  by  the  water 
molecule  to  give  the  corresponding  amino-2,3-diol  (139).  From  the 
spectroscopic  evidence,  the  intermediate  2-trimethylsiloxymethyl- 
aziridinium  ion,  had  not  been  generated.  Another  attempt  was  carried 
out  where  the  2,3-epoxyalcohol  was  stirred  with  trimethylsilyl 
trifluoromethanesulfonate  for  10  hours  before  the  nucleophile  was 
introduced.  After  the  work-up,  a  complex  mixture  was  again  isolated. 
99 The  IH  and  13C  NMR  spectra  of  the  crude  product  were  almost  identical 
to  the  previous  spectra.  The  route`  was  abandoned  due  to  the  difficulty 
in  performing  the  key  step. 
6.3  Synthesis  of  (1R,  2S  -2-Ethylamino-l-plýenvln..  ropa11s- 
1.3-diol 
It  is  known  that  2,3-epoxyalcohols  are  useful  intermediates  in  the 
synthesis  of  carbohydrates,  and  related  compounds.  93  In  a  recent 
report94  by  Roush  and  Adam,  2,3-epoxyalcohols  were  transformed  into 
their  2-amino-1,3-diols,  see  Scheme  52.  They  reported  that  the 
reaction  of  the  2,3-epoxyalcohols  with  an  isocyanate,  followed  by 
deprotonation  of  the  carbamate  (140)  with  sodium  hydride,  generated  a 
nitrogen  nucleophile  which  would  then  open  the  epoxide  ring 
regioselectively  to  afford  the  cyclic  carbamate  (141).  Basic  hydrolysis 
of  (141)  gave  the  2-amino-1,3-diol  (142). 
Scheme  52:  Synthesis  of  monomethylated  2-amino-1,3-diol  (142)  by  Roush  and 
Adam.  93 
100 In  the  procedure  of  Roush  and  Adam,  every  step  gave  a  yield  of 
at  least  80%  and  the  cyclisation  of  the  nitogen  anion  with  the  epoxide 
ring  was  highly  regiospecific.  These  two  characteristics  of  the 
procedure  made  it  ideal  for  the  synthesis  of  (1R,  2S)-2-ethylamino-1- 
phenylpropane-1,3-diol  (145).  The  synthesis  of  (1R,  2S)-2-ethylamino- 
1-phenylpropane-1,3-diol  is  shown  in  Scheme  53.  Treatment  of 
(2R,  3R)-2,3-epoxy-3-phenylpropan-l-ol  (135)  with  ethyl  isocyanate 
and  triethylamine  afforded  the  carbamate  (143)  in  93%  yield  after 
column  chromatography.  The  IR  spectrum  of  this  compound  showed  an 
absorption  at  1689  cm-1  due  to  the  carbamate  carbonyl.  Its  11-1  NMR 
spectrum  showed  a  triplet  at  5  1.05  for  the  methyl  group  and  a  quartet 
at  S  3.05  for  the  methylene  protons  of  the  ethyl  group.  The  13C  NMR 
spectrum  clearly  showed  the  presence  of  the  carbamate  carbonyl  at  6 
155.9. 
Scheme  53:  Synthesis  of  monomethylated  2-amino-1,3-diol. 
101 The  epoxyalcohol  (135)  was  assumed  to  be  optically  active  and-,  at 
this  point  it  was  decided  that  we  should  carry  out  a  range  .  of 
experiments  to  find  out  if  the  epoxycarbamate  (143)  was  still  optically 
active  too.  The  optical  rotation  was  -found  to  be  +  54.5  and  further 
experiments  were  carried  out  to  find  out  the  optical  purity  of  (143). 
The  initial  experiment  was  to  examine  the  1H  NMR  spectrum  of  the 
compound  after  addition  of  3%  (by  mole)  and  6%  of  the  chiral  shift 
reagent  europium  -  (III)  tris[3-(heptafluoropropylhydroxymethylene)- 
(+)-camphorato]  (146).  There  was  no  splitting  of  any  signals  but  they 
had  moved  downfield  as  a  result  of  paramagnetic  properties  of  the 
europium  atom.  Another  IH  NMR  experiment  was  carried  out,  this  time 
with  a  different  chiral  shift  reagent,  (+)-2,2,2-trifluoro-l-(9-anthryl)- 
ethanol  (147).  Again  no  splitting  of  the  signals  was  observed  in  the  111 
NMR  spectrum. 
These  NMR  experiments  with  chiral  shift  reagents  were  not 
sufficient  proof  that  the  epoxycarbamate  (143)  was  a  single 
enantiomer.  The  last  experiment  involved  the  use  of  chiral  column  gas 
chromatography.  Only  one  compound  was  observed.  These 
experiments  established  that  the  optical  purify  of  this  compound  must 
be  greater  than  95%. 
The  next  step  was  the  reaction  of  '  the  epoxycarbamate  (143)  with 
sodium  hydride  in  THE  This  provided  the  erythro-hydroxycarbamate 
(144)  in  80%  yield  after'  recrystallisation.  Its  optical  rotation  was  -52.5 
in  contrast  to  value  of  +54.5  for  (143).  The  IR  spectrum  of  (144) 
showed  absorptions  at  1760  and  3300  cm-1  due  to  the  carbamate 
carbonyl  and  OH  respectively.  Ring  strain  of  the  cyclic  ring  caused  the 
102 carbamate  carbonyl  stretch  to  shift  to  a  higher  frequency.  Its  III  NMR 
spectrum  suggested  that  the  epoxide  ring  was  cleaved.  The  13C  NMR 
spectrum  showed  that  the  carbonyl  carbon  was  deshielded  slightly 
(from  5  155.8  to  158).  The  compound  gave  a  correct  elemental 
composition. 
Roush  and  Adam  suggested  that  the  cyclisation  of  the  nitrogen 
anion  with  the  epoxide  ring  was  highly  regiospecific  giving  only  the 
carbamate  with  the  five-membered  ring.  94  We  decided  to  investigate 
whether  or  not  such  regioselectivity  was  observed  in  our  experiment. 
It  is  likely  that  there  is  hardly  any  difference  in  the  spectroscopic  data 
between  the  carbamate  with  the  five-  (144)  and  six-membered  ring 
(148). 
Since  both  compounds  are  isomers,  microanalysis  and  mass 
spectrometry  provided  little  help.  In  theory,  the  most  valuable  piece  of 
spectroscopic  data  which  should  establish  whether  it  was  a  carbamate 
with  a  six-  or  a  five-membered  ring  is  from  IR  spectra.  The  carbamate 
carbonyl  stretch  for  different  ring  sizes  should  be  different.  Such 
absorption  could  be  used  to  distinguish  clearly  between  the  carbamate 
carbonyl  groups  of  five-  and  six-membered  rings.  However,  a 
literature  search  provided  little  evidence  for  the  existence  of  an 
absorption  frequency  for  a  six-membered  carbamate.  Thus  IR 
spectrometry  is  not  ideal  to  be  used  to  establish  whether  the  cyclic 
carbamate  was  a  five-  or  six-membered  ring.  The  1H  NMR  spectrum  of 
(144)  might  be  the  solution  providing  that  the  CH  next  to  the  alcohol 
group  coupled  with  the  OH.  A  D20  exchange  experiment  was  carried 
out.  The  1H  NMR  spectrum  of  (144)  showed  only  one  signal  was 
affected.  It  could  be  concluded  that  the  signal  must  be  the  CIi  next  to 
103 the  alcohol  group.  On  D20  exchange,  this  signal  was  resolved  from  a 
multiplet  to  a  doublet.  This  suggested  that  the  compound  must  be  the 
carbamate  with  a  five-membered  ring  otherwise  the  CH  next  to  the 
alcohol  group  would  have  remained  a  multiplet  on  D20  exchange,  if  it 
was  in  the  six-membered  ring 
The  last  step  of  the  synthesis  of  (1R,  2S)-2-ethylamino-l- 
phenylpropane-1,3-diol  (145)  was  hydrolysis  of  the  hydroxycarbamate 
(144).  Hydrolysis  was  effected  using  lithium  hydroxide  in  a  mixture  of 
water  and  ethanol  to  give  the  2-ethylamino-1,3-diol  (145)  in  93%  yield. 
The  IR  spectrum  of  this  compound  showed  absorptions  at  3448,3286 
and  3083  cm-1  due  to  the  NH  and  two  OH  groups  respectively  and  the 
compound  gave  a  correct  elemental  composition. 
Compound  (145)  was  recrystallised  in  a  conical  flask  from 
analytical  grade  ethyl  acetate  and  hexane  giving  small  cubic  crystals. 
These  were  submitted  to  Miss  K.  McCormark  (University  of  Glasgow)  for 
X-ray  crystallographic  analysis.  The  displacement  ellipsoid  structure  of 
this  compound  is  shown  in  Diagram  10. 
As  expected  the  molecule  has  several  hydrogen  bonding 
interactions  (Diagram  11).  The  oxygen  and  hydrogen  atoms  of  the 
hydroxyl  groups,  and  the  nitrogen  and  hydrogen  atoms  of  the  amino 
group  are  all  involved  in  H-bonding.  Each  functional  group  is  H-bonded 
to  two  other  identical  molecules.  The  unit  cell  of  the  crystal  is  depicted 
in  Diagram  12. 
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Diagram  10:  The  displacement  ellipsoid  structure  of  (1  R,  2S)-2- 
ethylamino-  I  -phcnylpropane-  l 
.  3-diol  (145) 
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Diagram  12:  The  unit  ccll  of  (1/1,2S)-2-cthylam  ino-I-phcnyIII  ropane- 
I,  3-dial  (145) 
106 Since  the  overall  yield  for  the  synthesis  of  (1R,  2S)-2-ethylamino- 
1-phenylpropane-1,3-diol  was  excellent,  it  was  decided  to  apply  the 
procedure  of  Roush  and  Adam  to  the  synthesis  of  N-ethylsphingosine. 
However,  this  methodology  required  the  use  of  an  allyl  alcohol  as  a 
starting  material.  Therefore,  the  ene-allyl  alcohol  (149)  required  for 
the  synthesis  of  N-ethylsphingosine  had  to  be  prepared  from 
tetradecanal  (153).  This  material  is  commercially  available,  but  was 
found  to  be  too  impure  and  difficult  to  purify  because  of  its  instability. 
Therefore  fresh  material  had  to  be  prepared  from  tetradecanoic  acid 
(150).  The  preparation  of  (149)  and  its  use  in  the  synthesis  are 
outlined  in  Scheme  54. 
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Scheme  54:  Attempted  synthesis  of  N-ethylsphingosine 
108 To  prepare  the  hydroxydiene  (149),  tetradecanoic  acid  was 
treated  with  dry  HC1  in  methanol  to  afford  the  known  methyl  ester 
(151)95  in  95%  yield.  The  IR  spectrum  of  the  methyl  ester  (151) 
showed  a  absorption  at  1744  cm-1  due  to  the  ester  carbonyl.  Its  III 
NMR  spectrum  showed  a  singlet  at  8  3.53  corresponding  to  the  methoxy 
group  and  the  high  resolution  mass  spectrum  gave  a  value  for  the 
molecular  ion  of  242.2237  compared  with  a  theoretical  value  of 
242.2245. 
Reduction  of  the  methyl  ester  (151)  with  lithium  aluminium 
hydride  gave  the  known  alcohol  (152)96  in  94%  yield.  The  expected 
absorption  due  to  the  stretching  of  the  OH  was  found  at  3421  cnl'  1. 
The  1H  NMR  spectrum  of  (152) 
.  showed  a  triplet  at  6  3.52  for  the 
methylene  protons  nearest  to  the  hydroxyl  group. 
Swern  oxidation  of  (152)  to  the  known  aldehyde  (153)97  was 
achieved  in  84%  yield  using  dimethylsulfoxide,  oxalyl  chloride  and 
triethylamine.  Flash  chromatography  was  required  to  purify  the 
aldehyde.  The  IR  spectrum  showed  an  absorption  at  1720  cm-1  for  the 
aldehyde  carbonyl.  The  aldehyde  was  evident  from  signals  at  8  9.70  in 
the  1H  NMR  spectrum,  and  at  8  202.1  in  the  13C  NMR  spectrum. 
Wittig  condensation  was  then  required  to  convert  the  aldehyde 
into  the  known  diene  methyl  ester  (154)38.  The  first  step  involved 
deprotonation  of  methyl  (E)-4-dimethylphosphono-2-butenoatc 
followed  by  coupling  with  the  aldehyde  to  afford  the  diene  methyl 
ester.  The  diene  methyl  ester  was  isolated  in  62%  yield.  The  IR 
spectrum  of  the  diene  methyl  ester  (154)  showed  absorptions  at  1650 
and  1718  cm-1  for  the  C=C  and  (xß-unsaturated  ester  carbonyl.  Its  111 
NMR  spectrum  showed  a  singlet  at  8  3.70  for  the  methoxy  group  and  a 
multiplet  at  6  5.81  -  7.72  for  the  alkene  hydrogens.  Due  to  the 
complexity  of  this  multiplet,  the  coupling  constants  could  not  be 
estimated.  The  13C  NMR  spectrum  showed  that  it  was  only  partially 
pure  and  consisted  of  a  mixture  of  (2E,  4Z)-  and  (2E,  4E)-isomers.  These 
isomers  could  not  be  separated  using  column  chromatography  and  had 
to  be  used  directly  in  the  next  step  with  the  possibility  that  the 
products  of  the  next  step  would  give  a  better  separation  on  TLC. 
109 The  reduction  of  (154)  to  the  known  alcohol  (149)3  8  was 
achieved  in  80%  yield  using  lithium  aluminium  hydride.  The  expected 
OH  stretch  was  `  found  at  3318  cm-1.  The  IH  NMR  spectrum  showed  a 
doublet  at  5  4.05  for  the  methylene  protons  nearest  to  the  hydroxyl 
group.  The  splitting  patterns  of  alkene  protons  were  complex  and  so 
the  coupling  constants  could  not  be  determined.  A  small  trace  of  the 
(2E,  4Z)-isomer  was  shown  by  the  13C  NMR  spectrum.  Further  attempts 
to  separate  these  isomers  by  column  chromatography  failed. 
Nevertheless  the  mixture  was  used  in  the  next  reaction. 
Asymmetric  epoxidation  of  the  hydroxydiene  (149)  gave  the  new 
E-ene-epoxyalcohol  (155)  in  5%  yield  using  Sharpless  conditions.  The 
IR  spectrum  of  (155)  showed  absorptions  at  1245,1645  and  3200  cm-1 
due  to  the  C-O,  C=C  and  OH  respectively.  The  epoxide  protons  were 
observed  in  the  1H  NMR  spectrum  as  a  multiplet  at  8  3.03  for  the 
epoxide  proton  nearest  to  the  hydroxyl  group  and  a  double  of  doublets 
at  S  3.30  for  the  other  epoxide  proton.  Also  present  in  the  111  NMR 
spectrum  were  a  double  doublets  of  triplets  at  8  5.11  for  the  alkene 
proton  adjacent  to,  the  epoxide,  and  a  doublet  of  triplets  at  8  5.89  for 
the  other  alkene  proton.  The  coupling  constant  between  the  alkene 
protons  was  found  to  be  15.4  Hz  indicating  it  must  be  a  E-double  bond. 
The  reaction  also  gave  the  new  Z-ene-epoxyalcohol  (156)  which 
was  isolated  in  10%  yield.  There  was  little  spectroscopic  difference 
between  (155)  and  (156)  apart  from  their  1H  NMR  coupling  constants. 
The  alkene  protons  of  the  Z-ene-epoxyalcohol  were  found  to  have  a 
coupling  constant  of  11  Hz.  A  homo-decoupling  experiment  was  carried 
out  on  the  E-isomer  (155)  to  ensure  that  the  epoxidation  did  indeed 
occur  at  the  allylic  double  bond.  Irradiation  of  the  signal  at  8  5.89 
caused  the  signal  (saturated  methylene  protons)  at  8  2.01  to  collapse 
from  a  multiplet  to  a  triplet.  This  decoupling,  however,  had  no  effect  on 
the  methylene  protons  adjacent  to  the  hydroxyl  group.  Thus  it  could  be 
concluded  that  Sharpless  asymmetric  epoxidation  must  have  occurred 
at  the  allylic  double  bond.  The  same  finding  was  also  observed  for  the 
Z-isomer. 
110 Although  the  enantioselective  route  was  successful  in  the 
synthesis  of  (1R,  2S)-2-ethylamino-l-phenylpropane-1,3-diol  (145),  the 
route  to  the  corresponding  N-ethylsphingosine  came  to  a  halt  at  the 
Sharpless  epoxidation  stage.  The  yield  was  poor  for  the  Sharpless 
asymmetric  epoxidation  because  the  starting  material  had  a  tendency 
to  crystallise  out  of  the  reaction  mixture  at  low  temperature.  But  from 
room  temperature  to  0  °C,  the  starting  material  readily  dissolved  in 
dichloromethane.  Unfortunately,  it  was  necessary  to  carry  out  the 
Sharpless  asymmetric  epoxidation  around  -30  oC  in  order  to  achieve 
the  best  selectivity  and  to  ensure  the  formation  of  the  titanium 
complex.  Such  a  problem  has  to  be  overcome  as  this  is  the  key  step  of 
the  synthesis.  One  possible  solution  may  be  to  perform  the  epoxidation 
with  a  co-solvent.  However,  time  constraints  prevented  further 
development  of  this  route  towards  N-ethylsphingosine.  We  believe  that 
the  success  of  this  synthesis  probably  relies  solely  on  improving  the 
yield  of  the  Sharpless  epoxidation  as  the  three  remaining  steps  appear 
straightforward. 
6.5  Biological  Testing  of  a  Selection  of  Sphingosine  Analogues 
A  selection  of  compounds  was  tested  in  vitro  on  two  different 
cancer  lines  by  Dr  A.  T.  McGown  at  the  Paterson  Institute  in 
Manchester.  These  cell  lines  were  human  ovarian  carcinoma  and 
chronic  myelogenous  leukaemia.  Table  5  records  the  IC5  0  values  of 
these  compounds.  Comparison  of  IC50  values  for  both  assays  show  that 
the  order  of  potency  increases  when  the  hydrophobic  part  is  an  alkyl 
chain.  Compounds  (115),  (116)  and  (117)  were  the  most  potent  for 
both  cell  lines  having  IC50  values  of  about  1µM. 
Table  5 
IC50  values  (µ  M) 
Structure  A2780  cell  line  K562  cell  line 
CH1 
(158) 
Ph'ýOH 
NMe2 
>50  >50 
CH2 
(88) 
Ph""'OH 
NMe2 
>50  >50 
111 Table  5  (cont.  ) 
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OH 
HNv 
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OH- 
R---(  OH 
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H2N 
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OH 
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(  ) 
AcHN 
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14.4  15.3 
(119) 
AcHN 
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Further  testing  was  carried  out  by  Dr  McGown  on  the  most  active 
alkynes  (115),  (116)  and  (117).  They  were  tested  in  vitro  on  mouse 
112 P388  lymphoid  neoplasm  with  a  high  PKC  expression,  a  P388  cell  line 
with  a  low  PKC  expression  (ca.  10%)  resistant  to  bryostatin  (Br/D)  and  a 
humun  ovarian  carcinoma  resistant  to  adriamycin  (A2780ADR).  The 
results  shown  in  Table  6  demonstrate  that  these  alkynes  (115),  (116) 
and  (117)  are  effective  against  a  range  of  cancer  cell  lines  with  IC5  0 
values  of  about  1µM.  In  addition,  decreasing  the  PKC  expression  (ca. 
10%)  'in  the  P388  cell  line  decreases  the  IC50  values  of  compounds 
(116)  and  (117)  by  five  fold,  indicating  that  these  compounds  are 
exerting  some  effect  on  PKC. 
Table  6 
IC50  values  (µ  M) 
P338  Br/D  A2780ADR 
CH  6 
(116) 
6.56  1.5  0.63 
CH  7 
(117) 
7.87  1.18  0.69 
CH  8 
(115) 
1.53  0.59  1.13 
D-erythro- 
s  hin  osine 
3.8  4.4  1.13 
6.6  Future  Work 
Since  the  three  sphingosine  analogues  containing  a  triple  bond 
showed  very  promising  cytotoxic  effects  on  different  cancer  lines,  it  will 
be  of  great  interest  to  synthesise  the  corresponding  N-methylated 
compounds  to  see  how  such  a  modification  will  affect  the  anti-cancer 
activity.  As  discussed  in  Chapter  4,  N-methylation  of  the  aminodiol 
proved  to  be  more  difficult  than  first  anticipitated.  Such  a  problem 
may  be  overcome  by  using  the  retro  aza  Diels-Alder  procedure.  The 
main  attraction  of  this  procedure  was  the  fact  that  the  reaction  could 
proceed  in  the  presence  of  other  functional  groups.  Although  (S)-N- 
methylphenylalaninol  could  not  be  synthesised  using  this  procedure 
because  of  the  mixture  of  products  obtained  in  the  reduction  step,  we 
believe  that  once  the  conditions  and  reagents  for  this  reduction  have 
been  established,  this  procedure  will  be  a  powerful  way  to  carry  out  N- 
methylation. 
113 Sphingosine  was  only  produced  in  small  amount  in  the  reduction 
step  of  the  diastereoselective  synthesis.  It  was  too  low  to  be  used  to 
synthesise  sphingosine  analogues.  The  yield  of  the  reduction  step  must 
be  improved.  As  for  the  enantioselective  approach,  the  problem  was 
with  the  insolubility  of  the  starting  material  for  the  Sharpless 
epoxidation.  Achieving  enantioselective  synthesis  was  more  desirable 
than  the  diastereoselective  synthesis  because  the  final  product  of  the 
enantioselective  approach  would  be  N-alkylsphingosine  instead  of 
sphingosine  itself.  The  alkyl  group  of  N-alkylsphingosine  could  be 
varied  simply  by  using  different  isocyanates  in  the  carbamate 
formation  step.  It  would  be  desirable  to  have  a  route  in  which  N- 
methylsphingo  sine  could  be  synthesised,  providing  an  alternative  to  the 
usual  N-methylation  of  sphingosine. 
The  synthesis  of  deoxysphingosine  slowed  to  a  halt  until  (S)-3-(4- 
toluenesulfonyl)-4-(4-tolu  en  esulfonyloxymetlhyl)oxazolidin-2-one 
(124)  was  discovered.  The  use  of  (124)  in  the  alkynylation  step  was 
encouraging  even  though  the  yield  was  not  that  good.  Unfortunately 
there  was  insufficient  product  to  be  used  for  the  last  step  which  would 
be  the  Birch  reduction. 
114 CHAPTER  SEVEN 
Experimental  to  Chapters  4-6 
7.1  General 
Melting  points  (m.  p.  )  were  measured  with  a  Gallenkamp  apparatus. 
Infra-red  (IR)  spectra  were  obtained  on  a  Perkin  Elmer  983 
spectrophotometer  or  a  Perking  Elmer  PU  9800  PT-IR 
spectrophotometer.  1H  and  13C  NMR  spectra  were  obtained  on  a 
Bruker  WP200-SY  spectrometer  operating  at  200MHz  and  50MIHz 
respectively.  All  coupling  constants  quoted  arc  measured  in  Hz.  The 
numbering  schemes  shown  are  used  for  case  of  asssigning  the  NMR 
spectra.  Mass  spectra  (MS)  were  recorded  on  AEI  MS  12  or  MS902 
spectrometers.  Thin  layer  chromatography  (TLC)  was  carried  out  on 
silica  gel  G  plates  of  0.25mm  thickness  developed  with  hexane  -  ethyl 
acetate  unless  stated  otherwise  and  compounds  were  detected  with 
vanillin,  iodine  or  by  ultra-violet  radiation.  Column  chromatography 
was  carried  out  on  silica  gel,  70-230  mesh  with  the  same  solvent 
system. 
7.2  Experimental  to  Chapters  4 
(S)-N.  O-DiacetXlphenylalaninol  (7  )  72 
13 
Pyridine  (1.3  g,  16.6  mmol)  and  acetic  anhydride  (1.69  g,  16.6  mmol) 
were  added  sequentially  to  a  solution  of  (S)-phenylalaninol  (1.0  g,  6.62 
mmol)  in  dry  THE  (20  ml).  After  the  reaction  mixture  was  stirred  at 
room  temperature  for  10  h,  it  was  diluted  with  ethyl  acetate  (40  ml) 
and  washed  with  1M  hydrochloric  acid  (3  x  30  ml)  and  then  with 
saturated  sodium  bicarbonate  solution  (3  x  30  ml).  The  organic  layer 
was  dried  with  magnesium  sulfate  and  concentrated  to  give  white 
needles  (1.3  g,  84%);  mp  112-113  OC  {lit.,  72  114-115  oC};  Rf  0.6  (ethyl 
115 acetate);  [aID22  -13.0  (c  1  in  acetone)  {lit.,  72  [a]D22  -13  (c  1  in  acetone)); 
8H  (200MHz,  CDC13)  1.96  (3H,  s,  13-H3),  2.10  (3H,  s,  11-H3),  2.85  (211, 
ABX,  3-H2,  J  4.6,11.4  Hz),  4.10  (2H,  ABX,  1-H2,  J  6.4,13.7  Hz),  4.38  (111, 
m,  2-H),  5.67  (1H,  br  d,  NH),  7.26  (5H,  m,  aromatic  H);  5c  (50  MHz,  CDC13) 
20.8  (C-13),  23.3  (C-11),  37.4  (C-3),  49.4  (C-2),  64.7  (C-1),  126.7  (C-7), 
128.5  (C-5  and  -9  or  C-6  and  -8),  129.1  (C-5  and  -9  or  C-6  and  -8) 
136.9  (C-4),  169.8  (C-12),  171.0  (C-10);  vmax  (KBr  disc)/cm-1  1772 
(COO),  1684  (CON),  1271,1261,1045,1033;  m/z  235  (M+,  1.5%),  176 
(14.6,  M-  OCOCH3)  134  (9.6,  M-  OCCH3,  -  NHCOCH3),  120  (20.9),  102 
(51.2),  84  (72.9),  60  (100%);  (found  M+,  235.1211.  Calc.  for  C  13H  17NO3, 
235.1280).  (Found:  C,  66.13;  H,  7.36;  N,  5.90.  Calc.  for  C  13H  17NO3:  C, 
66.00;  H,  7.20;  N,  5.90  %). 
(R)-N.  0-Diacetyll2henylalaninol  (75)72 
13 
The  title  compound  was  prepared  in  the  same  way  as  for  the  (S)  - 
isomer  except  that  (R)-phenylalaninol  (1.0  g,  6.62  mmol)  was  used.  The 
compound  was  isolated  as  white  needles  (1.3  g,  84%);  mp  113-114  OC 
{lit.,  72  114-115  °C];  Rf  0.6  (ethyl  acetate);  [a]D22  +13.0  (c  1  in  acetone) 
{lit.,  72  [a]D22  +13  (c  1  in  acetone));  8H  (200MHz,  CDC13)  1.96  (3H,  s,  13- 
H3),  2.10  (3H,  s,  11-H3),  2.85  (2H,  RX,  3-H2,  J  4.5,11.4  Hz),  4.10  (2H, 
AB  X,  1-H2,  J  6.3,13.5  Hz),  4.38  (IH,  m,  2-H),  5.67  (IH,  br  d,  NH),  7.26 
(5H,  m,  aromatic  H);  6c  (50  MHz,  CDC13)  20.8  (C-13),  23.3  (C-11),  37.4  (C- 
3),  49.4  (C-2),  64.7  (C-1),  126.7  (C-7),  128.5  (C-5  and  -9  or  C-6  and  -8), 
129.1  (C-5  and  -9  or  C-6  and  -8),  136.9  (C-4),  169.8  (C-12),  171.0  (C- 
10)  ;  vm  ax  (KBr  disc)/cm-1  1772  (COO),  1684  (CON),  1271, 
1261,1045,1033;  m/z  (M+,  1.3%),  176  (14.6,  M-  OCOCH3)  134  (9.6,  M- 
OCCH3,  -  NHCOCH3  ),  120  (21.9),  102  (51.2),  84  (74.9),  60  (100%);  (found 
M+,  235.1214.  Calc.  for  C  13  H  17  NO3,235.1208).  (Found:  C,  66.19;  11, 
7.42;  N,  5.97.  Calc.  for  C13H17NO3:  C,  66.00;  H,  7.20;  N,  5.90%). 
116 (S)-N-tert-Butyloxycarbonylphenylalaninol  (77)73 
11 
Dioxan  (12  ml)  and  di-tert-butyldicarbonate  (2  g,  8.6  mmol)  were 
added  to  a  solution  of  (S)-phenylalaninol  (1.0  g,  6.62  mmol)  in  water 
(25  ml)  with  continuous  stirring  at  room  temperature  for  18  h.  The 
solvents  were  then  removed  with  ethanol  in  vactto  and  the  residue  was 
chromatographed  (ethyl  acetate-hexane;  1:  3)  to  give  an  oil  (1.66  g, 
97%);  Rf  0.4  (ethyl  acetate-hexane;  1:  1);  6ii  (200MHz,  CDC13)  1.41  (911,  s, 
11-,  12-  and  13-H3),  2.80  (2H,  d,  3-H2,  J  7.2  Hz),  2.89  (111,  br  s,  01l), 
3.56  (2H,  ABX,  1-H2,  J  3.7,11.0  Hz),  3.86  (IH,  m,  2-H),  4.76  (111,  br  d, 
NH),  7.26  (5H,  m,  aromatic  H);  8c  (50  MHz,  CDC13)  28.2  (C-11,  -12  and 
-13),  37.8  (C-3),  50.5  (C-2),  65.0  (C-1),  79.3  (C-14),  126.5  -  129.2 
(aromatic  CH),  137.2  (C-4),  155.1  (C-10);  vmax  (film)  /  cm-1  3418hr  (011), 
2914,1686  (OCON);  m/z  251  (M+,  0.3%)178  (10.9,  M-  OC4  H9),  160 
(19.2,  M-  COOC4H9),  91  (42.7,  M-  OHCH2CHNH000C4119),  57  (100%); 
(found  M+,  251.1530.  Calc.  for  C14H21N03,251.1521). 
(S)-2-[(tert-Butyloxycar  y  amino)-N-metliyl]Q 
methylphenylalaninol  (78) 
(using  the  procedure  of  Coggins  and  Benoiton74) 
11 
Sodium  hydride  (95%,  0.35  g,  21.6  mmol)  was  added  to  a  stirred 
solution  of  N-BOC-phenylalaninol  (77)  (1.8  g,  7.17  mmol)  and 
iodomethane  (4  ml,  21.2  mmol)  in  dry  THE  (20  ml).  After  the  mixture 
117 was  stirred  for  15  h  at  room  temperature,  the  mixture  was  poured  into 
ice  water  and  extracted  with  ethyl  acetate  (3  x  40  ml).  The  combined 
extracts  were  dried  with  magnesium  sulfate  and  concentrated  under 
reduced  pressure  to  afford  a  yellow  oil.  TLC  (ethyl  acetate-hexane;  1:  1) 
showed  three  spots  with  Rf  values  of  0.4,0.6  and  0.7.  Purification  of 
the  oil  by  column  chromatography  eluting  with  ethyl  acetate-hexane 
(1:  4)  gave  (S)-3-methyl-4-benzyloxazolin-2-one  (79),  N-tert- 
butyloxycarbonyl-O-methylphenylalaninol  (80),  and  the  title 
compound. 
The  title  compound  was  obtained  as  a  yellow  oil  (0.1  g,  5%);  Rf  0.7;  811 
(200MHz,  CDC13)  1,.  3  (9H,  s,  11-,  12-  and  13-H3),  2.30  (3H,  s,  16-113), 
2.71  (2H,  m,  3-H2),  3.16,  (2H,  m,  1-H2),  3.18  (3H,  s,  15-113),  3.81  (111,  m, 
2-H),  7.12  (5H,  m,  aromatic  H);  5C  (50  MHz,  CDC13)  28.3  (C-11,  -12  and 
-13),  33.8  (C-16),  37.7  (C-3),  51.5  (C-15),  58.7  (C-2),  72.5  (C-1),  79.4  (C- 
14)  126.2  (C-7),  128.4  (C-5  and  -9  or  C-6  and  -8),  129.3  (C-5  and  -9  or 
C-6  and  -8),  138.2  (C-4),  155.0  (C-10);  vmax  (film)  /  cm-1  2850,1745 
(OCON);  m/z  206  (9.1,  M-  OC4H9),  188  (23.5,  M-  COOC4H9),  134  (11.2, 
M-  N(CH3)COOC4H9,  -  CH3);  (found  M+  -  0C4119,206.1179.  Calc.  for 
C  12H  16NO2,206.1181). 
(S)-3-Methyl-4-benzyloxazolin-2-one  (79)  was  obtained  as  white 
needles  (0.30  g,  21%). 
m.  p.  90  oC;  Rf  0.4;  [a]D22  -58.1  (c  1.5  in  CHC13);  811  (200MHz,  CDC13)  2.75 
(2H,  m,  3-H2),  2.77  (3H,  s,  11-H3),  3.82  (2H,  m,  1-H2),  4.02  (11-1,  nl,  2-11), 
7.11  (5H,  m,  aromatic  H);  SC  (50  MHz,  CDC13)  29.4  (C-11),  38.2  (C-3),  58.2 
(C-2),  66.52  (C-1),  126.2  (C-7),  128.4  (C-5  and  -9  or  C-6  and  -8),  129.3 
(C-5  and  -9  or  C-6  and  -8),  135.5  (C-4),  158.42  (C-10);  vmA,,  (KBr  disc)  / 
cm-1  1750  (OCON);  m/z  191  (M+,  0.8),  117  (1.2),  100  (100,  M- 
C6H5CH2),  91  (13.9,  M-  CHCH2OO0NMe);  (found  M+,  191.0956.  Calc.  for 
C  11  H  13  NO2,191.0946).  (Found:  C,  69.26;  H,  6.98;  N,  7.14.  Calc.  for 
C11H13N02:  C,  69.11;  H,  6.77;  N,  7.32%). 
118 (S)-N-tert-Butyloxycarbonyl-O-methylphenylalaninol  (80)  was  obtained 
as  a  yellow  oil  (1.1  g,  57%). 
O/15 
0 
Rf0.6;  5H  (200MHz,  CDC13)  1.3  (9H,  s,  11-,  12-  and  13-H3),  2.71  (211,  m, 
3-H2),  3.16  (2H,  ABX,  1-H2,  J  3.7,11.2  Hz),  3.18  (3H,  s,  15-H3),  3.81  (1H, 
m,  2-H),  4.92  (1H,  br  d,  NH),  7.11  (5H,  m,  aromatic  H);  5c  (50  MHz,  CDC13) 
28.3  (C-11,  -12  and  -13),  37.7  (C-3),  51.5  (C-15),  58.7  (C-2),  72.5  (C-1), 
79.7  (C-14),  126.2  (C-7),  128.3  (C-5  and  -9  or  C-6  and  -8),  129.3  (C-5 
and  -9  or  C-6  and  -8),  138.2  (C-4),  155.0  (C-10);  vmax  (film)  /  cm-  1 
1745  (OCON);  m/z  192  (18.9,  M-  OC4H9),  174  (5.9,  M-  COOC4H9),  134 
(14.9,  M-  HNCOOC4H9,  -  CH3);  (found  M-  OC4H9,192.1018.  Calc.  for 
C11H14NO2,192.1024). 
(S)-N.  0-Dime  thyýýhenylýlaninol  ($I1 
0 
10 
A  solution  of  (S)-2-[(tert-butyloxycarbonylamino)-N-methyl]-O- 
methylphenylalaninol  (78)  (0.1  g,  38.4  mmol)  in  1M  HCl  in  ethyl 
acetate  (30  ml)  was  stirred  at  room  temperature  for  5  h.  The  reaction 
mixture  was  diluted  with  ethyl  acetate  (20  ml),  washed  with  1M 
sodium  hydroxide  (2  x  50  ml),  dried  with  magnesium  sulfate  and 
concentrated  to  give  the  title  compound  (0.04  g,  78%)  as  a  yellow  oil;  Rf 
0.4  (ethyl  acetate);  [a]D22  -1.4  (c  1.7  in  ethanol);  Stt  (200MHz,  CDC13) 
2.38  (3H,  s,  11-H3),  2.56  (1H,  br  s,  NH),  2.72  -  2.81  (3H,  m,  1-H2  and  2- 
H),  3.23  (2H,  m,  3-H2),  3.29  (3H,  s,  10-H3),  7.26  (5H,  m,  aromatic  H);  8c 
(50  MHz,  CDC13)  33.9  (C-11),  37.3  (C-3),  58.8  (C-10),  60.6  (C-2),  73.2  (C- 
1),  126.1  (C-7),  128.5  (C-5  and  -9  or  C-6  and  -8),  129.2  (C-5  and  -9  or 
119 C-6  and  -8),  138.7  (C-4);  Vmax  (KBr  disc)  /  cm-1  3431m  (NH);  m/z  179 
(M+,  3.0%),  134  (50,  M-  NHCH3,  -  CH3),  81  (100,  M-  C6H5CH);  (found 
M+,  179.1320.  Calc.  for  C11H17NO,  179.1320). 
S)-N-tert-Butvloxvcarbon  I  mcinvitiuvrnncnviaianina 
LU4 
(using  the  procedure  of  Corey  et  a!.  )98 
N-BOC-phenylalaninol  (77)  (3.24  g,  13.0  mmol),  imidazolc  (1.3  g,  20.0 
mmol),  and  tert-butyl-dimethylsilyl  chloride  (2.35  g,  14.3  mmol)  in  dry 
DMF  were  placed  in  a  250  ml  round  bottom  flask.  The  reaction  was 
stirred  for  1h  then  1M  hydrochloric  acid  (30  ml)  was  added  . 
The 
aqueous  layer  was  extracted  with  ethyl  acetate  (3  x  30  ml).  The 
combined  extracts  were  dried  with  magnesium  sulfate  and 
concentrated  under  reduced  pressure  to  give  an  oily  solid  (4.2  g,  89%); 
Rf0.6  (ethyl  acetate-hexane;  1:  2);  811  (200MHz,  CDC13)  -0.03  (611,  s,  15- 
and  16-H3),  0.88  (9H,  s,  17-,  18-  and  19-CH3),  1.43  (911,  s,  11-,  12-  and 
13-H3),  2.76  (2H,  d,  3-H2,  J  8.0  Hz),  3.41  (2H,  m,  1-112),  3.52  (111,  in,  2- 
H),  4.73  (1H,  br  d,  NH),  7.13  (5H,  m,  aromatic  H);  SC  (50  MHz,  CDC13)  -5.5 
(C-15  and  -16),  18.1  (C-20),  25.7  (C-17,  -18  and  -19),  28.3  (C-11,  -12 
and  -13),  37.3  (C-3),  53.0  (C-2),  62.9  (C-1),  79.1  (C-14),  121.5  (C-7), 
134.6  (C-5  and  -9  or  C-6  and  -8),  134.8  (C-5  and  -9  or  C-6  and  -8), 
138.2  (C-4),  155.4  (C-10);  vmax  (film)  /  cm-1  2953,1695  (OCON),  1256 
(Si(CH3)2),  1056,840  (SiO);  m/z  292  (2.1,  M-  OC4H9),  251  (100,  Mli  - 
Si(CH3)2C(CH3)3),  173  (50.1),  90  (87.6);  (found  M-  OC4H9,292.1690. 
Calc.  for  C  16H26SiNO2,292.1684). 
120 Attempted  preparation  of  (S)-2-[(tert-butylox  cay  rbon  lamino)-N- 
methyl]-O-tert-butyldimethylsilylphenylalaninol 
(using  the  procedure  of  Coggins  and  Benoiton74) 
0 
Sodium  hydride  (95%,  0.1  g,  4.2  mmol  )  was  added  to  a  solution  of  (S)- 
N-BOC-O-TBDMS-phenylalaninol  (84)  (1  g,  2.7  mmol)  in  dry  DMF  under 
nitrogen.  Once  the  hydrogen  gas  had  stopped  evolving,  methyl  iodide 
(1  g,  7.0  mmol)  was  added  dropwise  to  the  resulting  mixture.  After  the 
addition  was  complete,  the  flask  was  stirred  overnight  at  room 
temperature.  Ethyl  acetate  (50  ml)  was  added  followed  by  water  (30 
ml).  The  aqueous  layer  was  extracted  with  ethyl  acetate  (4  x  30  nil) 
and  the  combined  extracts  were  washed  with  brine  (3  x  30  ml),  water 
(3  x  30  ml),  dried,  filtered  and  concentrated  to  give  a  yellow  oil.  TLC 
and  all  spectral  properties  were  identical  to  N-BOC-O-TBDMS- 
phenylalaninol  (84).  This  reaction  was  repeated  several  times  under 
different  conditions,  all  of  which  were  unsuccessful.  Table  1 
summarises  the  outcomes. 
Azabicyclic  lic  (2.2.1)  heptene  (85 
(using  the  procedure  of  Grieco  and  Bahsas75) 
4 
121 Cyclopentadiene  (1.3  g,  19.6  mmol)  was  added  to  a  stirred  solution  of 
(S)-phenylalaninol  (1  g,  6.62  mmol),  trifluoroacetic  acid  (0.75  g,  6.62 
mmol)  and  formaldehyde  (37%,  1.2  g,  13.2  mmol)  in  water  (30  ml). 
After  1h  at  room  temperature,  the  hetrogenous  mixture  was  washed 
with  hexane  and  neutralised  with  saturated  sodium  bicarbonate 
solution.  The  resulting  solution  was  then  extracted  with  methylene 
chloride  (3  x  40  ml).  The  combined  organic  extracts  were  dried  over 
magnesium  sulfate  and  concentrated  to  give  an  oil  which  was  purified 
by  column  chromatography  eluting  with  methylenc  chloride/ 
methanol/  ammonium  hydroxide  (96:  3:  1)  to  afford  the  title  compound 
(1.0  g,  67%);  the  1H  NMR  spectrum  was  complex;  Sc  (50  MFiz,  CDC13) 
42.8  (C-2),  47.5  (C-6),  51.1  (C-8),  51.5  (C-5),  52.1  (C-1),  61.4  (C-7), 
128.3  (C-13),  129.3  (C-11  and  -15  or  C-12  and  -14),  130.2  (C-11  and 
-15  or  C-12  and  -14),  130.4  (C-3  or  -4),  136.8  (C-3  or  -4),  137.3  (C-15); 
Vmax  (film)  /  cm-1  3401,1680., 
Attempted  synthesis  of  (S  -N-methylphenylalaninol 
OH 
Trifluoroacetic  acid  (0.25  g,  2.18  mmol)  and  triethylsilane  (0.50  g,  4.4 
mmol)  were  added  to  a  solution  of  (121)  (0.5  g,  2.18  mmol)  in 
chloroform.  The  reaction,  mixture  was  stirred  at  room  temperature 
under  nitrogen.  After  20  h,  the  solvent  was  removed  under  pressure. 
The  crude  product  was  redissolved  in  chloroform  (50  ml),  treated  with 
1M  HCl  (50  ml)  and  washed  with  ether  (3  x  30  ml).  The  aqueous  layer 
was  neutralised  with  saturated  sodium  bicarbonate  solution  and 
extracted  with  methylene  chloride  (3  x  50  ml).  The  organic  extracts 
were  dried  over  magnesium  sulfate  and  concentrated  to  give  a  complex 
mixture. 
122 (S)-N.  O-Diformylphenylalaninol  86176 
0 
Formic  acid  (1.2  g,  31  mmol)  was  added  to  a  solution  of  (S)  - 
phenylalaninol  (1  g,  6.6  mmol)  in  toluene  (10  ml)  and  the  mixture  was 
heated  at  90  -  98  oC  for  13  h.  After  cooling  to  room  temperature,  the 
mixture  was  diluted  with  ethyl  acetate  (20  ml)  and  washed  with 
saturated  sodium  bicarbonate  solution  and  then  brine.  The  organic 
layer  was  dried  with  magnesium  sulfate,  filtered  and  concentrated 
under  reduced  pressure  to  give  a  yellow  oil  which  was 
chromatographed  (ethyl  acetate-hexane;  1:  1)  to  afford  a  white  solid  (1 
g,  83%);  mp  98  -  99  °C;  Rf0.3  (ethyl  acetate-hexane;  1:  1);  51;  (200M1iz, 
CDC13)  2.91  (2H,  d,  3-H2),  4.16  (2H,  d,  1-H2),  4.54  (111,  in,  2-11),  6.17 
(1H,  br  d,  NH),  7.20  (5H,  m,  aromatic  H),  8.07  (2H,  br  s,  10-11);  3c  (50 
MHz,  CDC13)  37.1  (C-3),  47.9  (C-2),  65.1  (C-1),  126.9  (C-7)  128.5  (C-5 
and  -9  or  C-6  and  -8),  129.2  (C-5  and  -9  or  C-6  and  -8),  136.4  (C-4), 
160.7  -  160.9  (C-10  and  -11);  vmax  (KBr  disc)  /  cm-1  3400,1718  (OCO), 
1668  (CON);  m/z  207  (M+,  4.2%),  162  (100,  M-  OCOH),  133  (18.3,  M- 
000H,  -  CHO),  115  (7.4,  M-  OCOH,  -  NHCHO),  91  (80,  M- 
HCOOCH2CHNHCHO);  (found  M+,  207.0870.  Cale.  for  C  111-113NO3, 
207.0895). 
(S)-N-Methylphenylalaninol  (87) 
OH 
Lithium  aluminium  hydride  (0.55  g,  14.4  mmol)  and  dry  THE  (30  nil) 
were  placed  in  a  flame  dried  three-necked  flask.  A  solution  of  (S)-N,  O- 
diformylphenylalaninol  (86)  (1  g,  4.8  mmol)  in  dry  THE  (20  nil)  was 
then  added  to  the  suspension  at  0  °C.  The  reaction  mixture  was  stirred 
for  1h  at  this  temperature  and  then  quenched  by  addition  of  saturated 
123 ammonium  chloride  solution  (50  ml).  The  resulting  mixture  was 
extracted  with  ethyl  acetate  (3  x  50  ml),  dried  with  magnesium  sulfate, 
filtered  and  concentrated  to  give  a  yellow  oil.  The  oil  was  partially 
purified  by  flash  chromatography  eluting  with  ethyl  acetate-ethanol 
(9:  1)  to  afford  the  title  compound  (0.65  g,  74%). 
(IS  2S)-N.  O.  O-Triformyl-2-amino-l-phenylpropanc-1.3-diol  (157)76 
0 
0 
Formic  acid  (1.4  g,  3.0  mmol)  was  added  to  a  solution  of  (IS,  2S)-2- 
amino-1-phenylpropane-1,3-diol  (1  g,  6.0  mmol)  in  toluene  (10  ml) 
and  the  mixture  was  heated  at  90  -  98  oC  for  13  h.  After  cooling  to 
room  temperature,  the  mixture  was  diluted  with  ethyl  acetate  (20  ml) 
and  washed  with  saturated  sodium  bicarbonate  solution  and  then  brine. 
The  organic  layer  was  dried  with  magnesium  sulfate,  filtered  and 
concentrated  under  reduced  pressure  to  give  a  yellow  oil  which  was 
chromatographed  (ethyl  acetate-hexane;  1:  1)  to  afford  an  oil  (1.3  g, 
86%);  Rf  0.4  (ethyl  acetate-hexane;  1:  1);  Stt  (200MHz,  CDC13)  3.80  (111, 
dd,  1-H,  J  5.4,11.4  Hz),  4.10  (1H,  dd,  1-H,  J  6.3,11.0  Hz),  4.67  (111,  m,  2- 
H),  5.93  (1H,  d,  3-H,  J  6.9  Hz),  7.25  (5H,  m,  aromatic  H),  8.73,7.95,8.02 
(3H,  3xs,  10-,  11-  and  12-H);  8c  (50  MHz,  CDC13)  49.7  (C-2),  62.0  (C-1), 
73.0  (C-3),  126.0  (C-5  and  -9  or  C-6  and  -8)  128.2  (C-5  and  -9  or  C-6 
and  -8),  128.9  (C-7),  135.5  (C-4),  159.3,160.3,161.4  (C-10,  -11  and 
-12);  Vmax  (KBr  disc)  /  cm-1  1718  v.  b  (OCO),  1668  v.  b  (CON);  ni/z  251 
(M+,  0.5%),  177  (5.8),  132  (14.7),  107  (23.8),  71  (100);  (found  M+, 
251.0808.  Calc.  for  C12H13N05,251.0810). 
124 Attempted  synthesis  of  (1S.  2S)-2-methylamino- 
diol 
OH 
OH 
Lithium  aluminium  hydride  (0.68  g,  20  mmol)  and  dry  THE  (30  ml) 
were  placed  in  a  flame  dried  three-necked  flask.  A  solution  of  (157)  (1 
g,  4.0  mmol)  in  dry  THE  (20  ml)  was  then  added  to  the  suspension  at  0 
0C.  The  reaction  mixture  was  stirred  for  1h  at  this  temperature  and 
then  quenched  by  addition  of  saturated  ammonium  chloride  solution 
(50  ml).  The  resulting  mixture  was  extracted  with  ethyl  acetate  (3  x  50 
ml),  dried  with  magnesium  sulfate,  filtered  and  concentrated  to  give  a 
complex  mixture. 
(S)-N.  N-Dimethylphenylalanino  (88) 
(using  the  procedure  of  Feldkamp  et  al.  77) 
OH 
Formaldehyde'  (36%,  0.8  g,  8.0  mmol)  was  added  to  a  solution  of  (S)  - 
phenylalaninol  (1  g,  '6.7  mmol),  palladium/carbon  catalyst  (10%,  0.1g) 
and  glacial  acetic  acid  (0.8  g,  13.4  mmol)  in  water  (30  ml).  Nitrogen  gas 
was  bubbled  through  the  reaction  mixture  for  5  min  before  hydrogen 
gas  was  introduced.  The  reaction  was  stirred  for  10  h  after  which  the 
catalyst  was  removed  through  Celite.  The  residue  was  diluted  with 
diethyl  ether  and  slowly  made  basic  with  2M  sodium  hydroxide 
solution.  The  ether  layer  was  separated  and  the  aqueous  layer  was 
extracted  with  diethyl  ether  (3  x  30  ml).  The  combined  extracts  were 
dried  with  magnesium  sulfate  and  concentrated  under  reduced 
pressure  to  give  a  yellow  oil.  TLC  (ethyl  acetate-pet  ether;  1:  1)  showed 
two  spots  with  Rf  values  of  0.2  and  0.5.  Purification  of  the  oil  by 
column  chromatography  eluting  with  ethyl  acetate-pet  ether  (1:  1) 
125 afforded  the  title  compound  and  (S)-3-methyl-4-benzyloxazolidine 
(89). 
The  title  compound  was  obtained  as  a  yellow  oil  (0.65  g,  54%);  Rf  0.2; 
[a]D22  -1.8  (c  1.56  in  ethanol)  {lit.,  78  [a]p22  -2.1  (c  1.56  in  ethanol));  51; 
(200MHz,  CDC13)  2.56  (6H,  s,  "10  and  11-H3),  2.81  (2H,  m,  3-H2),  3.2  (3H, 
m,  1-H2  and  2-H),  3.81  (1H,  br  s  OH),  7.12  (5H,  m,  aromatic  H);  8C  (50 
MHz,  CDC13)  30.5  (C-3),  40.1  (C-10  and  -11),  60.3  (C-1),  66.8  (C-2), 
126.1  (C-7)  128.4  (C-5  and  -9  or  C-6  and  -8),  128.9  (C-5  and  -9  or  C-6 
and  -8),  139.38  (C-4);  Vmax  (film)  /  cm-1  3390,2936,778;  in/z  179 
(M+,  0.1%),  148  (7.7,  M-  (CH3)2,  -  H),  133  (2.1),  88  (21.7),  59  (100); 
(found  M+,  179.1328.  Calc.  for  C  11  H  17NO,  179.13  10). 
(S)-3-Methyl-4-benzyloxazolidine  (89)  was  obtained  as  a  white  soild 
(0.2  g,  17%). 
Rf  0.5;  [a]D22  -2.4  (c  1.7  in  ethanol);  8H  (200MHz,  CDC13)  2.47  (311,  s,  10- 
H3),  2.52  (1H,  m,  2-H),  2.82  (2H,  m,  3-H2),  3.62  (2H,  m,  1-H2),  4.01  (111, 
d,  11-H,  J  4.4  Hz),  4.39  (1H,  d,  11-H,  J  4.4  Hz),  7.13  (5H,  m,  aromatic  11); 
He  (50  MHz,  CDC13)  38.7  (C-3),  40,0  (C-10),  66.8  (C-2),  (C-1),  88.2  (C-11), 
126.1  (C-7)  128.4  (C-5  and  -9  or  C-6  and  -8),  128.9  (C-5  and  -9  or  C-6 
and  -8),  138.7  (C-4);  vmax  (KBr  disc)  /  cm-1  2944,2856,2792;  mgthz  177 
(M+,  0.2%),  147  (1.4,  M-  OCH2),  91  (13,  M-  N(CH3)CH2OCH2CH,  86  (100, 
M-  C6H5CH2);  (found  M+,  177.1138.  Calc.  for  C11H15NO,  177.1154). 
(R)-N.  N-Dimethylphenylalaninol  (158) 
(using  the  procedure  of  Feldkamp  et  al.  77) 
The  title  compound  was  prepared  in  the  same  way  as  the  S-  isomer 
except  that  (R)-phenylalaninol  (1  g,  6.7  mmol)  was  used.  TLC  also 
126 showed  two  spots  with  the  same  Rf  values  as  the  S-isomer.  The 
mixture  was  purified  by  column  chromatography  eluting  with  ethyl 
acetate-pet  ether  (1:  1)  to  afford  partially  pure  (R)  -3  -methyl  -4- 
benzyloxazolidine  and  the  title  compound. 
The  title  compound  was  obtained  as  a  yellow  oil  (0.70  g,  64%);  Rf  0.2; 
[a]D22  +1.9  (c  1.56  in  ethanol)  {lit.,  78  [(X]D22  +2.1  (c  1.56  in  ethanol));  811 
(200MHz,  CDC13)  2.56  (6H,  s,  10  and  11-H3),  2.81  (2H,  m,  3-112),  3.2  (4H, 
m,  1-H2,  OH  and  2-H),  7.12  (5H,  m,  aromatic  H);  6c  (50  MHz,  CDC13)  30.5 
(C-3),  40.1  (C-10  and  -11),  60.3  (C-1),  66.8  (C-2),  126.1  (C-7)  128.4  (C-5 
and  -9  or  C-6  and  -8),  128.9  (C-5  and  -9  or  C-6  and  -8),  139.38  (C-4); 
umax.  (film)  /  cm-1  3390,2936,778;  m/z  179  (M+,  0.1%),  148  (7.7,  M- 
(CH3)2,  -  H),  133  (2.1),  88  (21.7),  59  (100);  (found  M+,  179.1328.  Calc. 
for  C  11  H  17NO,  179.1310). 
(R)-3-Methyl-4-benzyloxazolidine  (159)  was  obtained  as  a  yellow  solid 
(0.25  g,  21%). 
Rf0.5;  [a]D22  +2.3  (c'1.7  in'  ethanol);  8H  (200MHz,  CDC13)  2.47  (311,  s,  10- 
H3),  2.52  (1H,  m,  2-H),  2.82  (2H,  m,  3-H2),  3.62  (2H,  m,  1-112),  4.01  (111, 
d,  11-H,  J  4.4  Hz),  4.39  (1H,  d,  11-H,  J  4.4  Hz),  7.13  (5H,  m,  aromatic  H); 
5C  (50  MHz,  CDC13)  38.7  (C-3),  40.0  (C-10),  66.8  (C-2),  (C-1),  88.2  (C-11), 
126.1  (C-7)  128.4  (C-5  and  -9  or  C-6  and  -8),  128.9  (C-5  and  -9  or  C-6 
and  -8),  138.7  (C-4);  vmax  (KBr  disc)  /  cm-1  2944,2856,2792;  in/z  177 
(M+,  0.2%),  147  (1.4,  M-  OCH2),  91  (13,  M-  N(CH3)CH2OCH2CH,  86  (100, 
M-  C6H5CH2);  (found  M+,  177.1138.  Calc.  for  C11H15NO,  177.1154). 
127 (IS  2S)  2-Dimethylamino-1-phenylpropane-1.3-diol  (92) 
(using  the  procedure  of  Feldkamp  et  al.  77) 
OH 
Formaldehyde  (36%,  0.72  g,  7.2  mmol)  was  added  to  a  solution  of  (1S, 
2S)-2-amino-  1-phenylpropan-1,3-diol  (1  g,  6.0  mmol),  palladium/ 
carbon  catalyst  (10%,  0.1  g)  and  glacial  acetic  acid  (0.72  g,  12  mmol)  in 
water  (30  ml).  Nitrogen  gas  was  bubbled  through  the  reaction  mixture 
for  5  min  before  hydrogen  gas  was  introduced.  The  reaction  was 
stirred  for  10  h  after  which  the  catalyst  was  removed  through  Celite. 
The  residue  was  diluted  with  diethyl  ether  and  slowly  made  basic  with 
2M  sodium  hydroxide  solution.  The  ether  layer  was  separated  and  the 
aqueous  layer  was  extracted  with  diethyl  ether  (3  x  30  ml).  The 
combined  extracts  were  dried  with  magnesium  sulfate  and 
concentrated  under  reduced  pressure  to  give  a  yellow  oil.  Purification 
of  the  oil  by  flash  chromatography  eluting  with  ethyl  acetate  afforded 
the  title  compound  (0.3  g,  26%)  as  a  yellow  oil;  Rf0.1  (ethyl  acetate);  811 
(200MHz,  CDC13)  2.34  (6H,  s,  10-  and  11-H3  ),  2.46  (IH,  m,  2-H),  3.16 
(2H,  m,  1-H2),  4.15  (3H,  br  d,  3-H,  3-OH,  1-OH),  7.13  (5H,  m,  aromatic 
H);  8c  (50  MHz,  CDC13)  41.1  (C-10  and  -11),  57.7  (C-1),  70.8  (C-2  and  -3), 
126.9  (C-7),  128.3  (C-5  and  -9  or  C-6  and  -8),  128.5  (C-5  and  -9  or  C-6 
and  -8),  141.9  (C-4);  Vmax  (film)  /  cm-1  3400,3300,2930;  ni/z  195 
(M+,  0.4%),  164  (12.7,  M-  CH2OH),  134  (3.6,  M-  CH2OH,  -  (CH3)2,89 
(51),  58  (100,  M-  HN(CH)(CH3)2);  (found  M+,  195.1281.  Calc.  for 
C  11  H  17NO2,195.1259). 
N.  N.  N-Trimethyll2henylalaninol  iodide  (91)79 
128 A  solution  of  N,  N-dimethylphenylalaninol  (88)  (1  g,  5.64  mmol)  and 
methyl  iodide  (1.69  g,  11.3  mmol)  in  diethyl  ether  (30  ml)  was  stirred 
for  24  h  at  room  temperature.  The  solid  was  filtered  and  washed  with 
diethyl  ether  (3  x  40  ml)  to  give  a  yellow  solid  (1.1  g,  61%);  811  (200MHz, 
CD3  OD)  3.33  (9H,  s,  11-,  12-  and  13-H3),  3.67  (2H,  m,  3-H2),  4.06  (IH, 
m,  2-H),  4.80  (3H,  m,  1-H2,  -OH),  7.13  (5H,  m,  aromatic  H);  6c  (50  MHz, 
CD3  OD)  31.9  (C-3),  53.1  and  53.7  (C-10,  -11  and  -12),  57.7  (C-1),  77.1 
(C-2),  128.2  (C-7),  129.8  (C-5  and  -9  or  C-6  and  -8),  130.1  (C-5  and  -9 
or  C-6  and  -8),  137.3  (C-4);  vmax  (film)  /  cm-1  3348;  in/z  148  (43.9,  M 
-  C2H601),  133  (1.2),  119  (3.3),  88  (100);  (found  M-  C2H601,148.1106. 
Cale.  for  C  10H  14N,  148.1104). 
129 7.3  Experimental  to  Chapter  5 
(S)-Serine  methyl  ester  hydrochloride  (94)82 
3 
OH 
+I  ý  Cl  H3N  C  O2M4e 
1 
Hydrochloride  gas  was  bubbled  through  a  solution  of  (S)-serine  (10  g, 
95.2  mmol)  and  methanol  (150  ml)  until  all  the  serine  had  dissolved. 
After  stirring  the  solution  at  room  temperature  for  5  h,  methanol  was 
evaporated  off  under  reduced  pressure  to  afford  the  title  compound 
(14.0  g,  94%)  as  a  white  solid.  The  white  solid  was  stored  in  a 
desiccator  under  vacuum  overnight  with  pellets  of  potassium  hydroxide 
to  ensure  the  complete  removal  of  HCI.  St;  (200MHz,  D20)  3.57  (3H,  s, 
4-H3),  3.73  (1H,  dd,  3-H,  J  3.6,12.5  Hz),  3.85  (IH,  dd,  3-H,  J  4.0,12.5 
Hz),  4.01  (1H,  t,  2-H,  J  3.8  Hz);  Sc  (50  MHz,  D20)  50.3  (C-4),  51.3  (C-3), 
56.0  (C-2),  167.9  (C-1);  Vmax  (KBr)  /  cm-1  3417,2958,1747.  (Found:  C, 
30.8;  H,  6.4;  N,  9.0.  Calc.  for  C4H10NC10:  C,  30.73;  H,  6.52;  N,  8.92%). 
(S)-N-tert-But  loxycarbonylserine  meth  l  ester  95160 
ý  31 
OH 
2 
O4N  CO2Me 
H19 
Di-tert-butyldicarbonate  (17.8  ml,  77.2  mmol)  was  added  to  a  solution 
of  triethylamine  (18  ml,  12.9  mmol)  and  (S)-serine  methyl  ester 
hydrochloride  (94)  (10  g,  64.3  mmol)  in  dry  dichloromethane  (100  ml). 
After  the  reaction  mixture  was  stirred  for  10  h  at  room  temperature,  it 
was  diluted  with  dichloromethane  (50  ml)  and  washed  with  water  (3  x 
50  ml).  The  organic  layer  was  dried  with  magnesium  sulfate  and 
concentrated  to  give  a  yellow  oil.  This  was  purified  by  column 
chromatography  (hexane-ethyl  acetate;  9:  1)  to  give  the  title  compound 
(9  g,  64%)  and  (S)-N-tert-butyloxycarbonyl-O-tert-butyloxycarbonyl- 
serine  methyl  ester  (96)  (2  g,  11%). 
130 The  title  compound  was  isolated  as  a  clear  oil;  Rf0.1  (hexane-ethyl 
acetate;  9:  1);  [a]D22  -6.0  (c  3.6  in  CHC13)  {lit.,  58  [(XID22  -6.5  (c  3.6  in 
CHC13)  );  8H  (200MHz,  CDC13)  1.37  (9H,  s,  6-,  7-  and  8-H3),  3.37  (1  H,  br  t, 
OH),  3.78  (3H,  s,  9-H3),  3.81  (2H,  m,  3-H2),  4.29  (IH,  m,  2-H),  5.61  (IH, 
d,  NH);  Sc  (50  MHz,  CDC13)  28.2  (C-6,  -7  and  -8),  52.5  (C-9),  55.8  (C-2), 
63.0  (C-3),  80.1  (C-5),  155.8  (C-4),  171.5  (C-1);  vmax  (film)  /  cm-1  3400, 
2978,1713  br  (OCON  and  CO2Me);  m/z  160  (23,  M-  CO2Me),  146  (21.5, 
M-  OC4H9),  133  (79),  104  (32),  88  (39),  60  (100);  (found  M-  CO2M  e, 
160.0985.  Calc.  for  C7H14N03,160.0973). 
(S)-N,  O-Di-tert-butyloxycarbonylserine  methyl  ester  (96)  was  isolated 
as  a  white  solid;  mp  94  oC  (lit.,  83  94.5  °C) 
0 
3/''  12 
2 
O4  Ný  CO2Me 
H19 
1 
Rf0.3  (hexane-ethyl  acetate;  9:  1);  [a]D22  -33.0  (c  1.1  in  CHC13);  811 
(200MHz,  CDC13)  1.42  (6-,  7-  and  8-H3  or  12-,  13-  and  14-H3),  1.44  (6-, 
7-  and  8-H3  or  12-,  13-  and  14-H3),  3.74  (3H,  s,  1-H3  ),  4.25  (IH,  dd,  2- 
H,  J  3.5,10.9  Hz),  5.30  (1H,  d,  NH);  8C  (50  MHz,  CDC13)  27.6  (C-6,  -7  and 
-8  or  C-12,  -13  and  -14),  28.2  (C-6,  -7  and  -8  or  C-12,  -13  and  -14), 
52.6  (C-9),  52.8  (C-3),  66.3  (C-2),  80.2  (C-5  or  -11),  82.7  (C-5  or  -11), 
153.2  (C-4  or  C-10),  156.2  (C-4  or  C-10)  171.3  (C-1);  vmax  (Kßr  disc)  / 
cm-1  2933,1740,1712,1526;  m/z  260  (0.8,  M-  C02Mc),  205  (1.1,  M- 
(C4H9)2),  146  (5.3),  104  (19.2),  57  (100);  (found  M+,  206.1507.  Ca1c.  for 
C  12H  22N  O  5,260.1498).  (Found:  C,  52.6;  H,  7.8;  N,  4.3.  Calc.  for 
C  14H25N07:  C,  52.44;  H,  7.76;  N,  4.34%). 
131 S)-N-tert-butyloxycarbonyl-O-tert-btUt￿yldimethy  sil 
ester 
((using  the  procedure  of  Corey  et  al.  98) 
11  13 
10,14/-12 
ý 
Si-  9 
O3 
2 
O4N  CO2Me 
H1  15 
A  solution  of  compound.  (95)  (1  g,  4.57  mmol),  imidazolc  (0.62  g,  9.14 
mmol)  and  tert-butyldimethylsilyl  chloride  (0.9  g,  5.94  mmol)  in  dry 
DMF  (30  ml)  was  stirred  at  room  temperature  for  15  h.  The  mixture 
was  then  diluted  with  ethyl  acetate  (100  ml)  and  washed  with  brine  (5 
x  50  ml).  The  organic  layer  was  dried  with  magnesium  sulfate,  filtered 
and  concentrated  to  a  crude  oil.  The  oil  was  purified  by  flash 
chromatography  eluting  with  hexane-ethyl  acetate  (9:  1)  to  give  a  clear 
oil  (1.4  g,  92%);  Rf  0.8  (ethyl  acetate-hexane;  1:  2);  511  (200MI1z,  CDC13) 
0.00  (3H,  s,  9-  or  10-H3),  0.01  (3H,  s,  9-  or  10-113),  0.84  (911,  s,  11-,  12-, 
and  13-H3),  1.43  (9H,  s,  6-,  7-  and  8-H3),  3.71  (311,  s,  15-113),  3.76  (111, 
dd,  3-H,  J  3.0,10  Hz),  4.00  (1H,  dd,  3-H,  J  2.5,10  Hz),  4.34  (111,  m,  2-11), 
5.34  (1H,  br  d,  NH);  Sc  (50  MHz,  CDC13)  -5.7  (C-9  or  -10),  -5.6  (C-9  or 
-10),  18.1  (C-14),  25.6  (C-11,  -12  and  -13),  28.2  (C-6,  -7  and  -8),  52.1 
(C-15),  55.5  (C-2),  63.6  (C-3),  79.7  (C-5),  155.3  (C-4),  171.3  (C-1);  v,,,,,  x 
(film)  /  cm-1  2970,1752  (COOMe),  1720  (OCON),  1256  (SiMe2),  1088, 
840  (SiO);  m/z  260  (13.5,  M-  OC4H9),  220  (55.4),  176  (4.7),  89  (100); 
(found  M-  OC4H9,260.1312.  Calc.  for  C11H22NO4Si,  260.1318). 
(Found:  C,  54.1;  H,  9.3;  N,  4.2.  Calc.  for  C15H31NO5Si:  C,  53.94;  11,9.26;  N, 
4.41%). 
132 (S)-2-[(tert-Butyloxycarbonylamino]-3-tert- 
butyldimethy  silyloxyrropanal 
11, 
. 
13 
10\1  4/y--  12 
Si-  9 
A  stirred  solution  of  compound  (97)  (1.4  g,  4.2  mmol)  in  anhydrous 
toluene  (30  ml)  was  cooled  to  -78  oC  and  diisobutylaluminium  hydride 
(1.5M,  4.8  ml,  7.1  mmol)  was  added  dropwise,  keeping  the  internal 
temperature  below  -70  °C.  After  the  mixture  had  been  stirred  at  -78 
oC  for  a  further  2  h,  saturated  ammonium  chloride  solution  (30  nil)  was 
added.  The  mixture  was  poured  into  cold  1M  FICI  (50  nil)  and 
extracted  with  ethyl  acetate  (3  x  50  ml).  The  combined  extracts  were 
washed  with  brine  (2  x  50  ml),  dried  with  magnesium  sulfate,  filtered 
and  concentrated  to  afford  a  crude  oil.  This  oil  was  sufficiently  pure 
and  had  to  be  used  directly  for  the  next  step;  Rf0.75  (Hexane-ethyl 
acetate;  2:  1);  SH  (200MHz,  CDC13)  0.00  (6H,  s,  9-  and  10-113),  0.81  (911,  s, 
11-,  12-  and  13-H3),  1.41  (9H,  s,  6-,  7-  and  8-H3),  3.90  (311,  in,  2-11  and 
3-H2),  5.40  (1H,  br  d,  NH),  9.59  (1H,  s,  1-H);  5C  (50  MHz,  CDC13)  -5.6  (C-9 
and  -10),  18.1  -(C-14),  25.6  (C-11,  -12  and  -13),  28.2  (C-6,  -7  and  -8), 
61.3  (C-3),  61.5  (C-2)  79.7  (C-5),  155.2  (C-4),  199.3  (C-1);  v,  nax  (film)  / 
cm-1  1725  (CHO),  1720  (OCON),  1250  (SiMe2),  1090,839  (SiO). 
4S.  5R.  S)-4-tert-Dimethylsily,  lox, 
one 
14 
1 
\13 
/11 
16 
Si 
HN,  fO 
12  öý 
Hl"i 
0 
e(nvi-a-i  I  -nCXVIIVIlO)1 
4321 
CH2CH2CH2CH3 
133 BuLi  (1.5M,  4  ml,  6.0  mmol)  was  added  to  a  solution  of  1-hexyne  (0.54 
g,  6.6  mmol)  in  dry  THE  (30  ml)  at  -78  °C.  After  stirring  at  -78  OC  for 
30  min,  (S)-2-[(tert-butyloxycarbonyl)amino]-3-tert-butyldimethyl- 
silyloxypropanal  (93)  (1  g,  3.3  mmol)  in  anhydrous  TIIF  (10  ml)  was 
added  dropwise.  The  resulting  mixture  was  stirred  at  this  temperature 
for  a  further  2h  and  then  allowed  to  warm  up  to  room  temperature 
overnight.  Saturated  ammonium  chloride  solution  (40  nil)  was  added 
and  the  mixture  was  extracted  with  ethyl  acetate  (3  x  50  nil).  The 
combined  organic  extracts  were  washed  with  brine  (3  x  50  nil),  dried 
with  magnesium  sulfate,  filtered  and  concentrated  to  give  a  yellow  oil. 
The  mixture  of  diastereoisomers  was  separated  by  careful 
chromatography  eluting  with  hexane-ethyl  acetate  (9:  1). 
(4S,  5R)-4-tert-Dimethylsilyloxymethyl-5-(1-hexynyl)oxazolidine-2-one 
(100)  was  isolated  as  a  yellow  oil  (0.21  g,  20%). 
14 
1513_  /11 
Si 
16  12 
`O10 
H""ý 
HN 
H 
4321 
CH2CH2CH2CH3 
Rf  0.3  (hexane-ethyl  acetate;  9:  1);  [a]n22  -43.0  (c  1.1  in  CIICI3);  511 
(200MHz,  CDC13)  0.00  (6H,  s,  11-  and  12-H3),  0.82  (1211,  ni,  1-,  14-,  15- 
and  16-H3),  1.39  (4H,  m,  2-  and  3-H2),  2.14  (211,  dt,  4-11,  J  1.8,6.6  11z), 
3.56  (2H,  d,  10-H2,  J  3.3  Hz),  3.82  (IH,  m,  9-H),  5.20  (111,  dt,  7-11,  J  1.9 
and  7.7  Hz),  6.42  (1H,  br  s,  NH);  SC  (50  MHz,  CDC13)  -5.5  (C-11  and  -12), 
13.5  (C-1),  18.1  (C-13),  18.3,21.8  (C-2  and  -3),  25.7  (C-14,  -15  and 
-16),  30.1  (C-4),  55.9  (C-9),  63.4  (C-10),  68.1  (C-7),  72.0,91.1  (C-5  and 
-6),  158.4  (C-8);  vmax  (film)  /  cm-1  1740,1248  (SiMc2),  1092  (SiO);  In/Z 
254  (35,  M-  C4H  9  ),  224  (30,  M-  C4  H  9,  -  C2  H  6),  210  (60),  168  (40), 
115  (3.5),  75  (100);  (found  M-  C4H9,254.1243.  Ca1c.  for  C121I20NO3Si, 
254.1212). 
(4S,  5S)-4-tert-Dimethylsilyloxymethyl-5-(1-hexynyl)oxazolidine-2-one 
(101)  was  isolated  as  a  yellow  oil  (0.31  g,  30%). 
134 14 
15,13  /11 
43  16  12 
Si 
""-  10  HC  H21  p-\  2CH2CH2CH3  ýf  ,i5  H"'ý  g\6 
HN,  P￿0 
Rf0.25  (hexane-ethyl  acetate;  9:  1);  [aID22  -11.2  (c  1.4  in  C11C13);  8E1 
(200MHz,  CDC13)  0.00  (6H,  s,  11-  and  12-H3),  0.82  (1211,  m,  1-,  14-,  15- 
and  16-H3),  1.40  (4H,  m,  2-  and  3-H2),  2.25  (211,  dt,  4-11,  J  1.8,6.9  11z), 
3.56  (2H,  d,  10-H2,  J  4.7  Hz),  3.82  (IH,  m,  9-H),  4.90  (111,  dt,  7-11,  J  1.9 
and  5.2  Hz),  6.42  (1H,  br  s,  NH);  8c  (50  MHz,  CDC13)  -5.5  (C-I  I  and  -12), 
13.5  (C-1),  18.1  (C-13),  18.3,21.8  (C-2  and  -3),  25.6  (C-14,  -15  and 
-16),  30.2  (C-4),  60.9  (C-9),  63.5  (C-10),  68.3  (C-7),  75.8,89.2  (C-5  and 
-6),  158.8  (C-8);  Vmax  (film)  I  cm-1  1740,1248  (SiMc2),  1092  (SiO);  m  /Z 
254  (46.7,  M-  C4H9),  210  (78),  168  (36.9),  115  (3.5),  75  (100);  (found 
M-  C4H9,254.1203.  Calc.  for  C12H2ONO3Si,  254.1212). 
Meth  a  unvi-z.  -anncuwiox 
'  c.  1'LS2ililitlý-  ý  ! 
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A  solution  of  (S)-N-tert-butyloxycarbonylserine  methyl  ester  (95)  (3  g, 
13.7  mmol)  in  anhydrous  benzene  (150  ml)  with  2,2-dimethoxypropane 
(2.5  ml,  20.5  mmol)  and  p-toluenesulfonic  acid  (0.3  g)  was  heated 
under  Dean-Stark  conditions  for  2  h.  The  deep  yellow  coloured  reaction 
mixture  was  poured  into  saturated  sodium  bicarbonate  solution  (100 
ml)  and  extracted  with  ether  (3  x  50  ml).  The  combined  organic 
extracts  were  washed  with  water  (2  x  50  ml),  dried  with  magnesium 
sulfate,  filtered  and  concentrated  to  afford  a  crude  oil.  The  oil  was 
purified  by  column  chromatography  to  give  the  title  compound  (2.5  g, 
70%)  as  a  light  yellow  oil;  Rf  0.4  (hexane-ethyl  acetate;  4:  1);  [ec]o22  -46.0 
135 (c  1.3  in  CHC13)  {lit.,  58  [(X]D22  -46.7  (c  1.3  in  CHC13));  5I1  (200MIIz, 
CDC13)  1.34  (5H,  s,  9-,  10-  and  11-H3),  1.43  (511,  s,  9-,  10-  and  11-113  & 
5-  or  6-H3),  1.46  (2H,  s,  5-  or  6-H3),  1.57  (IH,  s,  5-  or  6-113),  1.60  (211, 
s,  5-  or  6-H3),  3.69  (3H,  s,  12-H3),  4.04  (2H,  m,  3-112),  4.30  (0.511,  dd,  2- 
H),  4.40  (0.5H,  dd,  2-H);  SC  (50  MHz,  CDC13)  24.2,24.8,25.0,25.9  (C-5 
and  -6),  28.1  (C-9,  -10  and  -11),  52.1,52.2  (C-12),  59.1  (C-2),  65.9,66.1 
(C-3),  80.1,80.7  (C-8),  94.3,94.9  (C-4),  155.1  (C-7),  171.2,171.6  (C-12); 
Vmax  (film)  /  cm-1  3065,2978,1725  (COOMe),  1702  (OCON);  iu/z  244 
(8.6,  M-  CH3),  200  (2.0,  M-  CO2Me),  186  (5.1,  M-  0C4119),  144  (100), 
100  (1.1),  84  (84);  (found  M-  CH3,244.1171.  Calc.  for  C1l  I11$  NO5, 
244.1185). 
(4S)-3-tert-Butyloxycarbonyl-2.2-dimcthyl-4-hcx-5- 
Xnvlcý  arbonyloxazolidinc  (104) 
10  11 
17 
BuLi  (1.5M,  4  ml,  4.6  mmol)  was  added  dropwise  at  -78  oC  to  a  solution 
of  1-hexyne  (0.4  g,  5  mmol)  in  dry  THE  (20  ml).  The  solution  was 
stirred  for  30  min  before  a  solution  of  methyl  (4S)-3-tert- 
butyloxycarbonyl-2,2-dimethyloxazolidine-4-carboxylate  (103)  (1  g, 
3.9  mmol)  in  dry  THE  (10  ml)  was  added.  The  resulting  solution  was 
stirred  at  -78  oC  for  a  further  4  h.  Saturated  ammonium  chloride 
solution  (20  ml)  was  added  and  the  organic  layer  was  separated.  The 
aqueous  layer  was  extracted  with  ethyl  acetate  (2  x  30  1111)  and  the 
combined  extracts  were  dried  with  magnesium  sulfate  and 
concentrated  to  give  an  oil.  The  oil  was  purified  by  column 
chromatography  eluting  with  hexane-ethyl  acetate  (6:  1)  to  give  the  title 
compound,  starting  material  and  methyl  2-(1  a  rt  - 
butyloxycarbonyl)aminoacrylate  (105). 
136 The  title  compound  was  isolated  as  *a  yellow  oil  (0.2  g,  17%);  Itf  0.3 
(hexane-ethyl  acetate;  3:  1);  6H  (200MHz,  CDC13)  0.81  (311,  t,  17-113),  1.35 
(19H,  m,  15-H2,16-H2,5-,  6-,  8-,  9-  and  10-113),  2.30  (211,  t,  14-112), 
4.04  (2H,  m,  3-H2),  4.28  (0.6,  dd,  2-H,  J  3.9,7.1  I-1z),  4.47  (0.411,  app.  t, 
2-H);  6c  (50  MHz,  CDC13)  13.3  (C-17),  18.7,21.8  (C-15  and  -16),  24.1, 
24.9,25.0,26.0  (C-5  and  -6),  28.0,28.3  (C-9,  -10  and  -11),  29,4  (C-14), 
65.2,65.6  (C-3),  66.5  (C-2),  80.6  (C-8),  80.8  (C-12),  95.2  (C-13),  155.9 
(C-7),  163.4  (C-1);  vmax  (KBr  disc)  /  cm-1  2200,2705,1680. 
Methyl  ,,  2-(tert-butyloxycarbonyl)aminoacrylatc  (105)87  was  isolated 
as  a  clear  oil  (0.15  g,  19%). 
Rf0.7  (hexane-ethyl,  acetate;  3:  1);  811  (200MHz,  CDC13)  1.35  (911,  s,  6-,  l- 
and  8-H3),.  3.75  (3H,  s,  9-H3),  5.65  (1H,  br  d,  N1l),  6.08  (111,  d,  3-11,  j  1.5 
Hz),  6.08  (1H,  br  s,  3-H);  Sc  (50  MHz,  CDC13)  28.2  (C-6,  -7  and  -8),  52.8 
(C-9),  80.3  (C-5),  118.1  (C-3),  155.9  (C-4),  164.4  (C-1)  ;  v1￿y,  x  (Kllr  disc)  / 
cm-1  1680,1750. 
First  attempted  preparation  of  phenyl  (45)-3-tart-huty  o  Upadmay.  L 
2.2-dimethyl  oxazolidinc-4-car  oxyjate. 
\ 
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A  solution  of  methyl  (4S)-3-tert-butyloxycarbonyl-2,2- 
dimethyloxazolidine-4-carboxylate  '  (103)  (0.5  g,  1.9  mmol)  in 
anhydrous  benzene  (150  ml)  with  phenol  (0.5  g,  5.7  mmol)  and  1p- 
toluenesulfonic  acid  (0.3  g)  was  heated  under  Dean-Stark  conditions  for 
6  h.  The  deep  yellow  coloured  reaction  mixture  was  poured  into 
saturated  sodium  bicarbonate  solution  (100  ml)  and  extracted  with 
137 ether  (3  x  50  ml).  The  combined  organic  extracts  were  washed  with 
water  (2  x  50,  ml),  dried  with  magnesium  sulfate,  filtered  and 
concentrated  to  afford  a  crude  oil.  TLC  analysis  and  NMR  spectra  were 
identical  to  those  of  starting  material. 
Second  attempted  nrenaration  of  C 
2.2-dimethyloxazolidine-4-carhox,  late 
Lithium  (13  mg,  0.9  mmol)  was  added  to  a  solution  of  phenol  (0.36  g, 
3.8  mmol)  An  dry  DMF  (25  ml).  A  solution  of  (4S)-3-tert- 
butyloxycarbonyl-2,2-dimethyloxazolidinc-4-carboxylatc  (103)  (0.5  g, 
1.9  mmol)  in  DMF  (5  ml)  was  then  added.  The  reaction  was  set  tip  as  a 
distillation.  The  resulting  solution  was  heated  at  95  OC  for  4  It  and  then 
allowed  to  cool  down  to  room  temperature.  The  mixture  was  poured 
into  ethyl  acetate  (30  ml)  and  water  (30  ml).  The  organic  layer  was 
separated  and  the  aqueous  layer  was  washed  with  ethyl  acetate  (3  x  30 
ml).  The  combined  organic  extracts  were  washed  with  brine  (4  x  50 
ml),  dried  with  magnesium  sulfate  and  concentrated  to  give  an  oil.  The 
oil  was  purified  by  flash  chromatography  cluting  with  hexane-ethyl 
acetate  (5:  1)  to  give  methyl  2-(tert-butyloxycarbonyl)aminoaerylate 
(105)  (0.35  g,  92%). 
4S1-3-tert-Butyloxycarbon,  l1- 
(10'j)86 
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A  stirred  solution  of  (4S)-3-tert-butyloxycarbonyl-2,2- 
dimethyloxazolidine-4-carboxylate  (103)  (2.2  g,  8.5  mmol)  in 
anhydrous  toluene  (30  ml)  was  cooled  to  -78  oC  and 
diisobutylaluminum  hydride  (1.5  M,  9.6  ml,  14.5  mmol)  was  added 
dropwise,  keeping  the  internal  temperature  below  -70  °C.  After  the 
mixture  had  been  stirred  at  -  78  oC  for  a  further  2  h,  methanol  (20  ml) 
was  slowly  added  with  the  internal  temperature  kept  below  -70  oC. 
The  reaction  mixture  was  poured  into  ice  cold  1M  lICI  (50  nil)  and 
138 extracted  with  ethyl  acetate  (3  x  50  ml).  The  combined  organic 
extracts  were  washed  with  brine  (3  x  50  ml),  dried  with  magnesium 
sulfate,  filtered  and  concentrated  to  afford  a  yellow  oil.  This  oil  was 
purified  by  flash  chromatography  (hexane-ethyl  acetate;  4:  1)  to  give 
title  compound  (1.2  g,  62%)  as  a  clear  oil;  Rf  0.36  (hexane-ethyl  acetate; 
4:  1);  [a]D22  -90.5  (c  1.34  in  CHC13)  (lit.,  58  [aID22  -91.7  (c  1.34  in  CIICI3)); 
St;  (200MHz,  CDC13)  1.36  (5H,  s,  9-,  10-  and  11-H3),  1.39  (511,  s,  9-,  10- 
and  11-H3  &  5-  or  6-H3),  1.43  (2H,  s,  5-  or  6-113),  1.44  (111,  s,  5-  or  6- 
H3),  1.48  (2H,  s,  5-  or  6-H3),  4.01  (2H,  m,  3-112),  4.11  (0.511,  m,  2-11), 
4.27  (0.5H,  m,  2-H),  9.47  (0.5H,  d,  1-H,  J  2.3  Hz),  9.52  (0.511,  (1,1-11,  J  2.3 
Hz);  8c  (50  MHz,  CDC13)  23.7,24.5,25.6,27.0  (C-5  and  -6),  28.1  (C-9,  -10 
and  -11),  63.3,63.8  (C-3),  64.6  (C-2),  80.9,81.2  (C-8),  94.7,94.7  (C-4), 
155.1,155.4  (C-7),  199.1,199.3  (C-1);  vmax  (film)  /  cnt-1  3072,2976, 
1725  (CHO),  1720  (OCON);  m/z  200  (10.5,  M-  CIlO),  156  (1.3,1`"t  - 
OC4H9),  146  (53),  100  (66),  84  (100),  72  (14.2);  (found  M-  CH  O, 
200.1278.  Calc.,  for  C1OH18NO3,200.1287). 
3-tert-Butvlox  carno  -4- 
dimeth,  yloxazolidine  (108) 
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A  solution  of  compound  (107)  (1.2  g,  5.2  mmol)  in  anhydrous  TIIi  (30 
ml)  was  added  dropwise  over  30  min  into  vinyl  magnesium  bromide 
(1M,  7.9  ml,  7.9  mmol)  at  -78  OC.  The  resulting,  mixture  was  stirred  at 
this  temperature  for  a  further  1h  before  saturated  ammonium  chloride 
solution  (30  ml)  was  added.  The  organic  layer  was  separated  and  the 
aqueous  layer  was  extracted  with  ether  (3  x  30  ml).  The  combined 
organic  extracts  were  washed  brine  (30  ml),  dried  with  magnesium 
sulfate,  filtered  and  concentrated  to  leave  an  oil.  Purification  by 
column  chromatography  (hexane-ethyl  acetate;  3:  1)  afforded  the  title 
compound  (1.1  g,  77%)  as  a  clear  oil;  Rf  0.28  (hexane-ethyl  acetate;  4:  1); 
SH  (200MHz,  CDC13)  1.38  (15H,  m,  5-,  6-,  9-,  10-  and  11-113),  3.90  (311, 
m,  2-H,  3-H2),  4.21  (1H,  br  s,  1-H),  5.10  (2H,  m,  13-112),  5.7  (111,  in,  12- 
139 H);  the  carbon  spectrum  was  complex;  Vmax  (KBr  disc)  /  cnr1  3415, 
1740,1696;  m/z  200  (3.1,  M-  C4H9),  184  (4.2,  M-  OC4119),  144  (20), 
57  (100);  (found  M-  C4H9,200.0938.  Calc.  for  C9H  14NO4,200.0923). 
(Found:  C,  60.7;  H,  8.9;  N,  5.4.  Calc.  for  C13H23N04:  C,  59.92;  11,8.88;  N, 
5.29%). 
General  procedure  1  for  alkynylation  of  aldehydc  (107) 
(using  the  procedure  of  Garner  et  nl.  58) 
BuLi  (1.5M,  0.014  mmol)  was  added  to  a  -23  oC  solution  of  the  alkyne 
(0.015  mmol)  in  dry  THE  (100  ml)  under  nitrogen.  The  resulting 
suspension  of  lithium  acetylide  was  stirred  at  the  same  temperature  for 
a  further  1h  and  then  a  solution  of  the  aldehyde  (107)  (0.01  mmol)  in 
dry  THE  (20  ml)  was  added.  The  reaction  was  complete  (monitored  by 
TLC)  after  2h  at  this  temperature  and  then  was  quenched  by  addition 
of  saturated  ammonium  chloride  solution  (50  ml).  The  organic  layer 
was  separated  and  the  aqueous  layer  was  extracted  with  ether  (3  x  30 
ml).  The  combined  organic  layers  were  washed  with  brine  (2  x  50  ntl), 
dried  with  magnesium  sulfate,  filtered  and  concentrated  to  give  a 
yellow  oil.  TLC  in  hexane-ethyl  acetate  (4:  1)  showed  formation  of  both 
diastereoisomers.  The  major  diastereoisomer  was  separated  by  careful 
chromatography  eluting  with  hexane-ethyl  acetate  (9:  1). 
4S)-3-tert-Butyloxycarbonyl-4-[(1  K  -Z  1=h 
dimethyloxazolidine(111) 
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Following  general  procedure  1,  the  title  compound  was  prepared  with 
these  reagents:  BuLi  (1.5M,  4  ml,  4.1  mmol),  1-nonyne  (0.81  g,  6.6 
mmol),  aldehyde  (107)  (1  g,  4.4  mmol).  The  compound  was  isolated  as 
140 a  clear  oil  (0.9,58%);  Rf  0.36  (ethyl  acetate-hexane;  1:  4);  [aID22  -40.2  (c 
2.4  in  CHC13);  5H  (200MHz,  CDC13)  0.81  (3H,  t,  20-H3),  1.18  (1011,  m,  15- 
H2  to  19-H2),  1.42  (15H,  m,  5-,  6-,  9-,  10-  and  11-H3),  2.12  (211,  dt,  14- 
H2,  J  1.7  and  6.8  Hz),  3.90  (IH,  br  s,  OH),  4.10  (211,  m,  3-112),  4.40  (111, 
m,  2-H),  4.70  (1H,  br  d,  1-H,  J  8.2  Hz);  8c  (50  MHz,  CDC13)  214.0  (C-20), 
18.5,22.4,28.4,28.7  (C-15  to  C-19),  25.2,25.6  (C-5  and  -6),  28.2  (C-9. 
-10  and  -11),  31.6  (C-14),  60.3  (C-2),  63.8  (C-1),  64.9  (C-3),  77.7,86.1 
(C-12  and  -13),  80.9  (C-8),  94.7  (C-4),  155.1  (C-7);  vmax  (filet)  /  cm-  1 
3308  (OH),  2932  2233,1693  (OCON);  m/z  297  (2.8,  M11  -  C4119),  200 
(27.4),  144  (29.6),  100  (100);  (found  MH  -  C4119,297.1931.  Calc.  for 
C  16H27NO4,297.1940). 
-tert-Butylox,  ycarbon,  yl-4-[(1  R)-  1-hý 
dimethyloxazolidine  (112) 
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General  procedure  1  was  used  with  the  following  reagents:  BuLi  (1.5M, 
4  ml,  4.1  mmol),  1-dodecyne  (1.1  g,  6.6  mmol),  aldehyde  (107)  (1  g,  4.4 
mmol).  The  compound  was  isolated  as  a  light  yellow  oil  (1.1  g,  63%);  Rf 
0.38  (hexane-ethyl  acetate;  4:  1);  [a  ID  22  -37.8  (c  1.3  in  C11C13  );  811 
(200MHz,  CDC13)  0.80  (3H,  t,  23-H3),  1.15  (16H,  in,  15-112  to  22-112), 
1.45  (15H,  m,  5-,  6-,  9-,  10-  and  11-H3),  2.13  (2H,  m,  14-112),  3.86  (111, 
br  s,  OH),  4.03  (2H,  m,  3-H2),  4.56  (IH,  m,  2-H),  4.70  (111,  br  d,  1-11,  J  8.2 
Hz);  8c  (50  MHz,  CDC13)  14.0  (C-23),  18.6,22.5,28.5,28.8,29.0,29.2, 
29.5,30.8  (C-15  to  C-22),  25.4  (C-5  and  -6),  28.6  (C-9,  -10  and  -11), 
31.8  (C-14),  62.7  (C-2),  63.9  (C-1),  64.9  (C-3),  77.7,86.1  (C-12  and  -13), 
80.9  (C-8),  94.8  (C-4),  15.3  (C-7);  vmax  (film)  /  cm-1  3245,2945,2270, 
1695;  m/z  339  (4.9,  MH  -  C4H9),  280  (6.3),  200  (73.9),  156  (3.8),  144 
(100);  (found  MH  -  C4H9,339.2411.  Calc.  for  C19H33NO4,339.2409). 
141 4S)-3-test-Butyloxycarbonyl-4-[(1  R)-I-hvdrox 
dimethyloxazolidine  (110) 
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General  procedure  1  was  used  with  the  following  reagents:  IluLi  (1.5M, 
4  ml,  4.1  mmol),  1-pentadecyne  (1.4  g,  6.6  mmol),  aldehyde  (107)  (1  g, 
4.4  mmol).  The  compound  was  isolated  as  a  light  yellow  oil  (1.3  g,  68%); 
Rf  0.4  (hexane-ethyl  acetate;  4:  1);  [a]D22  -41.2  (c  1.4  in  CI1C13)  {lit.,  ref7, 
[a]D22  -40.1  (c  1.4  in  CHC13)};  SH  (200MHz,  CDC13)  0.91  (311,  t,  26-113), 
1.21  (22H,  m,  15-H2  to  25-H2),  1.45  (15H,  m,  5-,  6-,  9-,  10-  and  11-113), 
2.15  (2H,  br  dt,  14-H2,  J  1.6  and  6.7  Hz),  3.90  (1H,  br  s,  011),  4.20  (211,  m, 
3-H2),  4.49  (1H,  m,  2-H),  4.70  (1H,  br  d,  1-H,  J  8.3  11z);  Sc  (50  N111z, 
CDC  13)  14.0  (C-26),  18.7,  *  22.6,28.5,28.8,29.1,29.3,29.5,29.6,31.5, 
31.9  (C-15  to  C-25),  25.3  (C-5  and  -6),  28.6  (C-9,  -10  and  -11),  31.8  (C- 
14),  62.7  (C-2),  64.0  (C-1),  65.0  (C-3),  78.4,87.2  (C-12  and  -13),  81.0  (C- 
8),  94.8  (C-4),  155.8  (C-7);  vmax  (film)  /  cm-1  3277  (011),  2856,2243, 
1704  (OCON);  m/z  381  (1.2,  M-  C4  H9),  200  (22.4),  144  (33.8),  100 
(100);  (found  M-  C4H9,381.2883.  Calc.  for  C221139NO4,381.2879). 
(Found:  C,  71.3;  H,  10.8;  N,  3.2.  Calc.  for  C26H47N04:  C,  71.14;  11,10.63; 
N,  3.38%). 
142 3-tert-Butyloxycarbonyl-4-[(1  R))-1-hv, 
dimethyloxazolidine  (113)60 
1 
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A  solution  of  (4S)-3-tert-butyloxycarbonyl-4-[(1R)-1-hydroxy-2- 
nonynyl]-2,2-dimethyloxazolidine  (111)  (1  g,  2.8  mmol)  in  dry  Till'  (10 
ml)  was  added  to  a  blue  solution  of  Li  (0.04  g,  5.6  mmol)  in  ammonia 
(50  ml)  at  -78  0C.  After  it  was  stirred  at  -78  oC  for  4  h,  the  reaction 
was  quenched  at  -78  oC  with  saturated  ammonium  chloride  solution 
(20  ml)  and  the  ammonia  was  allowed  to  evaporate  at  room 
temperature  overnight.  The  residue  was  redissolved  in  ethyl  acetate 
(100  ml),  washed  with  1M  HC1  (3  x  50  ml),  dried  with  magnesium 
sulfate  and  concentrated  to  give  a  yellow  oil.  The  oil  was  purified  by 
careful  chromatography  eluting  with  (hexane-ethyl  acetate;  9:  1)  to  give 
the  title  compound  as  a  yellow  oil  (0.1  g,  10%)  and  starting  material  (0.6 
g);  Rf0.38  hexane-ethyl  acetate,  (4:  1);  Stt  (200Mflz,  CDC13)  0.81  (311,  t, 
20-H3),  1.18  (10H,  in,  15-H2  to  19-H2),  1.42  (1511,  in,  5-,  6-,  9-,  10- 
and  11-H3),  2.20  (2H,  m,  14-H2),  4.00  (4H,  m,  011,2-11,3-112),  5.34  (111. 
dd,  12-H,  J  5.6  and  15.5  Hz),  5.66  (1H,  dt,  13-H,  J  6.6,15.4  IN);  SC  (50 
MHz,  CDC13)  14.1  (C-20),  22.6,29.1,29.2,31.8  (C-15  to  C-19),  25.7,26.2 
(C-5  and  -6),  28.7  (C-9,  -10  and  -11),  32.4  (C-14),  62.3  (C-2),  65.2  (C-3), 
74.1  (C-1),  81.1  (C-8),  94.4  (C-4),  128.0  (C-12),  133.4  (C-13),  155.4  (C- 
7);  vmax  (film)  /  cm-1  3301,1704,1645. 
143 Attempted  preparation  of  (4  r  (D 
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A  solution  of  (4S)-3-tert-butyloxycarbonyl-4-[(1  R)-1-Iiydroxy-2- 
pentadecynyl]-2,2-dimethyloxazolidine  (110)  (1  g,  2.8  mmol)  in  dry 
THE  (10  ml)  was  added  to  a  blue  solution  of  Li  (0.04  g,  5.6  mmol)  in 
ammonia  (50  ml)  at  -78  OC.  After  it  was  stirred  at  -78  oC  for  4  Ii,  the 
reaction'  was  quenched  at  -78  oC  with  saturated  ammonium  chloride 
solution  (20  ml)  and  the  ammonia  was  allowed  to  evaporate  at  roost 
temperature  overnight.  The  residue  was  redissolved  in  ethyl  acetate 
(100  ml),  washed  with  1M  HC1  (3  x  50  ml),  dried  with  magnesium 
sulfate  and  concentrated  to  give  a  yellow  oil.  NMR  spectroscopy  of  the 
crude  product  showed  that  the  major  component  was  starting  material 
but  there  was  a  small  trace  of  trans-double  bond  product  formed. 
General  procedure  2  for  d  oie  r  C  ona 
dimethyloxazolidine 
(lit.  procedure58  was  modified) 
02  .ý  ý_ 
The  3-tert-butyloxycarbonyl-2,2-dimethyloxazolidine  (1  mmol)  was 
dissolved  in  methanol  (40  ml)  and  toluene-p-sulfonic  acid  (4  mmol) 
was  added  to  the  solution.  '  The  reaction  mixture  was  stirred  at  room 
temperature  for  48  h  after  which  methanol  was  removed  under 
reduced  pressure.  The  crude  oil  was  redissolved  in  ethyl  acetate  (100 
ml),  and  the  solution  was  washed  with  saturated  sodium  bicarbonate 
solution  (3  x  50  ml),  brine  (2  x  50  ml),  dried  with  magnesium  sulfate 
and  concentrated  to  give  the  aminodiol. 
144 (2S.  3R)-2-Amino-1.3-dodec-4-yncdio  (116) 
OH 
General  procedure  2  was  used  with  the  following  reagents:  Tolucne-lp- 
sulfonic  acid  (1.4  g,  6.4  mmol),  (4S)-3-tert-butyloxycarbonyl-4-[(1  R)-  l- 
hydroxy-2-nonynyl]-2,2-dimethyloxazolidine  (111)  (0.5  g,  1.4  mntol), 
methanol  (50  ml).  The  compound  was  isolated  as  a  clear  yellow  oil  (0.3 
g,  87%);  Rf  0.1  (ethyl  acetate-ethanol;  9:  1);  [a]o22  -22.6  (c  0.7  in  C11C13); 
SH  (200MHz,  CDC13)  0.80  (3H,  t,,  12-H3),  1.20  -  1.40  (1011,  m,  7-112  to  II- 
H2),  2.14  (2H,  t,  6-H2,  J  6.1  Hz),  2.82  (IH,  m,  2-H),  3.90  (411,  br  s,  011,011, 
NH2),  3.60  (2H,  br  d,  1-H2,  J  4.8  Hz),  4.32  (1H,  br  d,  3-11,  J  4,711z);  SC  (50 
MHz,  CDC13)  14.0  (C-12),  18.6,22.4,28.4,28.7  (C-7  to  C-11),  31.6  (C-6), 
56.9  (C-2),  63.1  (C-i),  64.3  (C-3),  78.4,87.2  (C-4  and  -5);  vn,  ax  (KBr  disc) 
/  cm-1  3356  v.  br,  2932,2360;  m/z  196  (1.2  MH  -  1120),  100  (100),  83 
(26.5), 
, 
60  (7.8);  (found  MH  -  H2O,  196.1732.  Calc.  for  C  121122N  O, 
196.1701). 
(2S.  3R)-2-Amino-1.3-pentadcc-4-ynediot  (1,7) 
15 
13 
Following  general  procedure  2,  the  title  compound  was  prepared  with 
these  reagents:  Toluene-p-sulfonic  acid  (1.73  g,  6.4  mmol),  (4S)-3-tert- 
butyloxycarbonyl-4-[(1R)-1-hydroxy-2-dodeynyl]-2,2-ditncthyloxazo- 
lidine  (112)  (0.7  g,  1.8  mmol),  methanol  (50  ml).  The  compound  was 
isolated  as  a  white  solid  (0.41  g,  89%);  Rf  0.1  (ethanol-ethyl  acetate; 
1:  9);  [a]D22  -8.8  (c  1.1  in  CHC13);  8H  (200MHz,  CDC13)  0.80  (311,  t,  15-113). 
1.18  -  1.40  (16H,  m,  7-H2  to  14-H2),  2.13  (2H,  t,  6-H2,  J  7.0  11z),  2.82 
(1H,  m,  2-H),  3.45  (4H,  br  s,  OH,  OH,  NH2),  3.68  (211,  br  d,  1-112,  J  5.0  11z), 
4.32  (1H,  m,  3-H);  6c  (50  MHz,  CDC13)  14.0  (C-15),  18.6,22.5,28.5,28.8, 
29.0,29.2,29.5,30.8  (C-7  to  C-14),  31.8  (C-6),  57.0  (C-2),  62.9  (C-1). 
145 64.2  (C-3),  78.3,87.1  (C-4  and  -5);  Vmax  (film)  /  cm-1  3357v.  br,  2973, 
2338;  m/z  238  (0.9,  MH  -H20),  100  (100),  9.3  (12.7),  8.3  (14.0);  (found 
MH  -  H2O,  238.2166.  Calc.  for  C15H28NO,  238.2171). 
(2S.  3R)-2-Amino-1.3-octadec-4-,  nediol  115) 
OH 
General  procedure  2  was  employed  with  the  following  reagents: 
Toluene-p-sulfonic  acid  (2.1  g,  8.8  mmol),  (4S)-3-tert-hutyloxy. 
carbonyl-4-  [(1R)-1-hydroxy-2-pentadecynyl]-2,2-dimethyloxazolidinc 
(110)  (1.0  g,  2.2  mmol),  methanol  (50  ml).  The  compound  was  isolated 
as  a  yellow  solid  (0.6  g,  92%);  Rf0.1  (ethyl  acetate-ethanol;  9:  1);  [(X]1)22 
-6.1  (c  0.7  in  CHC13);  SH  (200MHz,  CDC13)  0.81  (311,  t,  18-113),  1.25  (2211, 
m,  7-H2  to  17-H2),  2.14  (2H,  t,  6-H2),  2.83  (111,  br  s,  2-11),  3.18  (411,  hr 
s,  OH,  OH,  NH2),  3.62  (2H,  br  d,  1-H2),  4.32  (111,  br  s,  3-11);  SC  (50  Mltz, 
CDC13)  14.1  (C-18),  18.7,22.6,28.6,28.9,29.1,29.3,29.5,29.6  (C-7  to  C- 
17),  31.9  (C-6),  56.9  (C-2),  63.2  (C-1),  64.4  (C-3),  78.3,87.4  (C-4  and  -5); 
Vmax  (KBr  disc)  /  cm-1  3398,3280,3100,2232;  m/z  280  (2.1,  h1  -  C113), 
279  (0.3,  M-  H2O),  153  (2.1),  102  (100),  85  (68);  (found  h1  -  N113, 
280.2390.  CaIc.  for  C  18H32O2,280.2402). 
(2S.  3R  -2-Acetamino-l.  3-diacetoxydodec-4-vile( 
(using  the  procedure  of  Garner  et  al.  58) 
0 
10  /7 
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146 A  solution  of  (2S,  3R)-2-amino-1,3-dodec-4-ynediol  (116)  (0.3  ,  g,  1.4 
mmol),  acetic  anhydride  (0.7  ml,  7  mmol)  and  4-dimethylamino- 
pyridine  (0.03  g)  in  triethylamine  (20  ml)  was  stirred  at  room 
temperature-  for  '8  h.  The  excess  of  triethylamine  was  removed  under 
reduced  pressure  and  the  residue  was  redissolved  in  ethyl  acetate  (50 
ml).  The  organic  layer  was  washed  with  1M  HCI  (3  x  50  nil),  saturated 
sodium  bicarbonate  solution  (3  x  50  ml),  brine  (50  nil),  dried  with 
magnesium  sulfate  and  concentrated  to  give  an  oil  which  was  purified 
by  flash  chromatography  eluting  with  hexane-ethyl  acetate  (5:  1)  to 
afford  the  title  compound  as  an  yellow  oil  (0.1  g,  21%)-,  Rf0.35  (hexanc- 
ethyl  acetate;  1:  1);  8H  (200MHz,  CDC13)  0.80  (311,  t,  12-113),  1.45  (1011,  in, 
7-H2  to  11-H2),  1.97,2.00,2.01  (9H,  3  s,  14-,  16-  and  18-113),  2.18  (211, 
br  dt,  6-H2,  J  2.0,7.1  Hz),  4.01  (IH,  dd,  1-H,  J  5.8,11.3  11z),  4.25  (111,  dd, 
1-H,  J  6.8,11.3  Hz),  4.48  (1H,  m,  2-H),  5.46  (111,  dt,  3-11,  J  2.0,3.8  11x), 
5.71  (1H,  br  d,  NH);  6c  (50  MHz,  CDC13)  14,0  (C-12),  16.6,22.5,28.2, 
28.6,28.8  (C-7  to  C-11),  20.7,20.8,23.3  (C-14,  -16  and  -18),  31.6  (C-6), 
50.6  (C-2),  62.5  (C-1),  63.8  (C-3),  74.2,89.2  (C-4  and  -5),  169.6,169.9, 
170.2  (C-13,  -15  and  -17);  vmax  (KBr  disc)  /  cm-1  3282,2360,1747, 
1659,1547;  m/z  339  (M+,  0.9%),  296  (1.5),  280  (5.4),  144  (23.4),  103 
(39.7),  84  (100);  (found  M+,  339.2065.  Cale.  for  C1  8H29NO5,339.2046). 
(2S.  3R)-2-Acetamino-1.3-diacctoxxpcntadcc-4-,  ync  (119) 
0 
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A  solution  of  (2S,  3R)-2-amino-1,3-pentadec-4-yncdiol  (117)  (0.5  g,  2.0 
mmol),  acetic  anhydride  (1  ml,  10  mmol)  and  dimethylaminopyridinc 
(0.05  g)  in  triethylamine  (25  ml)  was  stirred  at  room  temperature  for  8 
h.  The  excess  of  triethylamine  was  removed  under  reduced  pressure 
and  the  residue  was  redissolved  in  ethyl  acetate  (50  nil).  The  organic 
layer  was  washed  with  1M  HC1  (3  x  50  mnl),  saturated  sodium 
bicarbonate  solution  (3  x  50  ml),  brine  (50  ml),  dried 
:  with  magnesium 
sulfate  and  concentrated  to  give  an  oil.  The  oil  was  triturated  with 
147 hexane  (20  ml)  to  afford  the  title  compound  as  a  white  soild  (0.72  g, 
94%);  mp  98-99  OC;  [a]D22  -48.1  (c  1.2  in  CHC13);  811  (200MHz,  CDC13) 
0.80  (3H,  t,  15-H3),  1.35  (18H,  m,  7-H2  to  14-H2),  1.97,2.01,2.02  (911,3 
s,  17-,  19-  and  21-H3),  2.15  (2H,  dt,  6-H2,  J  2.0,7.1  llz),  4.05  (111,  dd,  1- 
H,  J  5.8,11.3  Hz),  4.25  (111,  dd,  1-H,  J  6.4,11.3  liz),  4.45  (111,  m,  2-11), 
5.48  (1H,  dt,  3-H,  J  2.0,3.8  Hz),  5.98  (1H,  br  d,  NH);  5C  (50  MHz,  CDC13) 
13.9  (C-15),  18.6,22.6,28.2,28.8,28.9,29.2,29.3,29.4  (C-7  to  C-14), 
20.7,20.9,23.1  (C-17,  -19  and  -21),  31.8  (C-6),  50.6  (C-2),  62.3  (C-1), 
65.8  (C-3),  73.5,89.0  (C-4  and  -5),  169.5,170.0,170.7  (C-16,  -18  and 
-20);  Vmax  (KBr  disc)  /  cm-1  3290,2370,1747,1660,1545;  m/z  381 
(M+,  0.4%),  338  (4.7),  322  (4.4),  278  (3.0),  144  (90.1),  102  (100);  (found 
M+,  381.2532.  Calc.  for  C21H35N05,381.2515). 
D-erythro-Sl2hingosinc  (14160 
OH 
16  15 
A  solution  of  (2S,  3R)-2-amino-  1,3-octadec-4-ynediol  (115)  (0.3  g,  I 
mmol)  and  lithium  aluminium  hydride  (0.11  g,  3  mmol)  in  DMZs  (20  ml) 
was  heated  under  reflux  for  10  h  and  then  allowed  to  cool  down  to 
room  temperature.  The  reaction  was  quenched  by  careful  addition  of 
saturated  ammonium  chloride  solution  (20  ml)  followed  by  ethyl 
acetate  (30  ml).  The  organic  layer  was  separated  and  the  aqueous  layer 
was  extracted  with  ethyl  acetate  (3  x  30  ml).  The  combined  organic 
extracts  were  washed  with  brine  (30  ml),  dried  with  magnesium 
sulfate,  filtered  and  concentrated  to  afford  a  yellow  oil.  Purification  of 
the  oil  by  flash  chromatography  eluting  with  ethanol-ethyl  acetate  (1:  9) 
afforded  the  title  compound  as  a  yellow  oil  (60  mg,  20%);  Rf0.0  (ethyl 
acetate-ethanol;  9:  1);  6H  (200MHz,  CDC13)  0.81  (3H,  t,  18-113),  1.13  (2211, 
m,  7-H2  to  17-H2),  1.94  (2H,  m,  6-H2),  2.73  (IH,  m,  2-I1),  3.65  (111,  dd, 
1-H,  J  3.3,11.4  Hz),  3.75  (IH,  dd,  1-H,  J  4.4,11.2  Hz),  4.23  (111,  in,  3-11), 
4.47  (4H,  br  s,  OH,  OH,  NH2),  5.38  (IH,  dd,  4-H,  J  5.8,15.3  11z),  5.72  (111, 
dt,  5-H,  J  6.7,15.2  Hz);  6c  (50  MHz,  CDC13)  14.8  (C-18),  22.6,29.0,29.2, 
29.3,29.4,29.6,31.9  (C-7  to  C-17),  32.4  (C-6),  48.1  (C-2),  59.7  (C-I), 
148 71.8  (C-3),  128.1  (C-4  or  '  -5),  133.7  (C-4  or  -5);  vmax  (KBr  disc)  /  cm-1 
3470,1680;  m/z  264  (0.7,  MH  -  H2O),  124  (14.8),  102  9100),  82  (15.4); 
(found  MH  -  H2O,  264.2664.  Calc.  for  C18H34N,  264.2691). 
N.  O  O-Triacetyl-D-erythro-sphingosine  (160)58 
24 
A  solution  of  D-erythro-sphingosine  (14)  (60  mg,  0.2  mmol),  acetic 
anhydride  (0.2  ml,  2  mmol)  and  4-dimetllylaminopyridine  (0.05  g)  in 
triethylamine  (25  ml)  was  stirred  at  room  temperature  for  8  h.  The 
excess  of  triethylamine  was  removed  under  reduced  pressure  and  the 
residue  was  redissolved  in  ethyl  acetate  (50  ml).  The  organic  layer  was 
washed  with  1M  HC1  (3  x  50  ml),  saturated  sodium  bicarbonate 
solution  (3  x  50  ml),  brine  (50  ml),  dried  with  magnesium  sulfate  and 
concentrated  to  give  an  oil.  The  oil  was  partially  purified  by  flash 
chromatography  eluting  with  hexane-ethyl  acetate  (4:  1)  to  afford  the 
title  compound  (60  mg,  70%);  Rf  041  (hexane-ethyl  acetate;  4:  1);  811 
(200MHz,  CDC13)  0.78  (3H,  t,  18-H3),  1.18  (22H,  m,  7-H2  to  17-112),  2.04 
(1H,  m,  6-H2,20-  22-  and  24-H3),  2.89  (1H,  m,  2-H),  3.99  (2H,  m,  1-112), 
5.22  (2H,  m,  3-H  and  4-H),  5.70  (1H,  dt,  5-H,  J  6.7,15.3  Hz);  8C  (50  Mliz, 
CDC13)  14.0  (C-18),  20.1,23.0,23.1  (C-20,  -22  and  -24),  22.6,28.6,29.1, 
29.3,29.4,29.5,29.6,30.9,31.9  (C-7  to  C-17),  32.2  (C-6),  56.6  (C-2), 
63.7  (C-1),  74.3  (C-3),  124.4  (C-4),  136.8  (C-5),  170.1,170.9  (C-19,  -21 
and  -23).  Attempted  further  purification  on  a  silica  column  caused  the 
title  compound  to  decompose. 
149 4-Methoxvcarbonvloxazolidi  n-2-one  (12 
6\ 
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(S)-Serine  methyl  ester  hydrochloride  (95)  (10  g,  64.3  mmol)  and 
potassium  hydrogen  carbonate  (6.7  g,  66.8  mmol)  were  dissolved  in 
water  (110  ml)  and  the  solution  was  stirred  at  room  temperature  for  10 
min.  Potassium  carbonate  (9.4  g,  67.8  mmol)  was  added  to  the  solution 
which  was  then  cooled  to  0  °C.  A  solution  of  phosgene  in  toluene  (2M, 
44  ml,  85.4  mmol)  was  added  dropwise  and  the  resulting  solution  was 
stirred  for  2h  at  0oC.  The  solvent  was  removed  under  reduced 
pressure  to  leave  a  white  solid  which  was  extracted  with 
dichloromethane  (3  x  100  ml).  The  extracts  were  dried  with 
magnesium  sulfate  and  concentrated  to  give  a  clear  oil  (7.5  g,  80%);  Rf 
0.45  (ethyl  acetate);  [a  I  D22  -18.6  (c  4.3  in  CH2C12);  6n  (200MHz,  CDC13) 
3.73  (3H,  s,  6-H3),  4.39  (1H,  dd,  3-H,  J  4.8,9.6  Hz),  4.52  (111,  dd,  3-I1,  J 
4.8,9.1  Hz),  4.67  (1H,  app.  t,  2-H,  J  9.6  Hz),  6.88  (1H,  br  s,  Nil);  8C  (50 
MHz,  CDC13)  51.3  (C-2),  52.1  (C-6),  65.2  (C-3),  157.8  (C-4),  169.3  (C-1); 
Vmax  (KBr  disc)  /  cm-1  3323,  '  1767,1740;  m/z  145  (M+,  5.4%),  87  (5), 
86  (100);  (found  M+,  145.0380.  Calc.  for  C5H7NO4,145.0375). 
4-Hvdroxymethvloxazolidin-2-one  (122 
HO 
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Sodium  borohydride  (1.36  g,  35.7  mol)  was  added  in  portions  to  a 
solution  of  compound  (121)  (5  g,  34.2  mmol)  in  ethanol  (100  nil)  at  0 
O  C.  The  reaction  mixture  was  allowed  to  warm  to  room  temperature. 
After  it  was  stirred  for  3h  at  this  temperature,  saturated  aqueous 
150 ammonium  chloride  solution  (30  ml)  was  added.  The  white  solid  was 
filtered  off  and  the  filtrate  was  concentrated  to  give  a  white  paste.  The 
white  paste  was  purified  by  flash  chromatography  eluting  with 
methanol-ethyl  acetate  (1:  4)  to  afford  the  title  compound  as  a  white 
solid  (2.5  g,  63%);  Rf0.28  (ethyl  acetate-hexane;  9:  1);  811  (200MHz,  D20) 
3.60  (2H,  2x  dd,  1-H2),  4.01  (1H,  m,  2-H),  4.19  (1H,  dd,  3-H,  J  5.1,8.7 
Hz),  4.45  (1H,  t,  3-H,  J  8.7  Hz);  8c  (50  MHz,  D20)  54.4  (C-2),  63.2  (C-i), 
68.8  (C-3),  159.6  (C-4);  v  max  (KBr  disc)  /  cm-1  3370,1740. 
(5)-4-(4-Toluenesulfonyloxymethyloxazolidin-2-one  (123)89 
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Tosyl  chloride  (6.3  g,  32.8  mmol)  was  added  at  0  OC  to  a  solution  of  the 
compound  (122)  (2.5  g,  21.3  mmol)  in  dry  triethylamine  (20  ml).  The 
reaction  was  stirred  at  room  temperature  overnight  after  which 
triethylamine  was  removed  under  reduced  pressure.  The  solid  was 
redissolved  in  dichloromethane  (100  ml),  washed  with  1M  HCl  (2  x  50 
ml)  and  the  organic  layer  was  dried  with  magnesium  sulfate,  filtered 
and  concentrated  to  give  a  yellow  oil.  The  oil  was  purified  by  column 
chromatography  to  give  the  title  compound  and  (S)  -3-  (4  - 
toluenesulfonyl)-4-(4-tolu  en  esulfonyloxymethyl)oxazolidin-2-one 
(124). 
The  title  compound  was  obtained  as  a  crystalline  solid  (3.5  g,  64%);  mp 
97  oC  (lit.,  99  96-99  °C);  Rf0.28  (methanol-ethyl  acetate;  1:  9);  [aID22  +6.0 
(c  0.54  in  CHC13);  SH  (200MHz,  CDC13)  2.33  (3H,  s,  1-H3),  4.04  (411,  in,  8. 
and  10-H2),  4.37  (IH,  m,  9-H),  6.33  (IH,  br  s,  NH),  7.27  (2H,  d,  2-  and  4- 
H),  7.73  (2H,  d,  5-  and  7-H);  Sc  (50  MHz,  CDC13)  21.6  (C-1),  50.8  (C-9), 
66.4  (C-8  or  -10),  69.7  (C-8  or  -10),  127.9  (C-2  and  -4),  130.3  (C-5  and 
-7),  131.7  (C-3),  145.6  (C-6),  159.3  (C-11);  vmax  (KBr  disc)  /  cm-1  3445, 
3300,1770.  (Found:  C,  48.7;  H,  4.86;  N,  5.16.  Calc.  for  Cl  IH  13  NS  05  :  C, 
48.65;  H,  4.63;  N,  5.02%). 
151 (S)  -3-  (4-  to  1u  en  es  u1  fo  nyl)  -4-  (4-to!  u  en  es  u1  fo  nyl  ox  y  methyl)  ox  az  01  din  -2- 
one  (124)  was  obtained  as  a  fluffy  white  solid  (1.0  g). 
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Rf0.40  (methanol-ethyl  acetate;  1:  9);  [a]D22  -50.1  (c  1  in  CHC13);  811 
(200MHz,  CDC13)  2.35  (3H,  s,  1-  or  18-H3),  2.37  (3H,  s,  1-  or  18-113), 
4.15  (2H,  2x  dd,  10-H2,  J  2.9,9.9  Hz),  4.24  (2H,  m,  8-H2),  4.56  (211,  m, 
9-H),  7.26  (4H,  app.  t,  2-,  4-,  14-  and  16-H),  7.66  (2H,  d,  5-  and  7-H  or 
13-  and  17-H),  7.78  (2H,  d,  5-  and  7-H  or  13-  and  17-H);  8C  (50  MHz, 
CDC13)  20.9  (C-1  or  -18),  21.6  (C-1  or  -18),  54.7  (C-9),  65.0  (C-10),  68.8 
(C-8),  127.8  (C-2  and  -4  or  C-14  and  -16),  '128.3  (C-2  and  -4  or  C-14 
and  -16),  129.9  (C-5  and  -7  or  C-13  and  -17),  130.1  (C-5  and  -7  or  C-13 
and  -17),  131.7  (C-3  or  -15),  134.1  (C-3  or  -15),  145.7  (C-6  or  -12), 
146.0  (C-6  or  -12),  151.7  (C-11);  Vmax  (KBr  disc)  /  cm-1  2930,1774, 
1363.  (Found:  C,  50.8;  H,  4.5;  N,  3.3.  Calc.  for  C18H19N07S2:  C,  50.71;  11, 
4.40;  N,  3.20%). 
Attempted  preparation  of  (R)-4-(2-hexadecynyl)oxazoli  din-2-one 
BuLi  (1.5M,  3  ml,  4.6  mmol)  was  added  dropwise  at  -78  OC  to  a  solution 
of  1-pentadecyne  (1.3  ml,  4.6  mmol)  in  dry  THE  (30  ml).  The  solution 
was  allowed  to  warm  to  room  temperature  and  stirred  for  30  min 
before  cooling  back  down  to  -78  °C.  Cul  (0.45  g,  2.4  mmol)  was  then 
added.  After  the  grey  suspension  was  stirred  for  2h  at  -  78  °C,  a 
solution  of  compound  (123)  (0.5  g,  1.8  mmol)  in  dry  THE  was  added 
dropwise  via  a  dropping  funnel.  This  suspension  was  stirred  at  -78  oC 
for  30  min  and  then  at  room  temperature  overnight.  The  organic 
152 solvent  was  removed  under  reduced  pressure.  The  resulting  blue 
solution  was  extracted  with  ethyl  acetate  (3  x  50  ml),  and  the  combined 
extracts  were  dried  with  magnesium  sulfate  and  concentrated  to  give 
an  oil.  All  spectral  data  were  identical  to  those  of  starting  material. 
(R)-3-(4-Toluenesulfonyl-4-(2-hexadecynyl)oxazoli  din-2-onc  (125) 
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BuLi  (1.5M,  0.64  ml,  0.96  mmol)  was  added  dropwise  at  -78  OC  to  a 
solution  of  1-pentadecyne  (0.3  ml,  0.96  mmol)  in  dry  THE  (20  ml).  The 
solution  was  allowed  to  warm  to  room  temperature  and  stirred  for  30 
min  before  cooling  back  down  to  -78  °C.  A  solution  of  compound  (124) 
(0.2  g,  0.48  mmol)  in  dry  THE  (10  ml)  was  added  to  this  mixture.  The 
resulting  solution  was  stirred  at  -78  OC  for  2h  and  at  room 
temperature  overnight.  Saturated  ammonium  chloride  solution  (20  nil) 
was  added  and  the  organic  layer  was  separated.  The  aqueous  layer  was 
extracted  with  ethyl  acetate  (2  x  30  ml)  and  the  combined  extracts 
were  dried  with  magnesium  sulfate  and  concentrated  to  give  an  oil. 
The  oil  was  purified  by  column  chromatography  eluting  with  hexane- 
ethyl  acetate  (2:  1)  to  give  the  title  compound  as  a  yellow  oil  (50  mg, 
23%);  Rf  0.4  (hexane-ethyl  acetate;  2:  1);  5H  (200MHz,  CDC13)  0.80  (3H,  t, 
1-H3),  1.18  (22H,  m,  2-H2  to  12-H2),  2.20  (4H,  m,  13-  and  16-H2),  2.37 
(3H,  s,  26-H3),  2.93  (IH,  m,  17-H),  3.91  (IH,  dd,  18-H,  J  6.1,1.2  Hz),  4.10 
(IH,  dd,  18-H,  J  4.7,1.2  Hz),  7.26  (2H,  d,  22-  and  24-H),  7.75  (2H,  d,  21- 
and  25-H);  8C  (50  MHz,  CDC13)  14.0  (C-1),  18,6,22.6,27.4,28.7,28.9, 
29.2,29.3,29.5,30.9  (C-2  to  C-12),  31.1  (C-13  or  -16),  31.9  (C-13  or 
-16),  36.8  (C-17),  64.1  (C-18),  72.3  (C-14  or  -15),  90.9  (C-14  or  -15), 
127.9  (C-22  and  -24),  129.7  (C-21  and  -25),  134.4  (C-23),  144.7  (C-20), 
152.9  (C-19);  Vmax  (KBr  disc)  /  cm-1  2927,2236,1715;  m/z  461  (M+, 
1.6%),  349  (20),  306  (30.8),  276  (7.6),  235  (100),  210  (20),  155  (100); 
(found  M+,  461.2575.  Calc.  for  C26H39NO4S,  461.2599). 
153 7.4  Experimental  to  Chapter  6 
(2R.  3R)  2.3-Epoxy-3-phenylpropan-1-01(135)92 
A  flame-dried  four-necked  flask  fitted  with  a  thermometer  and  two 
dropping  funnels  was  charged  with  (-)-diethyl  tartrate  (0.46  g,  2  ntmol) 
and  dichloromethane  (250  ml).  After  the  mixture  was  cooled  to  -20  °C, 
activated  powdered  4A  molecular  sieves  (1.5  g),  titanium 
tetraisopropoxide  (0.38  g,  1.4  mmol)  and  tert-butylhydroperoxide  (11 
ml  of  5-6  M  solution  in  decane;  ca.  55  mmol)  were  added  sequentially. 
The  mixture  was  stirred  at  -20  oC  for  1h  and  was  then  treated  with  a 
solution  of  freshly  distilled  (E)-3-phenylpropen-2-ol  (3.5  g,  26  mmol)  in 
dichloromethane  (10  ml).  After  3h  at  -20  °C,  the  reaction  was 
quenched  with  a  10%  solution  of  sodium  hydroxide  saturated  with 
sodium  chloride.  Before  removing  the  cold  bath,  ether  (20  nil)  was 
added  and  the  stirred  mixture  was  allowed  to  warm  up  to  10  oC, 
whereupon  magnesium  sulfate  (1  g)  and  Celite  (0.1  g)  were  added.  The 
mixture  was  then  filtered  through  Celite,  washed  with  diethyl  ether  and 
concentrated  to  give  a  yellow  oil.  The  oil  was  purified  by  column 
chromatography  eluting  with  hexane-ethyl  acetate;  (2:  1)  to  give  white 
crystals  (2.5  g,  64%);  mp  50-51  oC  (lit.,  92  51-53  OC);  Rf  0.3  (hcxane- 
ethyl  acetate;  2:  1);  5H  (200MHz,  CDC13)  3.16  (1  H,  br  s,  OH),  3.23  (1  H,  m, 
2-H),  3.75  (IH,  dd,  1-H,  J  4.2  and  12.8  Hz),  3.90  (IH,  d,  3-H,  J  2.2  Hz), 
4.00  (1H,  dd,  1-H,  J  2.2  and  12.8),  7.25  (5H,  m,  aromatic  H);  8C  (50  MHz, 
CDC13)  55.6  (C-2),  61.3  (C-1),  62.6  (C-3),  125.7  (C-5  and  -9  or  C-6  and 
-8), 
127.6  (C-7),  128.4  (C-5  and  -9  or  C-6  and  -8),  136.7  (C-4);  vmax  (KBr 
disc)  /  cm-1  3442  (OH),  1256;  m/z  150  (M+,  7.1%),  132  (28.2,  M-  H2O), 
119  (28.7),  91  (100,  M-  CHOCH2OH);  (found  M+,  150.0683.  Calc.  for 
C9H  1002,150.0680).  (Found:  C,  72.0;  H,  6.7.  Calc.  for  C9H  1002:  C,  71.72; 
H,  6.76%). 
154 (2R.  3R)-1-((P-Tolucnesulfonyl)oxY]-2.3-cPoxy-3-12licnylpronanc  (136) 
(using  the  procedure  of  Awad  et  n1.100) 
Tosyl  choride  (2.8  g,  14.6  mmol)  was  added  to  a  solution  of  (2R,  3R)-2,3- 
epoxy-3-phenylpropan-1-ol  (135)  (2  g,  13.3  mmol)  in  triethylamine 
(20  ml).  After  it  was  stirred  overnight  at  room  temperature,  the 
reaction  mixture  was  diluted  with  saturated  aqueous  ammonium 
chloride  solution  (30  ml)  and  extracted  with  ethyl  acetate  (3  x  30  ml). 
The  combined  extracts  were  dried  with  niagnesiuni  sulfate,  filtered  and 
concentrated  to  a  white  solid.  Recrystallisation  from  hexane-ethyl 
acetate  gave  white  crystals  (3.2  g,  80%);  mp  68  OC  (lit.,  ref  68-69  oC);  Rf 
0.8  (hexane-ethyl  acetate;  2:  1);  Stt  (200MHz,  CDC13)  2.44  (311,  s,  16-113), 
3.23  (1H,  m,  2-H),  3.75  (IH,  d,  3-11,  J  1.9  Hz),  4.14  (111,  dd,  1-11,  J  5.5  and 
11.5  Hz),  4.34  (1H,  dd,  1-H,  J  3.6  and  11.5  Hz),  7.28  (511,  in,  aromatic  11, 
11-  and  15-H),  7.80  (2H,  d,  12-  and  14-11);  8c  (50  MHz,  CDC13)  21.6  (C- 
16),  56.3  (C-2),  59.5  (C-3),  69.5  (C-1),  125.6  -  132.5  (aromatic  CII), 
135.4  (C-4),  136.1  (C-13),  145.2  (C-10);  vmux  (KBr  disc)  /  cni-1  2945, 
1356  (S020),  1175,960;  nz/z  304  (M+,  2.0%),  155  (47.2,  M- 
SO2OC6H5CH3),  133  (21.9),  91  (100);  (found  M+,  304.0782.  Cale.  for 
C  16H  16SO4,304.0769). 
22  R.  3R  -1-(N.  N-Diethylamino)2.3-cepoxy-3-phenyl  ro  anc  (137) 
(using  the  procedure  of  Rayner  et  A9  1) 
A  flame  dried  three-necked  flask  under  nitrogen  was  charged  with 
(2R,  3R)-1-[(p-toluenesulfonyl)oxy]-2,3-epoxy-3-plhenylpropane  (136) 
(2  g,  6.6  mmol),  potassium  iodide  (1.2  g,  7.3  mmol)  and  dry 
dimethylformamide  (20  ml).  Diethylamine  (0.96  g,  13.2  mmol)  was 
155 then  added  dropwise  to  the  mixture.  After  it  was  stirred  overnight  at 
room  temperature,  the  mixture  was  poured  into  ice  water  and  extracted 
with  ethyl  acetate  (3  x  20  ml).  The  combined  extracts  were  washed 
with  saturated  sodium  bicarbonate  solution,  dried  with  magnesium 
sulfate  and  concentrated  to  give  an  oil.  Purification  of  the  oil  by  flash 
chromatography  eluting  with  ethyl  acetate  afforded  a  yellow  oil  (0.3  g, 
22%);  Rf  0.05  (hexane-ethyl  acetate;  2:  1);  811  (200MHz,  CDC13)  0.97  (611, 
t,  11-  and  13-H3),  2.51  (5H,  m,  10-  &  12-112  and  1-11),  2.81  (111,  dd,  1- 
H,  J  4.1  and  11.5  Hz),  3.05  (IH,  m,  2-H),  3.52  (111,  d,  3-11,  J  1.9  11r.  ),  7.22 
(5H,  m,  aromatic  H);  5C  (50  MHz,  CDC13)  10.1  (C-11  and  -13),  45.9  (C-10 
and  -12),  53.4  (C-1),  55.4  (C-2),  59.8  (C-3),  123.9  (C-5  and  -9  or  C-6  and 
-8),  126.4  (C-7),  126.8  (C-5  and  -9  or  C-6  and  -8),  135.7  (C-4);  vniax 
(film)  /  cm-1  2934,1203;  n:  /z  205  (M+,  0.6%),  91  (8.3),  86  (100,  M- 
C6H5CHCH),  72  (10.7,  M-  C6H5CHCHCH2);  (found  M+,  205.1517.  Calc.  for 
C  13H  19NO,  205.1466). 
phenylpropanc-l  .  3-diol 
(using  the  procedure  of  Rayner  et  a!.  91) 
Trimethylsilyl  trifluoromethanesulfonate  (0.24  g,  1.1  mmol)  was  added 
to  a  solution  of  (2R,  3R)-1-(N,  N-dicthylamino)-2,3-epoxy-3- 
phenylpropane  (137)  (0.2  g,  0.9  mmol)  in  dry  dichloromethanc  (10  ml) 
at  -78  oC  under  nitrogen.  After  30  min,  water  (1  nil)  was  added  to  the 
solution  which  was  then  allowed  to  warm  to  room  temperature  and 
stirred  for  24  h.  Ethyl  acetate  (30  ml)  and  water  (20  nil)  were  added. 
The  organic  layer  was  separated,  washed  with  saturated  sodium 
bicarbonate  solution,  dried  with  magnesium  sulfate  and  concentrated  to 
give  an  oil.  NMR  spectroscopic  analysis  indicated  a  complex  mixture 
but  the  epoxide  ring  was  opened. 
156 (2R.  3R)-  l  -[(N-Ethylaminocarbonyl)oxy]-2.3-epoxyphcnylpropanc  (143) 
(using  the  procedure  of  Roush  et  al.  94) 
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Freshly  distilled  ethyl  isocyanate  (1.68  ml,  21.3  nlnlol)  was  added  to  a 
solution  of  (2R,  3R)-2,3-epoxy-3-phenylpropan-l-ol  (135)  (2  g,  13.3 
mmol)  and  triethylamine  (3.8  ml,  26.6  mmol)  in  dry  dichloromethane 
(20  ml).  After  it  was  stirred  overnight  at  room  temperature,  the 
reaction  mixture  was  diluted  with  saturated  aqueous  ammonium 
chloride  solution  (20  ml)  and  extracted  with  ethyl  acetate  (3  x  30  nll). 
The  combined  extracts  were  washed  with  brine,  dried  with  magnesium 
sulfate,  filtered  and  concentrated.  The  resulting  crude  poduct  was 
purified  by  column  chromatography  cluting  hexane-ethyl  acetate  (4:  1), 
to  give  the  title  compound  (2.3  g,  93%)  as  a  white  solid  which  proved  to 
be  >  95%  optically  pure  by  chiral  column  gas  chromatography  and  use 
of  shift  reagents  (+)-2,2,2-trifluoro-l-(9-anthryl)-ethanol  and  tris[3- 
(heptafluoroproylhydroxmethylene)-(-)-canlpllorato],  europium  (111) 
derivative;  mp  46  °C;  Rf0.4  (hexane-ethyl  acetate;  4:  1);  [aID22  +  54.5  (c 
0.29  in  CHC13);  Stt  (200MHz,  CDC13)  1.05  (311,  t,  12-113),  3.05  (311,  in,  11- 
H2  and  2-H),  3.70  (1H,  d,  3-H,  J  1.9  Hz),  4.01  (111,  dd,  1-11,  J  5.8  and  12.3 
Hz),  4.53  (1H,  dd,  1-H,  J  3.0  and  12.2  Hz),  7.19  (51I,  in,  aromatic  11);  8c 
(50  MHz,  CDC13)  15.1  (C-12),  35.9  (C-11),  56.2  (C-2),  59.8  (C-3),  64.3  (C- 
1),  125.7  (C-5  and  -9  or  C-6  and  -8),  128.4  (C-7),  128.5  (C-5  and  -9  or 
C-6  and  -8),  136.3  (C-4),  155.9  (C-10);  Vn,  ax  (KBr  disc)  /  cm-1  3316 
(CONH),  2972,1689  (OCON);  nm/z  226  (M+,  0.6),  150  (7.5%,  M- 
CONCH2CH3),  134  (8.8),  107  (100,  M-  C6115C1011).  91  (66.7);  (found 
M+,  221.1050.  Cale.  for  C  12H  15N03,221.1050).  (Found:  C,  65.2;  11,6.7; 
N,  6.3.  Calc..  for  C  12H  15N03:  C,  65.12;  H,  6.60;  N,  6.33%). 
157 2S.  3R)-3-Ethyl-4-(1-hydroxybcnzyl)-2-oxazol  idinonc  (14 
(using  the  procedure  of  Roush  et  xl.  94) 
Sodium  hydride  (95%,  0.88  g,  36  mmol)  was  added  to  a  solution  of 
(2R,  3R)-1-[(N-ethylaminocarbonyl)oxy]-2,3-epoxyphenylpropane  (143) 
(2  g,  9  mmol)  in  dry  THE  (30  ml).  After  the  reaction  mixture  had  been 
stirred  for  6  h,  it  was  quenched  by  addition  of  saturated  aqueous 
ammonium  chloride  solution  (30  ml)  and  extracted  with  ethyl  acetate 
(3  x  30  ml).  The  combined  extracts  were  dried  with  magnesium  sulfate 
and  concentrated  to  give  crystalline  crude  product.  Recrystallisation 
from  ethyl  acetate-hexane  afforded  light  brown  needles  (1.6  g,  80%); 
mp  98.5  OC;  Rf0.1  (hexane-ethyl  acetate;  4:  1);  [a]D22  -  52.5  (e  0.84  in 
CHC13);  81;  (200MHz,  CDC13)  0.98  (3H,  t,  12-H3),  2.91  (111,  dq,  11-11),  3.50 
(1H,  dq,  11-H),  3.91  (2H,  ©J3.  X,  1-H2),  4.25  (111,  m,  2-11),  4.85  (111,  in,  3- 
H)  (became  d  on  exchange  with  D20),  7.25  (511,  nt,  aromatic  11);  8C  (50 
MHz,  CDC13)  12.4  (C-12),  36.7  (C-11),  59.8  (C-2),  62.6  (C-1),  69.8  (C-3), 
125.8  (C-5  and  -9  or  C-6  and  -8),  127.9  (C-7),  128.6  (C-5  and  -9  or  C-6 
and  -8),  139.3  (C-4),  158.0  (C-10);  Vmax  (KIM  disc)  /  cn1-1  3300,2964, 
1760  (OCON);  m/z  114  (100,  M-  C5  H8N02),  107  (53.7,  M-  C611501011), 
77  (59.3).  (Found:  C,  65.2;  H,  6.7;  N,  6.3.  Cale.  for  C  121115N03:  C,  65.15; 
H,  6.74;  N,  6.27%). 
R.  2S)  2-Ethylamino-l-pheny]propane-1.3-ý 
(using  the  procedure  of  Roush  et  al.  94) 
A  solution  of  (2S,  3R)-3-ethyl-4-(1-hydroxybcnzyl)-2-oxazolidinone 
(144)  (1  g,  4.5  mmol)  and  lithium  hydroxide  (3.3  g,  0.14  mol)  in 
158 aqueous  ethanol  (30%,  20  ml)  was  heated  under  reflux  for  15  h.  After 
the  reaction  mixture  was  cooled  to  room  temperature,  it  was  diluted 
with  brine  (30  ml)  and  extracted  with  ethyl  acetate  (3  x  30  nil).  The 
combined  extracts  were  dried  with  magnesium  sulfate,  filtered  and 
concentrated  to  give  a  white  solid.  Recrystallisation  from  ethyl  acetate- 
hexane  afforded  white  needles  (0.82  g,  93%);  nip  75-76  OC;  [aID22  -  40.9 
(c  0.86  in  CHC13);  8j  (200MHz,  CDC13)  0.97  (311,  t,  11-113),  2.56  (311,  nt, 
10-H2  and  2-H),  3.40  (2H,  &3.  X,  1-H2),  3.71  (111,  br  s,  Nil),  4.80  (111,  d, 
3-H,  J  4.5  Hz),  7.19  (5H,  m,  aromatic  H);  6c  (50  Mllz,  CDC13)  15.0  (C-11), 
41.4  (C-10),  59.9  (C-1),  63.0  (C-2),  73.6  (C-3),  125.8  (C-5  and  -9  or  C-6 
and  -8),  127.3  (C-7),  128.3  (C-5  and  -9  or  C-6  and  -8),  141.9  (C-4);  vi￿ax 
(KBr  disc)  /  cm-1  3448,3286,3083,2973;  m/z  88  (100,  M-  C41I10NO), 
77  (13.6,  M-  C6H5CHOH).  (Found:  C,  67.7;  11,8.7;  N,  7.1.  Cale.  for 
C  11  H  17N02:  C,  67.66;  H,  8.85;  N,  7.09%). 
Methyl  tetradecanoate  (151)95 
14 
13  11  97 
ý 
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Hydrochloride  gas  was  kept  bubbling  through  a  solution  of 
tetradecanoic  acid  (10  g,  0.04  mmol)  and  methanol  (300  till)  until  all 
the  solid  dissolved.  After  stirring  the  solution  at  room  temperature  for 
5  h,  methanol  was  evaporated  off  under  reduced  pressure  to  afford  a 
white  solid.  The  white  solid  was  redissolved  in  ethyl  acetate  (150  till) 
and  water  (100  ml).  The  organic  layer  was  washed  with  saturated 
sodium  bicarbonate  solution  (3  x  100  ml),  dried  with  sodium  sulfate, 
filtered  and  concentrated  to  give  the  title  compound  as  a  clear  oil  (10.5 
g,  95,  %);  8H  (200MHz,  CDC13)  0.66  (3H,  t,  14-113),  1.04  -  1.39  (2211,  in,  3- 
H2  to  13-H2),  2.07  (2H,  t,  2-H2),  3.43  (3H,  s,  15-H3);  8c  (50  Mliz,  CDC13) 
13.8  (C-14),  22.5,24.8,29.0,29.1,29.2,29.3,29.4,31.8,33.8  (C-3  to  C- 
13),  34.1  (C-2),  50.9  (C-15),  173.7  (C-1);  Vmax  (film)  /  cm-1  2924,2854, 
1744;  m/z  242  (M+,  0.6%),  154  (10.8),  112  (43.2),  87  (31.3,74  (100); 
(found  M+,  242.2237.  Calc.  for  C15H30O2,242.2245). 
159 Tetradecan-  l  -ol  (152) 
(using  the  procedure  of  Weinreb  et  al.  38) 
14  OH 
A  solution  of  methyl  tetradecanoate  (151)  (5  g,  0.019  mmol)  in  dry  TIIF 
(20  ml)  was  added  dropise  at  0  oC  to  a  stirred  suspension  of  lithium 
aluminum  hydride  (0.72  g,  0.019  mmol)  in  dry  T111'  (100  ml).  After  the 
reaction  was  stirred  at  this  temperature  for  2  h,  it  was  quenched  by 
addition  of  saturated  ammonium  chloride  solution  (20  nil).  The  mixture 
was  extracted  with  ethyl  acetate  (3  x  50  nil)  and  the  combined  extracts 
were  dried  with  magnesium  sulfate,  filtered  and  concentrated  to  afford 
the  title  compound  as  a  white  solid  (3.8  g,  94%);  Rf  0.2  (hexane-ethyl 
acetate;  9:  1);  811  (200MHz,  CDC13)  0.78  (311,  t,  14-113),  1.18  (2211,  br  s,  3- 
H2  to  13-H2),  1.47  (2H,  m,  2-H2),  2.67  (1H,  br  s,  O11),  3.52  (211,  t,  1-112); 
8C  (50  MHz,  CDC13)  14.0  (C-14),  22.6,25.7,29.3,29.4,29.6,31.9  (C-3  to 
C-13),  32.6  (C-2),  62.6  (C-1);  vmax  (KBr)  /  cm-1  3421,2924,2853;  nj  /z 
196  (12.2,  M-  H2O),  168  (13.2),  111  (30.6),  97  (62.6),  55  (100);  (found 
M-  H2O,  196.2191.  Cal  c.  for  C14H28,196.2191). 
Tetradecanal  (153) 
(using  the  procedure  of  Swern  et  al.  101) 
14ý  ý842  ýi, 
vvvvvv 
13  11  9753 
Dimethylsulfoxide  (2.6  ml,  0.028  mol)  in  dry  dichloromethane  (20  ml) 
was  added  dropwise  via  dropping  funnel  to  a  cooled  -50  oC  solution  of 
oxalyl  chloride  (1.48  ml,  15.4  mmol)  in  anhydrous  dichloromethane 
(150  ml).  The  reaction  was  stirred  for  10  min  before  tetradccan-l-ol 
(152)  (3  g,  0.014  mol)  in  dry  dichloromethane  (20  nll)  was  introduced. 
Stirring  at  this  temperature  was  continued  for  Ih  and  triethylamine 
(10  ml,  0.14  mol)  was  then  added.  The  resulting  solution  was  allowed 
to  warm  to  room  temperature  and  stirred  for  a  further  30  min. 
Saturated  ammonium  chloride  solution  was  added  and  the  whole 
mixture  was  extracted  with  dichloromethane  (3  x  80ml).  The  combined 
160 extracts  were  dried  with  magnesium  sulfate,  filtered  and  concentrated 
to  give  a  yellow  oil.  The  oil  was  purified  by  flash  chromatography 
eluting  with  hexane-ethyl  acetate  (9:  1)  to  give  tht  title  compound  as  a 
waxy  solid  (2.5  g,  84%);  Sii  (200MHz,  CDC13)  0.82  (311,  t,  14-113),  1.30  - 
1.52  (22H,  m,  3-H2  to  13-H2),  2.30  (2H,  dt,  2-H2,  J  1.8  and  7.2  llz),  9.70 
(1H,  t,  1-H,  J  1.8  Hz);  3c  (50  MHz,  CDC13)  13.6  (C-14),  22.6,24.5,29.3, 
29.4,29.5,29.6,29.7,31.7,32.4  (C-3  to  C-13),  43.8  (C-2),  202.6  (C-1); 
umax  (KBr)  /  cm-1  2924,2864,1720;  m  hz  212  (M+,  0.5),  178  (10),  84 
(40),  74  (100);  (found  M+,  212.2314.  Calc.  for  C14H2803,212.2349). 
Methyl  (2E,  4E)-octadccadicnoatc  (154)38 
19 
17  . 
A  solution  of  methyl  4-dimethylphosphono-2-butenoate  (1.7  g,  9.4 
mmol)  in  dry  THE  (20  ml)  was  slowly  added  to  a  stirred,  cooled  (0  oC  ) 
solution  of  LDA  prepared  in  dry  THE  (30  nil)  from  diisopropylaminc 
(1.14  g,  11.3  mmol)  and  butyllithium  (1.6  M,  7.05  ml,  11.3  mmol)  for  1 
h  at  0oC.  The  red  solution  was  allowed  to  reach  -40  oC  and 
tetradecanal  (153)  (2  g,  9.4  mmol)  dissolved  in  dry  Till'  (20  nil)  was 
added  dropwise  to  the  reaction  mixture.  After  2h  the  reaction  was 
quenched  by  addition  of  water  (100  ml)  and  extracted  with  ether  (3  x 
80  ml).  The  combined  extracts  were  dried  with  magnesium  sulfate, 
filtered  and  concentrated  to  afford  an  oily  solid.  The  residue  was 
partially  purified  by  column  chromatography  eluting  with  hexanc-ethyl 
acetate  (20:  1)  to  give  the  title  compound  as  a  clear  oil  (1.7  g,  62%);  6jj 
(200MHz,  CDC13)  0.88  (3H,  t,  18-113),  1.30  (2211,  m,  7-112  to  17-112),  1.7  - 
2.3'  (2H,  m,  6-H2),  3.70  (3H,  s,  19-H3),  5.81  -  7.72  (4I1,  m,  2-,  3-,  4-  and 
5-H);  Sc  (50  MHz,  CDC13)  14.1  (C-18),  29.2,29.3,29.4,29.5,29.6,29.7, 
31.7,31.8  (C-7  to  C-17),  34.4  (C-6),  51.4  (C-19),  118.5,128.2,144.9  (C- 
2,  -3  and  -4),  120.0,126.3,137.8,141.7  (cis-isomer),  145.3  (C-5),  167.7 
(C-1);  Vmax  (KBr)  /  cm-1  1718,1650;  in/z  294  (M+,  10%),  264  (21),  195 
(100);  (found  M+,  294.2534,  Cale.  for  C  19113402,294.2558). 
161 (2E.  4@:  Octadecadien-l-ol  (149)38 
OH 
A  solution  of  methyl  (2E,  4E)-octadecadienoate  (154)  (1  g,  3.4  mmol)  in 
dry  ether  (20  ml)  was  slowly  added  to  a  cooled  0  oC  stirred  suspension 
of  lithium  aluminum  hydride  (0.12  g,  3.4  mmol)  in  dry  ether  (30  ml). 
After  it  was  stirred  for  0.5  h  at  -10  OC,  the  mixture  was  quenched  by 
addition  of  saturated  ammonium  chloride  solution  (50  ml)  and  then 
extracted  with  ether  (3  x  50  ml).  The  organic  layer  was  washed  with 
water,  dried  over  magnesium  sulfate,  filtered  and  concentrated  to  give 
a,  solid.  The  solid  was  partially  purified  by  column  chromatography 
eluting  with  hexane-ethyl  acetate  (9:  1)  to  give  the  title  compound  (0.72 
g,  80%)  as  a  white  solid;  mp  45  oC  (lit.,  ref  51  OC);  811  (200MHz,  CDC13) 
0.80  (3H,  t,  18-H3),  1.18  (22H,  m,  7-H2  to  17-112),  1.8-  2.1  (211,  in,  6- 
H2),  1.90  (1H,  br  s,  OH),  4.05  (2H,  d,  1-H2,  J  6.0  lllz),  5.51  -  6.40  (411,  in, 
2-,  3-,  4-  and  5-H),  -5C(50  MHz,  CDC13)  14.1  (C-18),  22.6,29.1,29.3,29.4, 
29.5,29.6,29.7,31.7,31.9  (C-7  to  C-17),  32.6  (C-6),  63.4  (C-1),  126.7, 
127.5,131.5,133.1  (cis-isomer),  129.3,131.9,135.7  (C-2,  -3,  -4  and  -5); 
umax  (KBr)  /  cm-1  3318,2921,1645. 
(2R.  3R)-4E-2.3-EPoxv-3-octadcc-4-ene-l-ol  (155) 
13  11 
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A  flame-dried  four-necked  flask  was  fitted  with  a  thermometer  and 
two  dropping  funnels  and  charged  with  (-)-diethyl  tartrate  (0.46  g,  2 
mmol)  and  dichloromethane  (100  ml).  After  the  mixture  was  cooled  to 
-20  O  C,  activated  powdered  molecular  sieves  (0.5  g),  titanium 
tetraisopropoxide  (0.38  g,  1.4  mmol)  and  tert-butylhydropcroxidc  (11 
ml  of  5-6  M  solution  in  decane;  ca.  55  mmol)  were  added  sequentially. 
The  mixture  was  stirred  at  -20  oC  for  1h  and  then  treated  with  a 
solution  of  (2E,  4E)-octadecadien-l-ol  (149)  (0.2  g,  0.75  mnlol)  in 
162 dichloromethane  (10  ml).  After  3h  at  -20  o  C,  the  reaction  was 
quenched  with  a  10%  solution  of  sodium  hydroxide  saturated  with 
sodium  chloride.  After  ether  (20  ml)  was  added,  the  cold  bath  was 
removed  and  the  stirred  mixture  was  allowed  to  warm  up  to  10  °C, 
whereupon  magnesium  sulfate  (1  g)  and  Celite  (0.1  g)  were  added.  The 
mixture  was  then  filtered  through  Celite,  washed  with  diethyl  ether  and 
concentrated  to  give  a  yellow  oil.  The  oil  was  purified  by  column 
chromatography  eluting  with  hexane-ethyl  acetate;  (9:  1)  to  give  the 
title  compound  (10  mg,  5%),  starting  material  (0.1  g)  and  (2R,  3R)-4Z- 
2,3-epoxy-3-octadec-4-ene-l-ol  (156)  (20  mg,  10%)  (57). 
The  title  compound  was  isolated  as  an  oily  solid;  Rf0.23  (hexane-ethyl 
acetate;  9:  1);  8H  (200MHz,  CDC13)  0.78  (3H,  t,  18-H3),  1.16  -  1.56  (22H, 
m,  7-H2  to  17H2),  2.01  (2H,  m,  6-H2),  3.03  (1H,  m,  2-H),  3.30  (1H,  dd,  3- 
H,  J  2.2  and  8.4  Hz),  3.70  (2H,  m,  1-112),  5.11  (111,  ddt,  4-H,  J  8.4  and 
15.5  Hz),  5.89  (1H,  dt,  5-H,  J  6.8  and  15.4  Hz);  8C  (50  MHz,  CDC13)  14.1 
(C-18),  22.6,29.2,29.4,29.5,29.8,29.9,30.9,31.9  (C-7  to  C-17),  32.4 
(C-6),  55.9  (C-2),  59.9  (C-3),  61.2  (C-1),  126.2  (C-4),  138.1  (C-5);  vmax 
(KBr  disc)  /  cm-1  3200,1645,1245,1340;  m/z  282  (M+,  4.2%),  251 
(36.5),  149  (5.4),  83  (100);  (found  M+,  282.2548.  Calc.  for  C18H34NO2, 
282.2559). 
(2R,  3R)-4Z-2,3-Epoxy-3-octadec-4-ene-l-ol  (156)  was  isolated  as  a 
solid. 
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Rf  0.25  hexane-ethyl  acetate,  (9:  1);  6H  (200MHz,  CDC13)  0.80  (3H,  t,  18- 
H3),  1.16  -  1.59  922H,  m,  7-H2  to  17-H2),  2.20  (2H,  m,  6-H2),  3.09  (111, 
m,  2-H),  3.60  (2H,  m,  1-H2),  3.90  (1H,  br  dd,  3-H),  5.00  (IH,  ddt,  4-H,  J 
9.0  and  11  Hz),  5.67  (IH,  dt,  5-H,  J  7.7  and  11  Hz);  6c  (50  MHz,  CDC13) 
14.1  (C-18),  22.6,22.8,29.2,29.4,29.7,29.8,29.9,31.6,31.9  (C-7  to  C- 
163 17),  31.9  (C-6),  51.3  (C-2),  59.7  (C-3),  61.0(C-1),  125,6  (C-4),  137.7  (C- 
5);  vmax  (KBr  disc)  /  cm-1  3250,1640,1340,1236;  m/z  282  (M+,  0.6%), 
269  (32.0),  239  (32.7),  137  (15.4),  109  (58),  95  (100);  (found  M+, 
282.2535.  Calc.  for  C18H34N02,282.2559). 
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